Marine Pharmacology in 2019‐2021: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti‐Inflammatory, Antiprotozoal, Antituberculosis and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action

Preprint

Review

Marine Pharmacology in 2019‐2021: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti‐Inflammatory, Antiprotozoal, Antituberculosis and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action

Altmetrics

Downloads

331

Views

110

Comments

A peer-reviewed article of this preprint also exists.

Submitted:

22 May 2024

Posted:

23 May 2024

You are already at the latest version

Alerts

Abstract

The current 2019-2021 marine pharmacology literature review provides a continuation of previous reviews covering the period 1998 to 2018. Preclinical marine pharmacology research during 2019-2021 was published by researchers in 42 countries and contributed novel mechanism of action pharmacology for 171 structurally characterized marine compounds. The peer-reviewed marine natural products pharmacology literature reported antibacterial, antifungal, antiprotozoal, antituberculosis,and antiviral mechanism of action studies for 49 compounds, 87 compounds with antidiabetic and anti-inflammatory activities as well as affecting the immune and nervous system, while another group of 51 compounds demonstrated novel miscellaneous mechanisms of action, which upon further investigation, may contribute to several pharmacological classes. Thus, in 2019-2021, a very active preclinical marine natural product pharmacology pipeline provided novel mechanism of actions as well as new lead chemistry for the clinical marine pharmaceutical pipeline targeting the therapy of several disease categories.

Keywords:

Subject: Medicine and Pharmacology - Pharmacology and Toxicology

1. Introduction

The aim of the present review is to consolidate the 2019-2021 preclinical marine pharmacology literature, with a similar format to our previous 12 reviews of this series, which cover the period 1998-2018 [1,2,3,4,5,6,7,8,9,10,11,12]. The scientific electronic databases MarinLit, PubMed, PubChem, ScienceDirect, and Google Scholar were used to search and retrieve the peer-reviewed published literature. In contrast with our previous reviews, we have focused the current review only on structurally characterized marine chemicals, classified into six major chemical classes, namely, polyketides, terpenes, peptides, alkaloids, shikimates,and sugars, including compounds with mixed biogenetic origin, using a modification of Schmitz’s chemical classification [13]. Mechanism of action studies of marine chemicals demonstrating antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral pharmacological activities are summarized in Table 1, and the corresponding structures are presented in Figure 1. Similarly, the mechanism of action studies with marine compounds with immune and nervous systems activities, as well as antidiabetic and anti-inflammatory bioactivities are listed in Table 2, with their respective structures consolidated in Figure 2. Finally, marine compounds with miscellaneous mechanisms of action shown to affect multiple cellular and molecular targets, but with no currently assigned pharmacological category, are presented in Table 3, with their structures depicted in Figure 3.

5.7 μM

2. Marine Compounds with Antibacterial, Antifungal, Antiprotozoal, Antituberculosis and Antiviral Activities

Table 1 presents 2019-2021 mechanism of action studies with 49 structurally characterized marine compounds (1–49) that demonstrated antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral pharmacological activities and that are shown in Figure 1.

2.1. Antibacterial Activity

As shown in Table 1, and Figure 1, during 2019-2021, studies with 22 structurally characterized marine natural products (1-22) isolated from bacteria, fungi, sponges, worms, shrimp, ascidians, bryozoa, octopus, fish and algae, reported novel antibacterial mechanisms of pharmacological action targeting bacterial coenzyme-A biosynthesis, membrane disruption, quorum sensing, efflux pumps, cytoskeletal FTsZ protein, biofilm formation, production of reactive oxygen species, DNA damage, and penicillin-binding protein (PBP)2a.

Gomez Rodriguez and colleagues identified the polyketide adipostatin E (1), discovered in the marine Streptomyces blancoensis strain 20733-1, as a potent inhibitor of Streptococcus pneumoniae coenzyme-A biosynthesis, by targeting phosphopantothenoylcysteine synthetase (PPCS), which was considered “an effective drug target” [14]. Elliott and colleagues investigated an amphipathic peptide arenicin-3 (2), found in the marine polychaete lugworm Arenicola marina, that induced a “potent and rapid antimicrobial activity in vitro against various multidrug-resistant Gram-negative bacteria and extensively drug-resistant pathogenic Gram-negative bacteria” by a mechanism of action that resulted from “bacterial membrane binding and disruption of membrane integrity” as well as ATP release [15]. Paderog and colleagues reported that the anthracycline polyketide bisanhydroaklavinone (3), isolated from Philippine marine-sediment derived Steptomyces griseorubens strain DSD069, was shown to cause cell membrane damage to multidrug-resistant Staphylococcus aureus by “leakage and loss of vital cell constituents…and increase membrane permeability” [16]. Wang and colleagues discovered the polyketide cladodionen (4), purified from the marine fungus Cladosporium sp. Z148, that was shown to be a novel quorum sensing inhibitor by a mechanism involving inhibition of quorum sensing-related gene expression as well as biofilm formation [17]. Gowrishankar and colleagues characterized the cyclic dipeptide cyclo(L-leucyl-L-prolyl) (5), isolated from the mangrove rhizosphere bacterium Bacillus amyloliquefaciens, that inhibited the uropathogen Serratia marcesens by a mechanism that involved inhibition of quorum sensing, as revealed by dose-dependent decrease in prodigiosin secretion at sub-minimum inhibitory concentrations, thus this study is “the first …to uncover the potent antibiofilm efficacy of (5) against a Gram-negative pathogen…” [18]. Silva de Figueiredo and colleagues showed that a known marine alga Canistrocarpus cervicornis-derived diterpene (6), decreased the minimum inhibitory activity of tetracycline against methicillin resistant S. aureus by 8-fold, suggesting this seaweed diterpene might be a “potential source(s) of antibiotic adjuvant, acting as (a) potential inhibitor of efflux pump” [19]. Davison and Bewley identified a new polyketide chrysophaentin analog (7), purified from laboratory cultures of the marine microalga Chrysophaeum taylorii NIED-1699, that demonstrated bacterial Gram-positive activity by competitive inhibition of the bacterial cytoskeletal FTsZ protein, a “promising target for novel antibiotic development” [20]. Wang and colleagues investigated the peptide crustin (8), uncovered in the deep-sea hydrothermal vent shrimp Rimicaris sp., that was lethal to Gram-positive bacteria by a mechanism that involved membrane disruption and depolarization [21]. Campana and colleagues reported that the marine bisindole alkaloid 2,2-bis(6-bromo-3-indolyl)ethylamine (9), discovered in the California marine tunicate Didemnum candidum and the New Caledonian marine sponge Orina spp., showed high antimicrobial activity against E. coli, S. aureus and K. pneumoniae by a mechanism that involved both biofilm formation inhibition and disaggregation, highlighting the “potential of (9) as antimicrobial and anti-biofilm agent” [22]. Liang and colleagues discovered that the peptide-polyketide doscadenamide A (10), found in the marine cyanobacterium Moorea bouillonii, modulated quorum sensing in the Gram-negative bacterium P. aeruginosa, by a mechanism that involved binding to intracellular receptor proteins, thus affecting a process that plays a critical role in bacterial pathogenesis [23]. Jabila and colleagues characterized the polyketide kalafungin (11), found in a marine Streptomyces in Staphylococcus aureus-infected zebrafish, that demonstrated beta-lactamase inhibition by a noncompetitive inhibition mechanism that resulted in “destruction of cell membrane” [24]. Maynard and colleagues showed that the known polyketide antibiotic korormicin A (12), isolated from the marine bacterium Pseudoalteromonas sp. J010, killed Gram negative bacteria that express the Na+-pumping NADH:quinone oxidoreductase by production of reactive oxygen species, “that cause damage to cells” [25]. Chung and colleagues determined that the polyketide lactoquinomycin A (13), purified from the marine bacterium Streptomyces bacillaris strain MBTC38, had potent activity against Gram-positive bacteria by damaging DNA by intercalation and “switch(ed) from the supercoiled to relaxed form” [26]. Jayathilaka and colleagues reported that the peptide octominin (14), derived from a Korean marine Octopus minor defense protein, demonstrated bactericidal activity against multidrug resistant Gram-positive bacterium Streptococcus parauberis, by causing “cytoplasmic membrane damage and permeability alterations…possible DNA binding” [27]. Yu and colleagues identified a cyclic dipeptide cyclo(_L-Tyr-_L-Pro) (15), isolated from the marine fungus Penicillium chrysogenum DXY-1, that decreased bacterial quorum sensing-mediated pathogenicity by competitively binding to the receptor protein active pocket, thus becoming “a potential pro-drug for treating drug-resistant P. aeruginosa infections” [28]. Pan and colleagues investigated the peptide piscidin 5 (16), discovered in the marine bass Morone chrysops, and determined that it damaged bacterial membranes by a mechanism involving pathogen-associated molecular patterns, and in addition “could interact with bacterial genome DNA” [29]. Kim and colleagues reported that the terpenoids phorbaketal B and C (17, 18), derived from the marine sponge Phorbas sp., and determined by transcriptional analysis that their bacterial antibiofilm activity resulted from the inhibition of the “expression of the biofilm-related hemolysin gen hla and the nuclease gene nuc1” [30]. Kizhakkekalam and colleagues purified an aryl-enclosed macrocyclic polyketide (19), found in the intertidal marine red macroalga Hypnea valentiae-associated heterotrophic bacterium Shewanella algae, that demonstrated both antibacterial and antioxidant bioactivity which correlated with docking “with the active site of target protein, penicillin-binding protein (PBP)2a” [31]. Chakraborty and colleagues similarly discovered a macrocyclic polyketide (20), isolated from the marine red macroalga Hypnea valentia-associated heterotropic bacterium Shewanella algae, with siderophore mode of action which correlated with docking “with the binding site of PBP2a”[32]. Hansen and colleagues characterized the alkaloid securamine H (21), purified from the Arctic marine bryozoan Securiflustra securifrons, which potently inhibited Staphylococcus aureus by a reduction of metabolic activity that did not appear to involve cell membrane disruption nor “interfere(nce) with DNA replication, transcription or translation” [33]. Hansen and colleagues reported the isolation and characterization of a cysteine-rich peptide turgencin A (22) from the Arctic marine colonial ascidian Synoicum turgens, which displayed potent Gram-negative and Gram-positive antimicrobial activity via a dose- and time-dependent mechanism that caused immediate loss of “ membrane integrity” resulting in a “rapid effect on cell viability” [34]. Reina and colleagues described a tyramine (23) from the Gram-negative marine bacterium Vibrio alginolyticus, and demonstrated that this quorum-sensing compound inhibited pyoverdine production and motility in P. aeruginosa, providing insight into “the use of naturally produced quorum-sensing inhibitors as a possible strategy to combat bacterial infections” [35].

2.2. Antifungal Activity

As shown in Table 1, and Figure 1, during 2019-2021, 7 studies with structurally characterized marine natural products (24-30), isolated from bacteria, fungi and sponges, reported novel pharmacological mechanisms of action targeting ergosterol-containing membranes, the fungal cell wall, 3-hydroxy-3-methylglutaryl CoA synthase, conversion of phytosphingosine to phytoceramide, echinocandin (CAS)-responding gene-induction, and fungal genes involved in filament formation and cell adhesion.

Elsadek and colleagues characterized a novel polyhydroxylated macrolide amantelide A (24), discovered in the marine cyanobacterium Lyngbya majuscula, and demonstrated that its mechanism of action is similar to polyene antifungals, as “it binds to ergosterol-containing membranes”, leading to cell death [36]. Yang and colleagues described the new dolabellane-type diterpenoid atranone Q (25), derived from the marine-derived fungus Stachybotrys chartarum, observing that at high in vitro concentrations it had a “destructive effect on the cell wall and cell membrane of C. albicans” [37]. Tang and colleagues identified a novel β-lactone fusarilactone A (26), found in the mangrove sediment-derived fungus Fusarium solani H915, that inhibited 3-hydroxy-3-methylglutaryl CoA synthase, an enzyme present in eukaryotes that when inhibited “as shown potential for antiviral, antibacterial and cardiovascular protection”[38]. Kim and colleagues investigated the known alkaloid 2-n-heptyl-4-hydroxyquinoline (27), isolated from a marine actinomycete Streptomyces sp. MBTG13, that affected the fungus C. albicans filamentous growth induction by inhibiting mRNAs “related to the cAMP-Efg1 (signaling) pathway” [39]. Dalisay and colleagues reported that the polyketide oceanapiside (28), purified from the marine sponge Oceanapia phillipensis, inhibited C. glabrata sphingolipid metabolism by targeting “the step converting phytosphingosine to phytoceramide” [40]. Tripathi and colleagues showed that the marine sesquiterpene quinone puupehenone (29), uncovered in the marine sponge Hyrtios sp., potentiated the clinically used antifungal echinocandin (CAS) against CAS-insensitive Candida neoformans, by inhibiting CAS-responding gene-induction that is required for fungal cell wall repair [41]. Meng and colleague characterized the shikimate 3-methyl-N-(2′-phenethyl)-butyrylamide (30), discovered in the marine bacterium Streptomyces olivaceus, that exhibited excellent activity against C. albicans by regulating expression of several genes “associated with filament formation and cell adhesion” [42].

2.3. Antiprotozoal and Antituberculosis Activity

As shown in Table 1, and Figure 1, in 2019-2021, 13 antiprotozoal (antimalarial, antileishmanial and antitrypanosomal) and antituberculosis studies with structurally characterized marine natural products (31-43), isolated from bacteria, sponges, ascidians, zoanthids, hydroids, fish and algae reported novel pharmacological mechanisms of action targeting Plasmodium falciparum (P. falciparum) lysyl-tRNA synthetase, P. falciparum proteins actin and sortilin, P. falciparum liver-stage parasite, P. falciparum transition ring to early trophozoite transition, amoebae Acanthamoeba castellani programmed cell death induction mechanisms, Trichomonas vaginalis membrane disruption, Trypanosoma cruzi trypomastigote and amastigotes plasma membrane integrity, Trypanosoma cruzi cysteine protease cruzain, and Schistosoma mansoni parasite egg-production.

Malaria, is a global disease in humans caused by protozoans of the genus Plasmodium (P. falciparum, P. ovale, P. vivax and P. malariae), which as described in the World Health Organization (WHO) website (https://www.who.int/news-room/fact-sheets/detail/malaria), currently affects several million people worldwide. Alhadrami and colleagues characterized the anthraquinone capillasterquinone B (31), discovered in a coculture of the Red Sea sponge-derived actinobacteria Actinokineospora spheciospongiae strain EG-49 and Rhodococcus sp. UR59, that showed antimalarial activity by binding to Plasmodium falciparum lysyl-tRNA synthetase at “several amino acids inside the enzyme’s active site” [43]. Sweeney-Jones and colleagues described a new cyclic peptide kakeromamide B (32), derived from the Fijian marine cyanobacterium Moorea producens, that was predicted to bind to Plasmodium falciparum proteins actin and sortilin, thus suggesting “possible interference with parasite invasion of host cells” [44]. Knestrick and colleagues identified a highly modified linear hexapeptide friomaramide (33), found in the Antarctic marine sponge Inflatella coelosphaeroide, that inhibited Plasmodium falciparum liver-stage parasite development showing “similar inhibitory activity to the known liver-stage antimalarial drug primaquine” [45]. Wright and colleagues communicated that the known terpene nitenin (34), isolated from the deep-water marine sponge Spongia lamella, potently inhibited Plasmodium falciparum chloroquine-resistant strain Dd2 by targeting the parasite’s early transition “from ring to early trophozoite”, a novel property for an antimalarial [46]. Rodríguez-Expósito and collaborators investigated the terpenoid 4-epi-arbusculin A (35), purified from the Canary Islands indigenous marine zoanthid Palythoa aff. clavata, that affected the life cycle of the free-living amoebae Acanthamoeba castellani Neff by several programmed cell death induction mechanisms [47]. Huang and colleagues reported that the antimicrobial peptide epinecidin-1 (36) uncovered in the marine grouper Epinephelus coloides was reported to decrease the metronidazole-resistant protozoan parasite Trichomonas vaginalis multiplication both in vitro and in vivo, with mechanism of action involving “membrane disruption” [48]. Lima and colleagues showed that the terpenoid isololiolide (37), discovered in the marine hydroid Macrorhynchia philippina, inhibited both trypomastigote and intracellular amastigotes of Trypanosoma cruzi by causing disruption “of the plasma membrane integrity and a strong depolarization of the mitochondrial membrane potential” [49]. Lorenzo-Morales and colleagues characterized the oxasqualenoid terpenoid dehydrothyrsiferol (38), derived from the marine red alga Laurencia viridis, which demonstrated cysticidal activity against Acanthamoeba castellanii trophozoites inducing chromatin condensation, mitochondrial dysfunction and increased membrane permeability [50]. Boudreau and colleagues determined that the peptide gallinamide A (39), originally reported from the Panamanian marine cyanobacterium Schizothrix sp., was cytotoxic to the intracellular amastigote stage of the Chagas disease-causative agent Trypanosoma cruzi, by potently inhibiting the ”validated drug target” cysteine protease cruzain, thus representing “a new candidate for the treatment of Chagas disease [51]. Cartuche and colleagues identified the indolocarbazole alkaloid 7-oxostaurosporine (40), found in cultures of the Ecuadorian mangrove-derived Streptomyces sanyensis PBLC04, inhibited anti-Acanthamoeba spp., an agent affecting “millions of people worldwide”, by a mechanism that resulted in “chromatin condensation”, as well as, “affecting membrane permeability and causing mitochondrial damage” [52]. Casertano and colleagues investigated the novel alkaloid polyaurine A (41), isolated from the Indonesian marine ascidian Polycarpa aurata, which while not cytotoxic to mammalian cells, affected blood-dwelling Schistosoma mansoni parasite egg-production, observed as being “smaller, deformed, and/or fragmented”[53].

Tuberculosis, is a disease caused by Mycobacterium tuberculosis in both human and animals, and as noted in the WHO’s website (https://www.who.int/news-room/fact-sheets/detail/tuberculosis), remains a global health challenge affecting millions of people worldwide, a fact that continues to stimulate ongoing search for novel marine-derived metabolites as potential therapeutic leads. As shown in Table 1 and Figure 1, during 2019-2021, two antituberculosis studies with structurally characterized marine natural products (42,43) reported novel mechanisms of pharmacological action.

Liu and colleagues reported a new bioactive polyketide polypropionate fiscpropionate A (42), isolated from a deep-sea-derived fungus Aspergillus fischeri FS452, that inhibited Mycobacterium. tuberculosis protein tyrosine phosphatase B by a noncompetitive inhibition mechanism [54]. Sudomova and colleagues determined that marine brown algal carotenoid terpenoid fucoxanthin (43), was bacteriostatic to all clinical Mycobacterium tuberculosis strains tested, by potently and competitively binding to “crucial drug targets” mycobacterial cell wall biosynthesis enzymes UDP-galactopyranose mutase and arylamine-N-acetyltransferase, thus demonstrating “great therapeutic value for the treatment of tuberculosis” [55].

2.4. Antiviral Activity

As shown in Table 1 and Figure 1, during 2019-2021, 3 antiviral studies with structurally characterized marine chemicals (44-49), isolated from bacteria, fungi, and dinoflagellates reported novel mechanisms of pharmacological action targeting zika virus, hepatitis C virus, Venezuelan and Eastern equine encephalitis viruses, and human immunodeficiency virus type 1 (HIV-1).

Liu and colleagues reported a new phenylspirodrimane-type dimer alkaloid chartarlactam Q (44), isolated from the fermentation broth of a marine sponge-derived fungus Stachybotrys chartarum WGC-25 C-6, that inhibited Zika virus African-lineage MR766 strain by affecting the in vitro accumulation of viral proteins NS5 and E “in a dose-dependent manner” [56]. Li and colleagues described two novel sesquiterpene-based analogues harzianoic acids A and B (45, 46), discovered in the marine sponge-associated fungus Trichoderma harzianum, that inhibited hepatitis C virus (HCV) life cycle in vitro by binding to both the HCV viral envelope E1/E2 glycoproteins as well as the host cells key protein CD81, thus suggesting “potential for development as HCV inhibitors” [57]. Lin and colleagues characterized the polyketide homoseongomycin (47), found in the marine actinomycete bacterium K3-1, that potently inhibited Venezuelan and Eastern equine encephalitis viruses, by affecting both the early and late stages (assembly and budding) of the viral life cycle, with concomitant low toxicity [58]. Tan and colleagues determined that a natural xanthone dimer polyketide penicillixanthone A (48), isolated from a marine jellyfish-derived fungus Aspergillus fumigates, potently inhibited HIV-1 by binding to white blood cell membrane receptors C-C chemokine receptor type 5 (CCR5) and C-C chemokine receptor type 4 (CCR4), thus suggesting that this new type of CCR5/CXCR4 dual-coreceptor antagonist has potential “ for the development of anti-HIV therapeutics”[59]. Izumida and colleages identified the spirocyclic imine polyketide portimine (49), purified from the benthic marine dinoflagellate Vulcanodinium rugosum, that exhibited significant inhibition of HIV-1 replication at the nM range, by targeting both the HIV-1 Gag or Pol protein as well as reverse transcriptase directly, and thus was proposed as “a potent lead compound for development of novel anti-HIV-1 drugs” [60].

3. Marine Compounds with Antidiabetic and Anti-Inflammatory Activity, and Affecting the Immune and Nervous System

Table 2 presents the 2019-2021 mechanism of action studies with structurally characterized marine compounds (50-124) shown in Figure 2, that demonstrated antidiabetic or anti-inflammatory activity as well as affected the immune or nervous system.

3.1. Antidiabetic Activity

Diabetes is a disease that is characterized by high glucose blood levels that may lead to cardiovascular disease, as well as, kidney and nerve damage (https://www.niddk.nih.gov/health-information/diabetes). As shown in Table 2, and Figure 2, during 2019-2021, studies with 8 structurally characterized marine natural products (43, 50-56) isolated from fungi, algae and mangrove, reported novel antidiabetic mechanism of pharmacological action targeting α-amylase and α-glucosidase, insulin signaling pathways, oxidative stress, glucose transporter 4, and tyrosine phosphatase 1B.

Das and colleagues contributed the limonoid terpenoid xyloccensin-1 (50), discovered in the mangrove Xylocarpus granatum, that demonstrated significant antidiabetic activity resulting from potent in vitro inhibition of α-amylase and α-glucosidase, observations confirmed with α-glucosidase enzyme molecular docking binding studies [61]. Luo and colleagues described a synthetic derivative of shikimate bromophenol CYC27 (51), derived from the marine red alga Rhodomela confervoides, which induced hypoglycemia in diabetic mice by increased phosphorylation of insulin receptors, enhancement of insulin signaling pathways and “most regulated phosphoproteins (were) related to RNA splicing, mRNA processing and RNA processing” [62]. Zaharudin and colleagues determined that the terpene fucoxanthin (43), found in the marine brown edible alga Undaria pinnatifida, strongly inhibited yeast α-glucosidase enzyme with mixed-type inhibition kinetics, commenting that “a compound that inhibits yeast α-glucosidase activity will not necessary inhibit mammalian α-glucosidase activity” [63]. Interestingly, Arthiya and colleages demonstrated that fucoxanthin (43), isolated from the marine microalga P. tricornutum, inhibited rat intestinal α-glucosidase enzyme by noncompetitive inhibition [64]. Hudlikar and colleagues evaluated the protective effect of fucoxanthin (43) on high glucose-induced oxidative stress in mouse kidney mesangial cells in vitro, observing that fucoxanthin modified epigenomic and transcriptomic biomarkers thus protecting mesangial cells “from high glucose-induced oxidative stress and damage”[65]. Chakraborty and Antony identified the terpenoid abeo-oleanene (52), purified from the intertidal marine red alga Gracilaria salicornia, and assessed potent in vitro antioxidant and antidiabetic potential with dual inhibition of starch digestive enzymes α-amylase and α-glucosidase, further confirmed by in silico molecular modelling studies, thus proposing this compound might “ constitute prospective anti-hyperglycemic pharmaceutical candidate” [66]. Yang and colleagues investigated the polyketide ishophloroglucin A (53), uncovered in the marine brown edible seaweed Ishige okamurae, demonstrating it affected glucose homeostasis in pancreas and muscle of high fat diet-fed (HFD) mice by targeting the glucose transporter 4 in the muscles, thus considering the compound a “a functional food for the prevention of diabetes” [67]. Paudel and colleagues reported the anti-diabetic potential of a shikimate bis-(2,3,6-tribromo-4,5-dihydroxybenzylmethyl ether) (54), discovered in the marine alga Symphyocladia latiuscula, and determined by both enzyme kinetics and in silico molecular modeling potent tyrosine phosphatase 1B and α-glucosidase inhibition, as well as, enhancement of both insulin sensitivity and glucose uptake, thus (54) “may represent a novel class of anti-diabetic drugs” [68]. Seong and colleagues showed that the fatty acid (Z)-hexadec-12-enoic acid (55), derived from the edible marine brown seaweed Hizikia fusiformis, by detailed enzyme kinetics and molecular docking studies was a potent tyrosine phosphatase 1B and α-glucosidase inhibitor [69]. Lopez and colleagues characterized the fatty acid tripalmitin (56), found in a mangrove-associated fungus Zasmidium sp. strain EM5-10, as a mixed inhibitor of α-glucosidase as determined by enzyme kinetic studies, with potential to bind the human intestinal α-glucosidase, and “the first report on α-glucosidase inhibitory activity of triglycerides” [70]

3.2. Anti-Inflammatory Activity

As shown in Table 2 and Figure 2, during 2019-2021, studies with 28 structurally characterized marine natural products (43, 57-83) isolated from bacteria, fungi, sponges, sea hare, dinoflagellates, diatoms, algae and mangrove reported novel anti-inflammatory pharmacological mechanisms of action that targeted NF-kB activation, pro-inflammatory cytokine production, and reactive oxygen species generation.

Several marine-derived natural products investigated mechanistically during 2019-2021 demonstrated significant anti-inflammatory functions by targeting signal transduction pathways, leading to NF-kB activation and pro-inflammatory cytokine production. The anti-inflammatory activity of the terpenoid xanthophyll fucoxanthin (43) was reported in several papers: Su and colleagues reported that the terpenoid fucoxanthin (43), discovered in the marine diatom Conticribra weissflogii ND-8, prophylactically attenuated LPS-induced sepsis in a whole animal mouse model, by blocking NF-kB activation and the production of pro-inflammatory cytokines [81]. Zheng and colleagues showed that edible brown seaweed-derived terpenoid fucoxanthin (43), demonstrated protective effects in an in vivo model of alcohol-induced liver damage by activation of the Nrf2-sginaling pathway and decreasing NF-kB activation [82]. Ha and colleagues further characterized the terpenoid fucoxanthin (43), and observed that in osteoclast-like RAW264.7 cells in vitro, fucoxanthin increased Nrf2 activation, decreased the expression of osteoclast-specific markers, as well as “osteoclast differentiation and bone resorption ability” [83]. Li and colleagues determined that the terpenoid fucoxanthin (43), protected against LPS-induced murine lung inflammation in vivo, by decreasing cellular infiltration and both lung tissue COX-2 and iNOS expression. Interestingly, molecular docking simulations demonstrated that fucoxanthin (43) blocked LPS-induced signaling by binding to the TLR4 pocket that is required for LPS stimulation [84]. Together, these findings indicate that fucoxanthin (43) from both marine diatoms and seaweed has the potential to attenuate inflammation in vitro and in vivo.

Wen and colleagues identified the polyketide phenolic aglycone (58), derived from the marine fungus Aspergillus sp., and showed that it decreased LPS-induced NO production and NF-kB-regulated cytokines such as IL-1β and IL-6 [72]. Keeler and colleagues investigated the polyketide brevenal (59), isolated from the marine dinoflagellate Karenia brevis, showing that in the context of lung inflammation, it blocked NF-kB activation and development of fully activated macrophages in vitro, which are critical players that promote lung inflammation [73]. Alvariño and colleagues reported the polyketide caniferolide A (60), found in the marine actinomycete Streptomyces caniferus, which blocked NF-kB, p38, JNK, and MAPK activation with a concomitant increase in NRf2 that promoted the survival of BV2 microglial cells, suggesting that (60) may target “many pathological markers of Alzheimer’s disease” [74]. Ding and colleagues showed that the polyketide/shikimate curdepsidone C (63), obtained from the marine fungus Curvularia sp. IFB-Z10, blocked bacterial-induced THP-1 cell IL-1β production as well as activation of MAPK signaling pathways, presumably through direct interactions with the TLR1/2 receptor [76]. Ku and colleagues characterized the alkaloid collismycin C (64), isolated from the marine red alga-associated Streptomyces sp. strain MC025, and determined that in vitro it decreased NF-kB phosphorylation of p38 and TNF-α production, as well as was protective in a PolyP model of murine sepsis in mice [77]. Oh and colleagues contributed the polyketide dieckol (65), purified from brown seaweed Ecklonia cava, and showed that it attenuated the development of nonalcoholic fatty liver disease by decreasing NLRP3 inflammasome formation and pyroptosis in a mouse high-fat diet model [78]. Kim and colleagues evaluated the terpenoid epiloliolide (67), uncovered in the marine brown alga Sargassum horneri, on human periodontal ligament cells in vitro in the presence of P. gingivalis lipopolysaccharide (LPS), and observed a decreased production of inflammatory mediators TNF-α, IL-6, IL-1β, and promotion of cell growth and proliferation via “regulation of PKA/CREB signaling” [80]. Li and colleagues determined that the terpenoid fucoxanthinol (68), discovered in the marine diatom Nitschia laevis, was able to block the LPS-induced inflammatory response by microglia in vitro by increasing Nrf2 with a subsequent loss of the expression iNOS, COX-2, and pro-inflammatory cytokines TNF-α and IL-6, and PGE-2 [85]. Jan and colleagues identified the terpenoid hirsutanol A (69), derived from the marine red alga-derived fungus Chondrostereum sp. NTOU4196, that attenuated LPS-induced lung inflammation in vivo and behavioral changes in a mouse endotoxemia model by blocking LPS-induction of STAT3 and MMP-9 [86]. Chen and colleagues explored the polyketide 2-epi-jaspine B (70) analog, isolated from the marine sponges Pachastrissa sp. and Jaspis. sp., and in an in vivo rat model of complete Freund’s adjuvant rheumatoid arthritis (RA), showed it acted as a SphK1 inhibitor in vitro and significantly improved RA symptoms measured by decreased pro-inflammatory cytokines TNF-α, IL-6, IL-1β, swelling volume, and arthritis score [87]. Daskalaki and colleagues investigated the diterpenes (71,72), obtained from the red seaweed Laurencia glandulifera, that demonstrated the ability to decrease the production of pro-inflammatory mediators in vitro and suppress the development of dextran sulfate sodium-induced murine colitis in vivo [88]. Kim and colleagues reported the alkaloid O-demethylrenierone (75), purified from the marine sponge Haliclona sp., suppressed NF-kB nuclear translocation and subsequent expression of NO synthase, cyclooxygenase-2, with a subsequent increase in Nrf2 using human epithelial cell and monocyte cell lines [91]. Lee and colleagues showed that the terpenoid deacetylphylloketal (77), a novel derivative uncovered in the marine sponge Phyllospongia sp., inhibited LPS-induced NO, PGE₂, and pro-inflammatory cytokines TNF-α, IL-6, IL-1β production in human epithelial cells and PMA-differentiated macrophages by blocking NF-kB nuclear translocation and increasing HO-1 levels [93]. Kim and colleagues characterized the grasshopper terpenoid ketone (79), discovered in the marine brown alga Sargassum fulvellum, that attenuated LPS-induced nitric oxide production and pro-inflammatory cytokines IL-6, TNF-α and IL-1β by blocking multiple signaling pathways, including NF-kB [95]. Abdelfattah and colleagues contributed the alkaloids butylcycloprodigiosin and undecylprodigiosin (80, 81), derived from the red sea sponge Spheciospongia mastoidea, which attenuated gastric inflammation and gastric mucosal apoptosis in vivo by decreasing both NF-kB and iNOS expression and while increasing HO-1 expression, suggesting that prodigiosins “exerted gastroprotective effects” [96]. Hwang and colleagues described the bis(indole) alkaloid topsentin (82), found in the marine sponge Spongosorites genitrix, observing that it protected a human epidermal keratinocyte cell line in vitro from ultraviolet-induced inflammation, by suppressing AP-1 and MAPK signaling pathways [97].

Other marine-derived natural products investigated mechanistically during 2019-2021 demonstrated significant anti-inflammatory functions by targeting signaling pathways involved in reactive oxygen radicals, i.e., superoxide and nitric oxide generation: Pereira and colleagues determined that the steroidal endoperoxide terpenoid 5α,8α-epidioxycholest-6-en-3β-ol (57), isolated from the sea hare Aplysia depilans, blocked the induction of nitric oxide (NO) levels by decreasing the expression of iNOS and other pro-inflammatory markers [71]. Van Thanh and colleagues evaluated two novel terpenoids (61, 62), purified from the leaves of the Vietnamese mangrove Calophyllum inophyllum, and observed that they blocked LPS-induced NO production and the production of pro-inflammatory cytokines by blocking the induction of iNOS and NF-kB activation, respectively [75]. Hu and colleagues identified the meroterpenoid dysiarenone (66), isolated from the marine sponge Dysidea arenaria, that blocked LPS-induction of inflammatory cytokines and other mediators, such as ROS by increasing the production of HO-1 via a Nrf2-dependent mechanism [79]. Herath and colleagues investigated the terpenoid mojabanchromanol (73), a chromanol uncovered in the marine brown alga Sargassum horneri, that decreased ROS-mediated responses and TLR2/4/7 activation in a type II alveolar epithelial cell line, suggesting that mojobanchromanol may become a potential treatment against airway inflammation induced by particulate matter [89]. Ha and colleagues reported the polyketide neuchromenin (74), discovered in the Antarctic marine-derived fungal strain Penicillium glabrum SF-7123, that in an in vitro model of microglial and macrophage activation demonstrated suppression of LPS-induced NO-synthase (iNOS) and cyclooxygenase-2 (COX-2) expression and downregulation of NF-kB and p38 pathways [90]. Chu and colleagues showed that the polyketide penicitrinone A (76), derived from the marine fungus Penicillium citrinum, decreased neutrophil activation and agonist-induced superoxide generation putatively “through Bcl-2, Bax and caspase 3 signaling cascades” [92]. Liu and colleagues contributed the polyketide sclerketide C (78), found in the marine coral-derived fungus Penicillium sclerotiorin, that inhibited NO production in LPS-induced macrophages, by binding to the active site of the iNOS enzyme and blocking its activity [94]. Kim and colleagues described the polyketide/terpenoid tuberatolide B (83), isolated from the marine brown alga Sargassum macrocarpum, that had both in vitro anti-inflammatory properties by attenuating LPS-induced NF-kB and MAPK phosphorylation, while in vivo, using a zebrafish model, (83) blocked the induction iNOS and subsequent NO production [98]. Taken together, these studies demonstrate the importance and potential of marine-derived compounds as therapeutic options in the treatment of inflammatory diseases.

3.3. Marine Compounds with Activity on the Immune System

As shown in Table 2 and Figure 2, during 2019-2021, studies with 9 structurally characterized marine natural products (65, 84-91) isolated from fungi, sea anemones, soft corals, mollusks, sea urchins, diatoms, algae reported novel immune system pharmacological mechanisms of action that indicate that marine-derived compounds have the ability to influence the immune system both in vitro and in vivo and provide evidence that these compounds could have significant therapeutic impact upon further investigation.

As shown in Table 2 and Figure 2, the ability of marine-derived compounds to modulate dendritic cell function varied depending on the source of the compound. Two compounds had anti-inflammatory effects both in vitro and in vivo. Firstly, Yin and colleagues, extended the pharmacology of the carotenoid pigment terpenoid astaxanthin (84), found in “microalgae and seafood”, and demonstrated it altered murine dendritic cell activation and reduced the production of pro-inflammatory cytokines TNF-α, IL-6, and IL-10 in vitro by increasing HO-1 and Nrf2 levels [99]. Secondly, Lin and colleagues reported that the cembranoid terpenoid crassolide (85), isolated from the soft coral Sarcophyton crassocaule, also negatively impacted LPS-induced activation of dendritic cells and downstream T cell responses in vitro, and these effects therapeutically attenuated the development of autoantibodies and associated thrombosis in vivo [100]. In contrast, Laborde and colleagues showed that the large pore-forming proteins sticholysins I and II, purified from the marine anemone Stichodactyla helianthus, enhanced bone marrow-derived dendritic cell maturation through a TLR4-specific manner that resulted in enhanced activation of CD8+ cytotoxic T cells [109]. Finally, Manzo and colleagues characterized an “unprecedented” polyketide phosphatidylmonogalactosyldiacylglycerol pool (91), uncovered in the marine diatom Thalassiosira weissflogii, which was also immunostimulatory to dendritic cells by acting directly as a TLR4 agonist that increased the ability of these cells to activate CD8+ T cells [110]. Taken together, the immunomodulatory effects of these molecules deserve further insight and investigation.

During this time period, three studies investigated the effect on immune function of the dark polyketide echinochrome A (87), isolated from sea urchins: Park and colleagues determined that echinochrome A (87) promoted the expansion of CD34+ hematopoietic precursors from the blood by decreasing p38-MAPK/JNK phosphorylation and ROS generation and subsequently enhancing activation of the p110δ/PI3K/Akt pathway in vitro [103]. Oh and colleagues reported that echinochrome A (87) attenuated experimental colitis in a mouse model of inflammatory bowel disease through the generation of regulatory T cells in vivo, “that modulate the inflammatory response and immune homeostasis” [104]. Finally, Park and colleagues described in another inflammatory autoimmune disease, that echinochrome A (87) alleviated bleomycin-induced scleroderma in vivo by decreasing the number of activated myofibroblasts and the number of pro-inflammatory macrophages and cytokine levels [105].

Additional studies during 2019-2021 demonstrated a significant impact of marine natural products on immune cell function both in vitro and in vivo. Li and colleagues contributed a novel pentadecapeptide (86), isolated from a marine cultured bivalve mollusk Cyclina sinensis, which showed enhanced activation of murine macrophage RAW 246.7 cells in vitro by increasing NF-kB and NLRP3, resulting in elevated release of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β [101]. Yang and colleagues identified a terpenoid cembranoid (90), purified from the South China sea soft coral Sinularia scabra, which attenuated the mitogenic responses of both T cells and B cells in vitro, suggesting that upon further study could become a “new class of potential immunosuppressive agents” [108]. Oh and colleagues investigated purified polyketide dieckol (65), obtained from marine brown alga Ecklonia cava, in an in vivo rat model of spontaneous hypertension, and observed that it attenuated endothelial dysfunction in both the gut and aorta by modulating the Treg/Th17 axis towards Tregs that are immunoprotective [102]. Han and colleagues studied the polyketide eckol (88), discovered in the marine brown alga Ecklonia cava, noting that it attenuated IgE-mediated mast cell activation and cytokine production in vitro and IgE-mediated allergic murine ear swelling in vivo [106]. Tai and colleagues, reported for the first time that the polyketide/terpenoid phomaketide A (89), derived from the marine fungus Phoma sp. NTOU4195, decreased lymphatic endothelial cell lymphangiogenesis in vitro by decreasing VEGFR-3 phosphorylation and eNOS. Additional studies demonstrated the in vivo significance of these effects in that (89) blocked the development of lymphatic vessels and tumor growth in a mouse tumor model, suggesting “this natural product could potentially treat cancer metastasis” [107].

3.4. Marine Compounds Affecting the Nervous System

As shown in Table 2 and Figure 2, in 2019-2021 studies with 38 structurally characterized marine natural compounds (43, 54, 84, 87, 88, 92-124) isolated from bacteria, fungi, sponges, soft corals, sea anemones, worms, cone snails, shrimp, sea urchins, sea cucumbers, dinoflagellates and algae reported novel nervous system mechanisms of action pharmacology that affected ion channels and membrane potential, increasing the antioxidant response pathway reducing reactive oxygen species (ROS), increasing survival factors and decreasing apoptotic factors.

Four compounds (92-95) were shown to reduce seizurogenic activity. Wang and colleagues reported the terpenoid alternarin A (92), discovered in the South China Sea soft coral Lobophytum crissum-derived fungus Alternaria sp., suppressed seizurogenic 4-aminopyridine (4-AP) induced hyperactive spontaneous calcium oscillations in murine neocortical cultures [111]. Andrud and colleagues showed that the alkaloid anabaseine (93), derived from the Pacific Ocean marine worm Paranemertes peregina, demonstrated in vitro binding to α4β2 and α7 nicotinic acetylcholine receptors (nAChRs) that are commonly expressed in the brain, and caused depolarization in tsA201 cells expressing the human α4β2 nAChR [112]. Copmans and colleagues studied the alkaloids TMC-120A (94) and TMC-120B (95), found in the marine fungus Aspergillus insuetus, ameliorated epileptiform discharges in a pentylenetetrazole (PTZ)-induced seizure model in zebrafish and reduced seizure duration in a mouse psychomotor seizure model induced by corneal electrical stimulation [113].

Four compounds (84, 96-98) were observed to be neuroprotective and inform the development of novel Alzheimer’s Disease (AD) therapeutics. Yang and colleagues extended the pharmacology of the fatty acids arachidonic acid (Ara, 96) and eicosatrienoic acid (EtRA, 97), purified from the Pacific Ocean edible seaweed Hizika fusiforme, by showing them to be noncompetitive inhibitors of acetylcholine esterase (AChE) with a modified Ellman’s method, and also displayed antioxidant properties and anti-neuroinflammatory properties. Thus, these compounds indicate putative anti-AD properties by reducing acetylcholine breakdown, which is diminished in AD, as well as the antioxidant properties potentially reducing amyloid β (Aβ) and tau tangles which are caused by oxidative damage [114]. Han and colleagues contributed findings with the terpenoid astaxanthin (84), present in the red-orange pigment Asteroidea, salmon, trout, and the shells of crustaceans, that protected against memory impairment in a murine model of AD via binding to signal transducer and activator of transcription 3 (STAT3) and inhibiting phosphorylation and activation, resulting in reduced Aβ levels and β-secretase (BACE1) activity [115]. Taksima and colleagues determined that the terpenoid astaxanthin (84) decreased reactive oxygen species (ROS) that may contribute to oxidative damage and protein aggregation and decreased Aβ levels, thus improving cognitive dysfunction in a rat model of AD assessed using the Morris water maze, novel object recognition, and novel object location tests [116]. Lee and Jun described the polyketide 8,8’-bieckol (98), discovered in the edible brown seaweed Ecklonia cava, was a competitive inhibitor of AChE and a noncompetitive inhibitor BACE1, and thus should enhance cholinergic activity as well as decreasing Aβ protein aggregation [117].

Three compounds (99-101) were shown to affect ion channel flux. Konoki and colleagues investigated the polyketide brevetoxin (99), a voltage-gated sodium channel (VGSC) activator produced by the marine dinoflagellate Karenia brevis, showing that it binds to the VGSC at neurotoxin receptor 5 in Na_v1.2 (brain isoform) and Na_v1.4 (skeletal muscle isoform), shifting the voltage-dependence more negative and slowing inactivation in vitro using TsA-201 cells [118]. Jin and colleagues identified the novel peptides conorfamides As1a (100) and As2a (101), derived from the Mexican cone snail Conus austini, that inhibited neuronal α7 nAChR, resulting in an inhibition of calcium ion flow into the intracellular space in SH-SY5Y human neuroblastoma cell line [119].

Four compounds (102-104) demonstrated effects on pain perception. Niu and colleagues reported that a novel terpenoid conosteroid (102), found in the cone snail Conus geographus, was a negative allosteric modulator (NAM) of type-a γ-aminobutyric acid receptor (GABA_AR), resulting in murine pain inhibition using the hot plate model, but did not display anesthetic properties via the von Frey test, or effects on inflammatory pain with the formalin test [120]. Guo and colleagues showed that the peptide α-conotoxin Lv1F (103), isolated from the sea snail Conus lividus, competitively bound and inhibited α3β2 nAChR, resulting in a voltage-dependent blockade in Xenopus oocytes expressing rat α3β2 nAChR, which are normally expressed in the dorsal-root ganglion (DRG) of the spinal cord and are involved in pain and sensory perception [121,122]. Similarly, Qiang and colleagues studied the α-conotoxin Lv1d, from the same species, observing that it showed analgesic effects in both the murine hotplate test and the formalin test, suggesting it was also effective for inflammatory pain [121,122]. Liu and colleagues communicated that a helical conantokin peptide Con-T[M8Q] (104), purified from the genus Conus, was an antagonist of the GluN2B subunit of the N-methyl-D-aspartate receptor (NMDAR), which showed inhibition of physiological and psychological morphine dependence and attenuated withdrawal symptoms, as examined by naloxone-induced jumping and conditioned place preference tests in a murine model of morphine addiction [123].

Two compounds (105, 87) showed neuroprotective effects post-stroke. Wu and colleagues described that the terpenoid dictyol C (105), uncovered in the marine brown alga Dictyota sp., demonstrated neuroprotection of cerebral ischemia-reperfusion injury (CIRI) when given to rats two hours prior to middle cerebral artery occlusion (MCAO). Moreover, analysis in PC12 cells suggested that cryprotection resulted form an increase in nuclear factor erythroid 2–related factor 2 (Nrf2)/antioxidant response element (ARE) signaling pathway as examined with H₂O₂-induced oxidative damage [124]. Kim and colleagues determined that polyketide echinochrome A (87), discovered in sea urchins, mitigated cerebral ischemic injury in rat MCAO when given after reperfusion as demonstrated in improved performance in the forced swim test as well as in histological preparations showing reduced brain infarct volume and reduced edema. Further analyses demonstrated increased cell growth and survival factors brain-derived neurotrophic factor (BDNF), B-cell leukemia/lymphoma 2 protein (Bcl-2), phospho-extracellular signal-regulated kinase (pERK), and phospho-protein kinase B (pAKT) expression and decreased pro-apoptotic factors caspase-3 and Bcl2 associated X (BAX) [125].

Twelve compounds (43, 54, 88, 106-114) showed promising effects for various neurodegenerative disorders. Paudel and colleagues evaluated the polyketide eckol (88), derived from the brown alga Ecklonia stolonifera, as an agonist of dopamine receptor 3 (D3) and dopamine receptor 4 (D4), that reduced Gα_i/o-mediated G-protein coupled receptor (GPCR) signaling resulting reduction in adenylyl cyclase in chinese hamster ovary (CHO) cells stably transfected and expressing human dopamine receptors [126]. Silva and colleagues identified the terpenoid eleganolone (106), found in the brown seaweed Bifurcaria bifurcata, as an inhibitor of 6-hydroxydopamine (6-OHDA) toxicity in SH-SY5Y cells, by increasing catalase activity which protects from ROS damage, decreasing ROS levels, and reducing depolarization of mitochondrial membrane potential. Additionally, it decreased pro-apoptotic factor caspase 3, and increased cytoplasmic localization of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a key regulator of apoptotic/inflammatory events [127]. Chalorak and colleagues reported that the terpenoid frondoside A (107), isolated from the sea cucumber Cucumaria frondosa, inhibited dopaminergic neuronal degeneration via an increase in the free-radical scavenging gene superoxide dismutase (SOD-3), an increase in genes associated with the protein degradation pathway, a reduction of the α-synuclein accumulation, and a decrease in apoptotic genes in a Caenorhabditis elegans model of PD [128]. Gan and colleagues showed that the terpenoid fucosterol (108), purified from brown alga, reduced intracellular levels of Aβ via a decrease in amyloid precursor protein mRNA and increased the mRNA levels anti-apoptotic factor neuroglobin (Ngb) [129]. Additionally, Hannan and colleagues studied fucosterol (108) with in silico analysis to identify binding affinity to tropomyosin receptor kinase B (TrkB), which is involved in neuronal growth and survival and BACE1, the enzyme involved in the production of Aβ in the brain [130]. Chen and colleagues contributed observations that the terpenoid fucoxanthin (43), extracted from a brown seaweed, reduced corneal denervation in a rat UVB-induced photokeratitis model by increasing Nrf2 expression and reduced intracellular ROS, as well as decreased symptoms of inflammatory pain (eye wipe behavior) and decreased transient receptor potential cation channel subfamily V member 1 (TRVP1) signaling that contributes to hyperalgesia [131]. Moreover, Wu and colleagues showed that fucoxanthin (43) binds to Kelch-like ECH-associated protein 1 (Keap1), a Nrf2 inhibitor and sensor of oxidative stress, at the same binding site as Nrf2 thus enhancing Nrf2/ARE signaling in PC12 cells [132]. Kalina and colleagues described the APETx-like peptides Hcr 1b-2, Hcr 1b-3, and Hcr 1b-4 (109-111), discovered in the sea anemone Heteractis crispa, that inhibited rat acid-sensing ion channel (rASIC) 1a that is highly expressed in the central nervous system. Rat ASIC1a was expressed in Xenopus laevis oocytes and Hcr 1b-3 and -4 (109-110) reversibly inhibited the channel in a dose-dependent manner, indicating therapeutic potential for pathological conditions associated with prolonged acidosis including PD, multiple sclerosis, epilepsy, and ischemic stroke [133]. Tangrodchanapong and colleagues determined that the polyketide 2-butoxytetrahydrofuran (112), derived from the sea cucumber Holothuria scabra, inhibited Aβ-induced paralysis in C. elegans by suppression of Aβ oligomer formation and deposition via upregulation of autophagy genes important for clearing misfolded and abnormally aggregated proteins and a decrease in ROS levels that contribute to oxidative damage and protein degradation [134]. Fan and colleagues explored a novel terpenoid/shikimate neo-debromoaplysiatoxins E (113) and F (114), found in the marine cyanobacterium Lyngbya sp., that exhibited potent blocking activity against potassium channel 1.5 (Kv1.5), an ion channel expressed in neurons and smooth muscle cells and is important for cellular repolarization [135].

Three compounds (115-117) were reported to show neurotoxic effects. Jiao and colleagues reported that exposure to the polyketide okadaic acid (115), a marine shellfish toxin, resulted in neural tube defects in chicken (Gallus gallus) embryos via inhibition of the Nrf2 signaling pathway and increased ROS levels, as well as increasing cellular proliferation, decreasing neuronal differentiation, and decreasing pro-apoptotic factor caspase-3 [136]. Benoit and colleagues showed that the polyketide pinnatoxins (PnTXs) A (116) and G (117), isolated from the marine dinoflagellate Vulcanodinium rugosum, blocked synaptic transmission at the neuromuscular junction by competitive antagonism of muscle-type nAChR in mice, consistent with death via muscle paralysis and respiratory depression in vivo [137].

Two compounds (118-119) were shown to modulate neurotransmitter signaling. Seong and colleagues studied the polyketide phlorofucofuroeckol-A (PFF-A, 118), obtained from the brown alga Ecklonia stolonifera, noting that it was a noncompetitive inhibitor of human monoamine oxidase (MAO) -A and -B which prevented the breakdown of dopamine and other neurotransmitters. Additionally, PFF-A (118) was a D3 and D4 receptor agonist which stimulated Ga_i/o-mediated-GPCR signaling resulting in inhibition of adenylyl cyclase, as well as an antagonist to D1, serotonin 1a receptor (5HT1A), and neurokinin-1 (NK₁) indicating multifactorial effects on the dopaminergic and serotonergic systems that may be important for treating depression and/or PD [138]. Lee and colleagues characterized the terpenoid sargachromanol (119) compounds, purified from the brown alga Sargassum siliquastrum, potently inhibited AChE via a mixed reversible inhibition, suggesting that it binds to both an active site and a non-catalytic site of AChE, suggesting potential therapeutic development for the treatment of AD [139].

Two compounds (120-121) demonstrated important effects on reducing misfolded proteins. Chen and colleagues contributed the alkaloid santacruzamate A (120), discovered in a marine cyanobacterium, that increased KDEL, a receptor known for regulation the endoplasmic reticulum retrieval system important for regulating misfolded proteins both in vitro in PC12 and SH-SY5Y cells and in vivo in mouse brain tissue. It also increased mitochondrial space assembly protein 40 (Mia40) an augmenter of liver regeneration (ALR), potentially suppressing mitochondrial fission and apoptosis pathways. Notably, it improved behavioral results in a mouse model of AD, indicating that KDEL receptor played a role in improved memory impairment [140]. Jiang and colleagues described the novel terpenoid cembranoid (121), derived from the soft coral Sinularia sp., that bound to the c-terminal of Aβ monomers and inhibited Aβ aggregation, indicating a new source for novel therapeutics for AD [141].

Four compounds (54, 122-124) demonstrated neuroprotective effects. Paudel and colleagues determined that the shikimate bromophenol (54), found in the red alga Symphyocladia latiuscula was a human dopamine D4 receptor agonist, which may provide a novel therapeutic for treating cognitive deficits associated with schizophrenia. It also demonstrated lesser human dopamine D3 receptor agonist activity, potentially as a novel therapeutic for PD management [142]. [143]. Paudel and colleagues additionally evaluated the bromophenol (54), as a mixed-type inhibitor of AChE, a competitive inhibitor of butyrylcholinesterase (BChE), as well as noncompetitive inhibition of BACE1 in vitro, indicating therapeutic potential for AD management [144]. Liu and colleagues identified the sugar glucuronomannan GM2 (122), isolated from the brown seaweed Saccharina japonica, that improved cell viability by inhibiting lactate dehydrogenase (LDH) release, reduced ROS levels in PC12 cells, improved the ratio of anti-apoptotic Bcl-2 and pro-apoptotic Bax, and reduced caspases 3 and 9, attenuating apoptosis. Feng and colleagues investigated the terpenoid stellettin B (123), purified from the marine sponge Jaspis stellifera, that increased Nrf2/ARE signaling, decreased ROS-positive cells, and decreased caspase-3 signaling in SH-SY5Y cells. Additionally, reversed zebrafish locomotion deficits in a 6-OHDA-induced model of PD, suggesting therapeutic potential [145]. Sheng and colleagues demonstrated that the terpenoid 5α-androst-3β, 5α, 6β-triol (124), discovered in the soft coral Nepthea brassica, demonstrated protection of retinal ganglion cells in a mouse model of retinal ischemic injury via negative regulation of Keap1 resulting in an upregulation of Nrf-2/ARE signaling [146].

4. Marine Compounds with Miscellaneous Mechanisms of Action

As reported in the 2019-2021 peer-reviewed literature, Table 3 presents 55 marine compounds (43, 65, 88, 118, 125-170) with miscellaneous mechanisms of action shown to affect multiple cellular and molecular targets, but with no currently assigned pharmacological category, and that have been isolated from marine bacteria, cyanobacteria, seahorses, sharks, crinoids, octopuses, mussels, oysters, sponges, fungi, and algae, with their corresponding structures shown in Figure 3: marine cyanobacterium Okeania sp.-derived linear peptide amantamide (125) that selectively stimulated C-X-C chemokine receptor type 7 and increased extracellular signal-regulated kinase 1 phosphorylation [147]; marine octopus Amphioctopus neglectus-derived macrocyclic lactone (126) with radical-scavenging capacity and anti-hypertensive activity against angiotensin converting enzyme [148]; marine edible shellfish Arca subcrenata-derived peptides D2-G1S-1 and G2-G1S-2 (127, 128) that demonstrated potent radical scavenging activities and extended worm Caenorhabditis elegans lifespan, thus suggesting “applications in functional cosmetics additives” [149]; marine fugal strain Aspergillus sp. F452-derived polyketide aspermytin A (129) that inhibited Staphylococcus aureus-derived sortase A by a reversible mixed inhibitor mechanism that affected “bacterial adherence to fibronectin-coated surfaces” [150]; marine sponge-derived terpenoid avarol (130) that reduced synthesis of cholesteryl ester by potent inhibition of sterol O-acyltransferase and concomitant reduction in lipid droplet accumulation in CHO-K1 cells [151]; marine brown alga Ecklonia cava-derived polyketide pyrogallol-phloroglucinol-6,6-bieckol (131) that decreased murine hypertension resulting from a high-fat diet by affecting aortic endothelial to mesenchymal transition as well as LOX-1 and MMP-9 gene expression [152]; marine red algae-derived shikimate 3-bromo-4,5-dihydroxybenzaldehyde (132) that enhanced antioxidant enzyme HO-1 expression and increased Nrf2 expression, phosphorylation and nuclear translocation [153]; marine oyster Crassostrea gigas-derived novel peptide (133) that promoted MC3T3-E1 osteoblast-like cells proliferation by binding to the α5β1 integrin [154]; an additional marine oyster Crassostrea gigas-derived peptide (134) which inhibited thrombin by a competitive inhibition mechanism [155]; marine sponge Dysidea herbacea-derived polyketide diphenyl ether (135) that inhibited bacterial α-_D-galactosidase by irreversibly inactivating the active-site of the enzyme [156]; marine brown alga Ecklonia cava-derived shikimate dieckol (65) that reduced oxidative stress-exposed porcine oocytes by increasing the level of glutathione and antioxidant enzymes [157], and suppressed ultraviolet radiation-induced skin damage in human dermal fibroblasts by increasing collagen synthesis and reducing proinflammatory cytokines and metalloproteinases [158]; marine brown alga Ishige okamurae-derived polyketide diphlorethohydroxycarmalol (DPHC) (136) that dose-dependently reduced high-fat diet-induced obesity in mice by reducing critical adipogenic-specific, lipogenic enzyme expression, and exerted vasodilatory effects via calcium signaling [159,160,161]; marine brown alga Ecklonia stolonifera-derived phlorotannin (137) with potential antioxidant and tyrosinase inhibitory activity [162]; marine alga Ecklonia cava-derived polyketide eckol (88) that reduced ROS generation in particulate matter 2.5-induced skin damage to keratinocytes by inhibiting MAPK signaling [163]; marine fungus Streptomyces nitrosporeus YBH10-5-derived polyketide farnesylquinone (138) observed to have fat-reducing effects by enhancing mitochondrial β-oxidation rate and modifying energy metabolism genes’ transcription [164]; marine brown alga Eisenia bicyclis polyketide fucofuroeckol-A (139) that suppressed melanogenesis in murine B16 melanoma cells by down regulation of tyrosinase-related protein-2 activity suggesting it might be beneficial as a “melanin control drug for hyperpigmentation disorders” [165]; marine brown alga Sargassum wightii-derived terpenoid fucoxanthin (43) that inhibited angiotensin 1-converting enzyme by a non-competitive mechanism and binding to the active site of the enzyme [166], and alleviated oxidative stress in glomerular mesangial cells by stimulating Akt/Sirt1/FoxO3 α signaling [167]; marine fungal strain Aspergillus sp. SF-5929-derived polyketide funalenone (140) that dose-dependently inhibited PTP1B enzyme by a non-competitive mechanism targeting “ a site that is distinct from the catalytic site of PTP1B” [168]; deep-sea-derived actinomycete Streptomyces lusitanus SCSIOLR32 polyketide grincamycin B (142) that targeted isocitrate dehydrogenase 1 and might become a “potential target for hematological malignancies intervention in the future” [169]; mangrove endophytic fungus Tilachlidium sp.-derived novel thiodiketopiperazine alkaloid GQQ-792 (141) shown to be a non-ATP competitive inhibitor of phosphoglycerate kinase 1 [170]; marine edible seahorse Hippocampus abdominalis-derived peptides HGSH and KGPSW (143,144) that protected against H₂O₂-induced oxidative damage in human umbilical vein endothelial cells by activating the nuclear transcription factor-erythroid 2-related factor signaling pathway, suggesting these peptides as a “ promising agent for oxidative stress-related cardiovascular diseases” [171]; marine brown alga Sargassum horneri-derived monoterpene (-)-loliolide (145) that suppressed both lipid accumulation in 3T3-L11 adipocytes and expression of adipogenic and lipogenic proteins, thus might be a “lipid-lowering agent in the management of patients who suffer from obesity” [172]; marine sponge Monanchora pulchra-derived alkaloid monanchomycalin B (146) observed to be a “slow-binding irreversible” inhibitor of α-galactosidase from marine γ-proteobacterium Pseudoalteromonas sp. KMM 701 targeting two alkaloid binding sites on the molecule [173]; marine sponge Clathria frondifera associated fungus Monascus sp. NMK7-derived polyketide monacolin X (147) that suppressed angiogenesis by downregulation of the VEGFR2 signaling pathway [174]; marine sponge Diacarnus erythraeanus-derived norterpene peroxide (-)-muqubilin A (148) found to be a retinoic acid receptor α positive allosteric modulator and retinoic acid signaling enhancer [175]; marine sponge Mycale aff. nullarosette-derived polyketide mycalolide A (149) that inhibited cytokinesis by disruption of F-actin and binucleation induction [176]; marine blue mussel Mytilus edulis-derived dodecapeptide (150) that promoted growth of osteoblasts, bone loss reduction in ovariectomized mice and interacted with integrins 1L5G and 3V14 [177]; tilapia Oreochromis niloticus-derived oligopeptide (151) shown to be protective of angiotensin II-induced hypertensive endothelial injury by affecting Nrf2 and NF-kB signaling pathways [178]; marine fungus Penicillium sp. KFD28-derived indole-terpenoid penerpene A (152) that potently inhibited protein tyrosine phosphatase B by binding to the active site pocket [179]; mangrove endophytic fungus Penicillium janthinellum-derived alkaloid penicisulfuranol A (153) discovered as a novel Hsp90 C-terminus inhibitor at “cysteine residues near amino acid region responsible for dimerization of Hsp90” [180]; marine endophytic fungal strain Pestalotiopsis neglecta SCSIO41403 polyketide pestalotioquinoside C (154) that acted as a putative liver X receptor alpha agonist as demonstrated by the upregulation of downstream gene ABCA1 [181]; marine sponge-derived fungal strain Aspergillus sp. 151304 cyclohexapeptide petrosamide C (155) that dose-dependently inhibited pancreatic lipase by a non-competitive mechanism [182]; marine sponge Phakellia fusca-derived cycloheptapeptide phakefustantin A (156) that inhibited the PI3K/Akt signaling pathway by regulating the transcriptional function of retinoic X receptor-α [183]; marine brown alga Ecklonia cava-derived phlorotannin shikimate 2-phloroeckol (157) that inhibited tyrosinase by a slow-binding competitive inhibition of the active site of the enzyme [184]; marine brown alga Ecklonia cava-derived functional polyphenol polyketide phlorofucofuroeckol A (118) shown to modulate human tracheal fibroblast collagen type 1 protein expression by downregulation of MAPKs and SMAD 2/3 signaling pathways [185], and enhance bone marrow osteoblastogenesis [186]; marine fungus Penicillium polonicum-derived diketopiperazine alkaloid polonimide analog (158) with inhibitory activity against agricultural insect pest Ostrinia furnacalis GH18 chitinase OfChi-h supported by docking studies with the enzyme [187]; marine red alga Polysiphonia morrowii shikimate 5-bromo-3,4-dihydroxybenzaldehyde (132) that inhibited adipogenesis in 3T3-L1 adipocytes by regulation of adipogenic transcription factors as well as activation of the AMP-activated protein kinase pathway [188]; marine fungus Penicillium sp. SF-5497-derived meroterpenoid preaustinoid A6 (159) which inhibited protein tyrosine phosphatase B in a noncompetitive manner [189]; marine red alga Pyropia yezoensis-derived peptide (160) assessed as protective against synthetic glucocorticoid dexamethasone-induced myotube atrophy [190]; crinoid Himerometra magnipinna-derived anthraquinone polyketide rhodoptilometrin (161) that significantly increased wound healing and cell migration as well as increased FAK, fibronectin and type 1 collagen protein and gene expression in human hGF-1 gingival fibroblasts [191]; marine alga Sargassum serratifolium-derived terpenoid sargahydroquinoic acid (162) that stimulated beige-like adipocytes by lipid catabolic pathway activation [192]; shark-derived marine bile terpenoid 5β-scymnol (163) demonstrated to be a novel agonist of the TGR5 receptor by causing sustained intracellular Ca²⁺ release, thus “showing therapeutic potential for treating atherosclerosis [193]; fungus Aspergillus quadrilineatus FJJ093-derived epipolythiodioxopiperazine alkaloid secoemestrin C (164) determined to be an uncompetitive inhibitor of isocitrate lyase (ICL) in the glyoxylate cycle of Candida albicans and also inhibit ICL mRNA expression [194]; marine ascidian Didemnum proliferum-derived alkaloid shishijimicin A (165) noted to bind to double-stranded DNA’s minor groove with its β-carboline moiety playing a role “in the binding through intercalation” [195]; marine green alga Codium cylindricum Holmes-derived terpenoid siphonaxanthin (166) that induced transcription factor Nrf2 protein expression and signaling in HepG2 cells [196]; marine alga Symphyocladia latiuscula-derived bromophenol polyketide (54) that competitively inhibited both melanin and tyrosinase in melanoma cells [197]; marine bacterium Saccharothrix sp. 10-10-derived polyketide tetracenomycin X (167) that induced cell cycle arrest by downregulating cyclin D1 as a result of proteosomal degradation [198]; cyanobacterium Schizothrix sp.-derived cyclodepsipeptide tutuilamide A (168) that demonstrated as a potent and reversible inhibitor of the pancreatic serine protease elastase [199]; marine brown edible alga Undaria pinnatifida peptide KNFL (169) that inhibited angiotensin-1 converting enzyme via a non-competitive inhibition mechanism and binding to the ACE non-active site via hydrogen bonds, suggesting it could become a “functional food ingredient(s) against hypertension” [200]; marine Dunaliella salina microalga-derived terpenoid zeaxanthin heneicosylate (170) that ameliorated age-associated rat cardiac dysfunction by stimulation of retinoid receptors [201].

5. Reviews on Marine Pharmacology and Pharmaceuticals

In 2019-2021 a large number of reviews were published that covered general and/or specific areas of marine preclinical pharmacology: (a) marine pharmacology and marine pharmaceuticals: marine natural products and their relevant biological activities published in 2019, 2020 and 2021 [202]; advances in marine natural products therapeutic potential [203]; polar marine terpenoids and their potential for drug discovery [204,205,206]; bioactive properties of marine phenolics [207]; chemistry and biological activities of marine flavonoids [208]; marine-derived spirotetronates and potential pharmaceutical applications [209]; bioactivities of marine-derived hydroperoxides [210]; marine-derived macrocyclic alkaloids as a potential source of drugs [211]; pharmacology of thiazole-based marine-derived peptides [212]; marine meroterpenoids and cembranoids biological activities [213,214]; marine-derived macrolides chemical and biological diversity [215]; pharmacology of cyanobacterial-derived natural products [216,217,218,219,220,221]; marine natural products from microalgae: an -omics overview [222,223]; pharmacological potential of macroalgae natural products [224,225,226,227,228,229,230,231]; bioactive compounds from Bryozoa and Cnidaria [232,233,234,235]; genus Didemnum secondary metabolites pharmacological properties [236]; marine fungi-derived bioactive compounds [237,238,239]; pharmacological significance of marine microbial natural compounds [240,241,242,243,244]; marine sponge-derived pharmacological activity [245,246]; pharmacological activity of mangrove-derived natural products [247,248,249]; bioactive marine natural products from Indonesia (1970-2017) and the Red Sea [250,251]; marine-derived bioactive compounds in China (2009-2018) [252]; marine bioactive natural products from the Yucatan Peninsula [253]; marine natural products as source of new drugs: a patent review and productivity (2015-2018) [254,255]; natural product based antibody drug conjugates: clinical status as of November 9, 2020 [256]; the global marine pharmaceutical pipeline: approved marine-derived compounds and in Phase I, II and III of clinical development https://www.marinepharmacology.org/; (b) antimicrobial, antifungal and antiviral marine pharmacology: marine bacteria-derived antimicrobial natural products [257,258,259,260]; marine bacteria as source of quorum sensing inhibitors [261,262,263,264]; marine natural products targeting multidrug-resistant bacteria [265,266,267]; ascidian-derived marine antimicrobial natural products [268]; epinecidin-1, and other marine antimicrobial peptides [269,270]; marine fungi-derived antimicrobial natural products [271,272]; marine macrolides with antibacterial and/or antifungal activity [273]; antimicrobial lipids from marine organisms [274]; marine tryptophan-derived antimicrobial alkaloids [275]; recent advances on marine-based antifungals [276]; marine natural products for RNA virus infections including SARS-CoV-2 [277,278,279]; natural products targeting hepatitis C and respiratory viruses [280,281]; marine algae-derived compounds as antivirals [282,283,284]; (c) antiprotozoal and antimalarial marine pharmacology: antiprotozoal activities of marine polyether triterpenoids [285]; recent advances in novel antiprotozoal agents [286,287]; marine drugs as new drug lead for trypanosomatids and malaria [288,289]; marine-sponge-derived antimalarial metabolites [290]; antituberculosis marine natural products [291]; marine natural products and latent tuberculosis drug resistance [292]; d) immuno- and anti-inflammatory marine pharmacology: anti-inflammatory marine natural products [293]; marine-derived compounds for rheumatoid arthritis treatment [294]; marine anti-inflammatory alkaloids [295]; anti-inflammatory compounds from marine fungi [296]; anti-inflammatory prostaglandins and peptides in marine organisms [297,298]; marine polypeptides as inhibitors of neutrophil elastase [299]; anti-inflammatory marine n-3 polyunsaturated fatty acids [300,301,302]; anti-inflammatory pharmacology of fucoxanthin [303]; antioxidant properties of marine algae [304]; Sargassum seaweed as a source of anti-inflammatory natural products [305]; microalgae with immunomodulatory activities [306]; immunodulation by marine invertebrate-derived natural products [307,308]; marine-derived vaccine adjuvants [309] (e) cardiovascular and antidiabetic marine pharmacology: marine-derived anti-atherosclerotic and lipid-lowering compounds [310,311]; marine-derived anti-thrombotics and patents [312,313]; marine-derived sulfated polysaccharides as antithrombotics [314]; microalgae-derived bioactive compounds for cardiovascular pharmacology and inflammation [315]; anti-obesity and anti-diabetic effect of marine algae [316,317,318,319]; antidiabetic properties of Indian mangroves [320]; anti-obesity and anti-diabetic benefits of the carotenoids astaxanthin and fucoxanthin [321,322]; brown seaweeds for management of metabolic syndrome [323,324]; (f) nervous system marine pharmacology: neuroprotective potential of marine natural products [325,326]; marine omega-3 phospholipids and brain health [327]; pharmacological diversity of conotoxins [328,329]; biological activities and pharmacological applications of conopeptides [329]; marine toxins and gastrointestinal visceral pain therapeutics [330]; marine algae anti-inflammatory and neuroprotective pharmacology [331,332,333]; marine compounds for Alzheimer’s therapeutics [334,335,336,337,338]; cyanobacterial bioactive compounds for Alzheimer’s disease [339]; marine natural products for Parkinson’s Disease [340]; neuroprotective pharmacology of astaxanthin [341,342,343]; cnidarian peptide neurotoxins as modulators in central nervous system diseases [344]; marine toxins targeting mammalian voltage-gated potassium channels [345]; marine excitatory amino acids [346] ; marine natural products with monoamine oxidase inhibitory activity [347]; (g) miscellaneous molecular targets, methodologies and uses: marine natural product databases [348,349]; metabolomic tools used in marine natural product drug discovery [350]; chemical genetics approach for biologically active marine natural products discovery [351]; marine-derived cellular signal transduction inhibitors [352]; seaweed-derived signal transduction pathway modulators [353]; astaxanthin modulation of autophagy signal transduction pathways and ocular diseases [354,355]; marine natural product protein kinase inhibitors [356]; marine natural products as ATP-competitive mTOR kinase inhibitors [357]; drug potential of the marine-derived protein kinase C modulators bryostatins [358,359]; natural products as eukaryotic protein secretion modulators [360]; marine natural products targeting eukaryotic cell membranes and cytoskeleton [361,362]; marine natural products as pregnane X receptor ligands [363]; ubiquitin-proteasome system modulation by marine natural products [364]; intracellular calcium signal modulation by marine natural products [365]; cyanobacterial natural products for skin protection and cosmetic applications [366,367,368]; seaweed bioactive compounds as nutraceuticals and cosmeceuticals [369,370,371].

6. Conclusions

This review covering the peer-reviewed marine pharmacology literature published in 2019-2021 is the 12th contribution to the marine preclinical pharmacology pipeline review series that was initiated by AMSM in 1998 [1,2,3,4,5,6,7,8,9,10,11], with the purpose of presenting a consolidated and systematic overview of selected peer-reviewed preclinical marine pharmacological literature published during 2019-2021. Global preclinical marine pharmacology mechanism of action research involved chemists and pharmacologists from 41 countries, namely, Australia, Belgium, Brazil, Canada, Chile, China, Costa Rica, Cuba, Czech Republic, Denmark, Egypt, Ecuador, France, Germany, Greece, Hungary, India, Indonesia, Iran, Ireland, Italy, Japan, Jordan, Malaysia, Mexico, the Netherlands, Norway, Panama, Portugal, Romania, Russian Federation, Saudi Arabia, Singapore, South Korea, Spain, Switzerland, Thailand, Taiwan, the Philippines; United Kingdom, Vietnam, and the United States. Thus, during 2019-2021 the marine preclinical pharmaceutical pipeline continued to generate novel marine chemical leads for the active marine clinical pharmaceutical pipeline. As currently shown on the marine pharmaceutical pipeline website https://www.marinepharmacology.org/ (May 2024) there are 15 marine-derived pharmaceuticals approved by either the U.S. Food and Drug Administration, Australia, Japan and/or China, and 33 compounds in either Phase I, II and III of clinical pharmaceutical development.

Author Contributions

Conceptualization: A.M.S.M., M.S.M, M.L.P., A.D.R, F.N., O.T.S; methodology: A.M.S.M., V.A.M., M.S.M, M.L.P., A.D.R, F.N., O.T.S; 2019-2021 literature analysis: A.M.S.M., V.A.M., M.S.M, M.L.P.; figures 1, 2 and 3: A.D.R, F.N., O.T.S.; writing original draft preparation: A.M.S.M., V.A.M., M.S.M, M.L.P.; writing—review and editing: A.M.S.M., V.A.M., M.S.M, M.L.P., A.D.R, F.N., O.T.S.; funding: AM.S.M., A.D.R, O.T.S. All authors have read and agreed to the published version of the manuscript.

Acknowledgments

We thank the contributions of students Linda Huang, Neal Patel, Patrick Patel, Katelyn Howe, and Asmaa Alawsi from the Chicago College of Pharmacy, Midwestern University for the retrieval of 2019, 2020 and 2021 marine pharmacology literature reviewed in this article, and Colleen Bannon, Midwestern University Library for Endnote database assistance. We also thank the secretarial assistance of Victoria Sears from the Pharmacology Department, College of Graduate Studies. We gratefully acknowledge financial support from Midwestern University to AMSM; and NIH-SC1 Award (Grant 1SC1GM086271-01A1) of the University of Puerto Rico to ADR, and a grant from EU within the MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project no. PE00000007, INF-ACT)” to OTS. The content of this review is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Declarations of Interest

The authors declare no conflicts of interest.

References

Mayer, A.M.S.; Lehmann, V.K.B. Marine pharmacology in 1998: marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, anthelmintic, antiplatelet, antiprotozoal, and antiviral activities;with actions on the cardiovascular, endocrine, immune, and nervous systems; and other miscellaneous mechanisms of action. The Pharmacologist 2000, 42, 62-69.
Mayer, A.M.; Hamann, M.T. Marine pharmacology in 1999: compounds with antibacterial, anticoagulant, antifungal, anthelmintic, anti-inflammatory, antiplatelet, antiprotozoal and antiviral activities affecting the cardiovascular, endocrine, immune and nervous systems, and other miscellaneous mechanisms of action. Comp Biochem Physiol C Toxicol Pharmacol 2002, 132, 315-339. [CrossRef]
Mayer, A.M.S.; Hamann, M.T. Marine pharmacology in 2000: marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antituberculosis, and antiviral activities; affecting the cardiovascular, immune, and nervous systems and other miscellaneous mechanisms of action. Mar. Biotechnol. (NY) 2004, 6, 37-52. [CrossRef]
Mayer, A.M.; Hamann, M.T. Marine pharmacology in 2001-2: marine compounds with anthelmintic, antibacterial, anticoagulant, antidiabetic, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems and other miscellaneous mechanisms of action. Comp Biochem. Physiol C. Toxicol. Pharmacol 2005, 140, 265-286. [CrossRef]
Mayer, A.M.; Rodriguez, A.D.; Berlinck, R.G.; Hamann, M.T. Marine pharmacology in 2003-4: marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Comp Biochem. Physiol C Toxicol. Pharmacol 2007, 145, 553-581.
Mayer, A.M.; Rodriguez, A.D.; Berlinck, R.G.; Hamann, M.T. Marine pharmacology in 2005-6: Marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Biochim. Biophys. Acta 2009, 1790, 283-308. [CrossRef]
Mayer, A.M.; Rodriguez, A.D.; Berlinck, R.G.; Fusetani, N. Marine pharmacology in 2007-8: Marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous system, and other miscellaneous mechanisms of action. Comp Biochem. Physiol C. Toxicol. Pharmacol 2011, 153, 191-222. [CrossRef]
Mayer, A.M.; Rodriguez, A.D.; Taglialatela-Scafati, O.; Fusetani, N. Marine Pharmacology in 2009-2011: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis, and Antiviral Activities; Affecting the Immune and Nervous Systems, and other Miscellaneous Mechanisms of Action. Mar. Drugs 2013, 11, 2510-2573. [CrossRef]
Mayer, A.M.S.; Rodriguez, A.D.; Taglialatela-Scafati, O.; Fusetani, N. Marine Pharmacology in 2012-2013: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis, and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action. Mar Drugs 2017, 15, 273. [CrossRef]
Mayer, A.M.S.; Guerrero, A.J.; Rodriguez, A.D.; Taglialatela-Scafati, O.; Nakamura, F.; Fusetani, N. Marine Pharmacology in 2014-2015: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis, Antiviral, and Anthelmintic Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action. Mar Drugs 2019, 18. [CrossRef]
Mayer, A.M.S.; Guerrero, A.J.; Rodriguez, A.D.; Taglialatela-Scafati, O.; Nakamura, F.; Fusetani, N. Marine Pharmacology in 2016-2017: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action. Mar Drugs 2021, 19. [CrossRef]
Mayer, A.M.S.; Pierce, M.L.; Howe, K.; Rodríguez, A.D.; Taglialatela-Scafati, O.; Nakamura, F.; Fusetani, N. Marine pharmacology in 2018: Marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiprotozoal, antituberculosis and antiviral activities; affecting the immune and nervous systems, and other miscellaneous mechanisms of action. Pharmacol Res 2022, 183, 106391. [CrossRef]
F.J. Schmitz, B.F. Bowden, Toth, S.I., Antitumor and Cytotoxic Compounds from Marine Organisms, in: D.H. Attaway, O.R. Zaborsky (Eds.) Plenum Press, New York and London, 1993, pp. 197-308.
Gomez-Rodriguez, L.; Schultz, P.J.; Tamayo-Castillo, G.; Dotson, G.D.; Sherman, D.H.; Tripathi, A. Adipostatins E-J, New Potent Antimicrobials Identified as Inhibitors of Coenzyme-A Biosynthesis. Tetrahedron Lett 2020, 61. [CrossRef]
Elliott, A.G.; Huang, J.X.; Neve, S.; Zuegg, J.; Edwards, I.A.; Cain, A.K.; Boinett, C.J.; Barquist, L.; Lundberg, C.V.; Steen, J.; et al. An amphipathic peptide with antibiotic activity against multidrug-resistant Gram-negative bacteria. Nat Commun 2020, 11, 3184. [CrossRef]
Paderog, M.J.V.; Suarez, A.F.L.; Sabido, E.M.; Low, Z.J.; Saludes, J.P.; Dalisay, D.S. Anthracycline Shunt Metabolites From Philippine Marine Sediment-Derived Streptomyces Destroy Cell Membrane Integrity of Multidrug-Resistant Staphylococcus aureus. Front Microbiol 2020, 11, 743. [CrossRef]
Wang, M.; Zhao, L.; Wu, H.; Zhao, C.; Gong, Q.; Yu, W. Cladodionen Is a Potential Quorum Sensing Inhibitor Against Pseudomonas aeruginosa. Mar Drugs 2020, 18. [CrossRef]
Gowrishankar, S.; Pandian, S.K.; Balasubramaniam, B.; Balamurugan, K. Quorum quelling efficacy of marine cyclic dipeptide -cyclo(L-leucyl-L-prolyl) against the uropathogen Serratia marcescens. Food Chem Toxicol 2019, 123, 326-336. [CrossRef]
de Figueiredo, C.S.; Menezes Silva, S.M.P.; Abreu, L.S.; da Silva, E.F.; da Silva, M.S.; Cavalcanti de Miranda, G.E.; Costa, V.C.O.; Le Hyaric, M.; Siqueira Junior, J.P.; Barbosa Filho, J.M.; et al. Dolastane diterpenes from Canistrocarpus cervicornis and their effects in modulation of drug resistance in Staphylococcus aureus. Nat Prod Res 2019, 33, 3231-3239. [CrossRef]
Davison, J.R.; Bewley, C.A. Antimicrobial Chrysophaentin Analogs Identified from Laboratory Cultures of the Marine Microalga Chrysophaeum taylorii. J Nat Prod 2019, 82, 148-153. [CrossRef]
Wang, Y.; Zhang, J.; Sun, Y.; Sun, L. A Crustin from Hydrothermal Vent Shrimp: Antimicrobial Activity and Mechanism. Mar Drugs 2021, 19. [CrossRef]
Campana, R.; Favi, G.; Baffone, W.; Lucarini, S. Marine Alkaloid 2,2-Bis(6-bromo-3-indolyl) Ethylamine and Its Synthetic Derivatives Inhibit Microbial Biofilms Formation and Disaggregate Developed Biofilms. Microorganisms 2019, 7. [CrossRef]
Liang, X.; Matthew, S.; Chen, Q.Y.; Kwan, J.C.; Paul, V.J.; Luesch, H. Discovery and Total Synthesis of Doscadenamide A: A Quorum Sensing Signaling Molecule from a Marine Cyanobacterium. Org Lett 2019, 21, 7274-7278. [CrossRef]
Jabila Mary, T.R.; Kannan, R.R.; Muthamil Iniyan, A.; Carlton Ranjith, W.A.; Nandhagopal, S.; Vishwakarma, V.; Prakash Vincent, S.G. beta-lactamase inhibitory potential of kalafungin from marine Streptomyces in Staphylococcus aureus infected zebrafish. Microbiol Res 2021, 244, 126666. [CrossRef]
Maynard, A.; Butler, N.L.; Ito, T.; da Silva, A.J.; Murai, M.; Chen, T.; Koffas, M.A.G.; Miyoshi, H.; Barquera, B. Antibiotic Korormicin A Kills Bacteria by Producing Reactive Oxygen Species. J Bacteriol 2019, 201. [CrossRef]
Chung, B.; Kwon, O.S.; Shin, J.; Oh, K.B. Antibacterial Activity and Mode of Action of Lactoquinomycin A from. Mar Drugs 2020, 19. [CrossRef]
Thulshan Jayathilaka, E.H.T.; Liyanage, T.D.; Rajapaksha, D.C.; Dananjaya, S.H.S.; Nikapitiya, C.; Whang, I.; De Zoysa, M. Octominin: An antibacterial and anti-biofilm peptide for controlling the multidrug resistance and pathogenic Streptococcus parauberis. Fish Shellfish Immunol 2021, 110, 23-34. [CrossRef]
Yu, X.; Li, L.; Sun, S.; Chang, A.; Dai, X.; Li, H.; Wang, Y.; Zhu, H. A Cyclic Dipeptide from Marine Fungus. ACS Omega 2021, 6, 7693-7700. [CrossRef]
Pan, Y.; Zheng, L.B.; Mao, Y.; Wang, J.; Lin, L.S.; Su, Y.Q.; Li, Y. The antibacterial activity and mechanism analysis of piscidin 5 like from Larimichthys crocea. Dev Comp Immunol 2019, 92, 43-49. [CrossRef]
Kim, Y.G.; Lee, J.H.; Lee, S.; Lee, Y.K.; Hwang, B.S.; Lee, J. Antibiofilm Activity of Phorbaketals from the Marine Sponge. Mar Drugs 2021, 19. [CrossRef]
Kizhakkekalam, V.C., K.; Joy, M. Antibacterial and antioxidant aryl-enclosed macrocyclic polyketide from intertidal macroalgae associated heterotrophic bacterium Shewanella algae. Med. Chem. Res. 2020, 29, 145-155. [CrossRef]
Chakraborty, K.; Kizhakkekalam, V.K.; Joy, M. Macrocyclic polyketides with siderophore mode of action from marine heterotrophic Shewanella algae: Prospective anti-infective leads attenuate drug-resistant pathogens. J Appl Microbiol 2021, 130, 1552-1570. [CrossRef]
Hansen, K. Antimicrobial activity of securamines from the bryozoan Securiflustra securifrons 2021.
Hansen, I.K.O.; Isaksson, J.; Poth, A.G.; Hansen, K.O.; Andersen, A.J.C.; Richard, C.S.M.; Blencke, H.M.; Stensvag, K.; Craik, D.J.; Haug, T. Isolation and Characterization of Antimicrobial Peptides with Unusual Disulfide Connectivity from the Colonial Ascidian Synoicum turgens. Mar Drugs 2020, 18. [CrossRef]
Reina, J.C.; Perez-Victoria, I.; Martin, J.; Llamas, I. A Quorum-Sensing Inhibitor Strain of Vibrio alginolyticus Blocks Qs-Controlled Phenotypes in Chromobacterium violaceum and Pseudomonas aeruginosa. Mar Drugs 2019, 17. [CrossRef]
Elsadek, L.A.; Matthews, J.H.; Nishimura, S.; Nakatani, T.; Ito, A.; Gu, T.; Luo, D.; Salvador-Reyes, L.A.; Paul, V.J.; Kakeya, H.; et al. Genomic and Targeted Approaches Unveil the Cell Membrane as a Major Target of the Antifungal Cytotoxin Amantelide A. Chembiochem 2021, 22, 1790-1799. [CrossRef]
Yang, B.; He, Y.; Lin, S.; Zhang, J.; Li, H.; Wang, J.; Hu, Z.; Zhang, Y. Antimicrobial Dolabellanes and Atranones from a Marine-Derived Strain of the Toxigenic Fungus Stachybotrys chartarum. J Nat Prod 2019, 82, 1923-1929. [CrossRef]
Tang, X.X.; Yan, X.; Fu, W.H.; Yi, L.Q.; Tang, B.W.; Yu, L.B.; Fang, M.J.; Wu, Z.; Qiu, Y.K. New beta-Lactone with Tea Pathogenic Fungus Inhibitory Effect from Marine-Derived Fungus MCCC3A00957. J Agric Food Chem 2019, 67, 2877-2885. [CrossRef]
Kim, H.; Hwang, J.Y.; Chung, B.; Cho, E.; Bae, S.; Shin, J.; Oh, K.B. 2-Alkyl-4-hydroxyquinolines from a Marine-Derived Streptomyces sp. Inhibit Hyphal Growth Induction in Candida albicans. Mar Drugs 2019, 17. [CrossRef]
Dalisay, D.S.; Rogers, E.W.; Molinski, T.F. Oceanapiside, a Marine Natural Product, Targets the Sphingolipid Pathway of Fluconazole-Resistant. Mar Drugs 2021, 19. [CrossRef]
Tripathi, S.K.; Feng, Q.; Liu, L.; Levin, D.E.; Roy, K.K.; Doerksen, R.J.; Baerson, S.R.; Shi, X.; Pan, X.; Xu, W.H.; et al. Puupehenone, a Marine-Sponge-Derived Sesquiterpene Quinone, Potentiates the Antifungal Drug Caspofungin by Disrupting Hsp90 Activity and the Cell Wall Integrity Pathway. mSphere 2020, 5. [CrossRef]
Meng, L.; Sun, C.; Zhang, C.; Song, S.; Sun, X.; Ju, J.; Deng, Y. Efficacy of Compounds Isolated from Streptomyces olivaceus against the Morphogenesis and Virulence of Candida albicans. Mar Drugs 2019, 17. [CrossRef]
Alhadrami, H.A.; Thissera, B.; Hassan, M.H.A.; Behery, F.A.; Ngwa, C.J.; Hassan, H.M.; Pradel, G.; Abdelmohsen, U.R.; Rateb, M.E. Bio-Guided Isolation of Antimalarial Metabolites from the Coculture of Two Red Sea Sponge-Derived Actinokineospora and Rhodococcus spp. Mar Drugs 2021, 19. [CrossRef]
Sweeney-Jones, A.M.; Gagaring, K.; Antonova-Koch, J.; Zhou, H.; Mojib, N.; Soapi, K.; Skolnick, J.; McNamara, C.W.; Kubanek, J. Antimalarial Peptide and Polyketide Natural Products from the Fijian Marine Cyanobacterium Moorea producens. Mar Drugs 2020, 18. [CrossRef]
Knestrick, M.A.; Wilson, N.G.; Roth, A.; Adams, J.H.; Baker, B.J. Friomaramide, a Highly Modified Linear Hexapeptide from an Antarctic Sponge, Inhibits Plasmodium falciparum Liver-Stage Development. J Nat Prod 2019, 82, 2354-2358. [CrossRef]
Wright, A.E.; Collins, J.E.; Roberts, B.; Roberts, J.C.; Winder, P.L.; Reed, J.K.; Diaz, M.C.; Pomponi, S.A.; Chakrabarti, D. Antiplasmodial Compounds from Deep-Water Marine Invertebrates. Mar Drugs 2021, 19. [CrossRef]
Rodríguez-Expósito, R.L.; Nocchi, N.; Reyes-Batlle, M.; Sifaoui, I.; Suárez-Gómez, B.; Díaz-Marrero, A.R.; Souto, M.L.; Piñero, J.E.; Fernández, J.J.; Lorenzo-Morales, J. Antiamoebic effects of sesquiterpene lactones isolated from the zoanthid Palythoa aff. clavata. Bioorg Chem 2021, 108, 104682. [CrossRef]
Huang, H.N.; Chuang, C.M.; Chen, J.Y.; Chieh-Yu, P. Epinecidin-1: A marine fish antimicrobial peptide with therapeutic potential against Trichomonas vaginalis infection in mice. Peptides 2019, 112, 139-148. [CrossRef]
Lima, M.L.; Romanelli, M.M.; Borborema, S.E.T.; Johns, D.M.; Migotto, A.E.; Lago, J.H.G.; Tempone, A.G. Antitrypanosomal activity of isololiolide isolated from the marine hydroid Macrorhynchia philippina (Cnidaria, Hydrozoa). Bioorg Chem 2019, 89, 103002. [CrossRef]
Lorenzo-Morales, J.; Diaz-Marrero, A.R.; Cen-Pacheco, F.; Sifaoui, I.; Reyes-Batlle, M.; Souto, M.L.; Hernandez Daranas, A.; Pinero, J.E.; Fernandez, J.J. Evaluation of Oxasqualenoids from the Red Alga Laurencia viridis against Acanthamoeba. Mar Drugs 2019, 17. [CrossRef]
Boudreau, P.D.; Miller, B.W.; McCall, L.I.; Almaliti, J.; Reher, R.; Hirata, K.; Le, T.; Siqueira-Neto, J.L.; Hook, V.; Gerwick, W.H. Design of Gallinamide A Analogs as Potent Inhibitors of the Cysteine Proteases Human Cathepsin L and Trypanosoma cruzi Cruzain. J Med Chem 2019, 62, 9026-9044. [CrossRef]
Cartuche, L.; Reyes-Batlle, M.; Sifaoui, I.; Arberas-Jimenez, I.; Pinero, J.E.; Fernandez, J.J.; Lorenzo-Morales, J.; Diaz-Marrero, A.R. Antiamoebic Activities of Indolocarbazole Metabolites Isolated from Streptomyces sanyensis Cultures. Mar Drugs 2019, 17. [CrossRef]
Casertano, M.; Imperatore, C.; Luciano, P.; Aiello, A.; Putra, M.Y.; Gimmelli, R.; Ruberti, G.; Menna, M. Chemical Investigation of the Indonesian Tunicate Polycarpa aurata and Evaluation of the Effects Against Schistosoma mansoni of the Novel Alkaloids Polyaurines A and B. Mar Drugs 2019, 17. [CrossRef]
Liu, Z.; Wang, Q.; Li, S.; Cui, H.; Sun, Z.; Chen, D.; Lu, Y.; Liu, H.; Zhang, W. Polypropionate Derivatives with Mycobacterium tuberculosis Protein Tyrosine Phosphatase B Inhibitory Activities from the Deep-Sea-Derived Fungus Aspergillus fischeri FS452. J Nat Prod 2019, 82, 3440-3449. [CrossRef]
Sudomova, M.; Shariati, M.A.; Echeverria, J.; Berindan-Neagoe, I.; Nabavi, S.M.; Hassan, S.T.S. A Microbiological, Toxicological, and Biochemical Study of the Effects of Fucoxanthin, a Marine Carotenoid, on Mycobacterium tuberculosis and the Enzymes Implicated in Its Cell Wall: A Link Between Mycobacterial Infection and Autoimmune Diseases. Mar Drugs 2019, 17. [CrossRef]
Liu, D.; Li, Y.; Guo, X.; Ji, W.; Lin, W. Chartarlactams Q-T, Dimeric Phenylspirodrimanes with Antibacterial and Antiviral Activities. Chem Biodivers 2020, 17, e2000170. [CrossRef]
Li, B.; Li, L.; Peng, Z.; Liu, D.; Si, L.; Wang, J.; Yuan, B.; Huang, J.; Proksch, P.; Lin, W. Harzianoic acids A and B, new natural scaffolds with inhibitory effects against hepatitis C virus. Bioorg Med Chem 2019, 27, 560-567. [CrossRef]
Lin, S.C.; Lehman, C.W.; Stewart, A.K.; Panny, L.; Bracci, N.; Wright, J.L.C.; Paige, M.; Strangman, W.K.; Kehn-Hall, K. Homoseongomycin, a compound isolated from marine actinomycete bacteria K3-1, is a potent inhibitor of encephalitic alphaviruses. Antiviral Res 2021, 191, 105087. [CrossRef]
Tan, S.; Yang, B.; Liu, J.; Xun, T.; Liu, Y.; Zhou, X. Penicillixanthone A, a marine-derived dual-coreceptor antagonist as anti-HIV-1 agent. Nat Prod Res 2019, 33, 1467-1471. [CrossRef]
Izumida, M.; Suga, K.; Ishibashi, F.; Kubo, Y. The Spirocyclic Imine from a Marine Benthic Dinoflagellate, Portimine, Is a Potent Anti-Human Immunodeficiency Virus Type 1 Therapeutic Lead Compound. Mar Drugs 2019, 17. [CrossRef]
Das, S.K.; Samantaray, D.; Sahoo, S.K.; Pradhan, S.K.; Samanta, L.; Thatoi, H. Bioactivity guided isolation of antidiabetic and antioxidant compound from Xylocarpus granatum J. Koenig bark. 3 Biotech 2019, 9, 198. [CrossRef]
Luo, J.; Jiang, B.; Li, C.; Jia, X.; Shi, D. CYC27 Synthetic Derivative of Bromophenol from Red Alga Rhodomela confervoides: Anti-Diabetic Effects of Sensitizing Insulin Signaling Pathways and Modulating RNA Splicing-Associated RBPs. Mar Drugs 2019, 17. [CrossRef]
Zaharudin, N.; Staerk, D.; Dragsted, L.O. Inhibition of alpha-glucosidase activity by selected edible seaweeds and fucoxanthin. Food Chem 2019, 270, 481-486. [CrossRef]
Kawee-Ai, A.K., A.; Kim, S. . Inhibitory activities of microalgal fucoxanthin against α-amylase, α-glucosidase, and glucose oxidase in 3T3-L1 cells linked to type 2 diabetes. J. Oceanol. Limnol. 2019, 37, 928-937. [CrossRef]
Hudlikar, R.R.; Sargsyan, D.; Li, W.; Wu, R.; Zheng, M.; Kong, A.N. Epigenomic, Transcriptomic, and Protective Effect of Carotenoid Fucoxanthin in High Glucose-Induced Oxidative Stress in Mes13 Kidney Mesangial Cells. Chem Res Toxicol 2021, 34, 713-722. [CrossRef]
Chakraborty, K.A., T. First report of antioxidative abeo-oleanenes from red seaweed Gracilaria salicornia as dual inhibitors of starch digestive enzymes. Med. Chem. Res. 2019, 28, 696-710. [CrossRef]
Yang, H.W.; Son, M.; Choi, J.; Oh, S.; Jeon, Y.J.; Byun, K.; Ryu, B. Effect of Ishophloroglucin A, A Component of Ishige okamurae, on Glucose Homeostasis in the Pancreas and Muscle of High Fat Diet-Fed Mice. Mar Drugs 2019, 17. [CrossRef]
Paudel, P.; Seong, S.H.; Park, H.J.; Jung, H.A.; Choi, J.S. Anti-Diabetic Activity of 2,3,6-Tribromo-4,5-Dihydroxybenzyl Derivatives from Symphyocladia latiuscula through PTP1B Downregulation and alpha-Glucosidase Inhibition. Mar Drugs 2019, 17. [CrossRef]
Seong, S.H.; Nguyen, D.H.; Wagle, A.; Woo, M.H.; Jung, H.A.; Choi, J.S. Experimental and Computational Study to Reveal the Potential of Non-Polar Constituents from Hizikia fusiformis as Dual Protein Tyrosine Phosphatase 1B and alpha-Glucosidase Inhibitors. Mar Drugs 2019, 17. [CrossRef]
Lopez, D.; Cherigo, L.; Mejia, L.C.; Loza-Mejia, M.A.; Martinez-Luis, S. alpha-Glucosidase inhibitors from a mangrove associated fungus, Zasmidium sp. strain EM5-10. BMC Chem 2019, 13, 22. [CrossRef]
Pereira, R.B.; Pereira, D.M.; Jimenez, C.; Rodriguez, J.; Nieto, R.M.; Videira, R.A.; Silva, O.; Andrade, P.B.; Valentao, P. Anti-Inflammatory Effects of 5alpha,8alpha-Epidioxycholest-6-en-3beta-ol, a Steroidal Endoperoxide Isolated from Aplysia depilans, Based on Bioguided Fractionation and NMR Analysis. Mar Drugs 2019, 17. [CrossRef]
Wen, H.; Chen, C.; Sun, W.; Zang, Y.; Li, Q.; Wang, W.; Zeng, F.; Liu, J.; Zhou, Y.; Zhou, Q.; et al. Phenolic C-Glycosides and Aglycones from Marine-Derived Aspergillus sp. and Their Anti-Inflammatory Activities. J Nat Prod 2019, 82, 1098-1106. [CrossRef]
Keeler, D.M.; Grandal, M.K.; McCall, J.R. Brevenal, a Marine Natural Product, is Anti-Inflammatory and an Immunomodulator of Macrophage and Lung Epithelial Cells. Mar Drugs 2019, 17. [CrossRef]
Alvarino, R.; Alonso, E.; Lacret, R.; Oves-Costales, D.; Genilloud, O.; Reyes, F.; Alfonso, A.; Botana, L.M. Caniferolide A, a Macrolide from Streptomyces caniferus, Attenuates Neuroinflammation, Oxidative Stress, Amyloid-Beta, and Tau Pathology in Vitro. Mol Pharm 2019, 16, 1456-1466. [CrossRef]
Van Thanh, N.; Jang, H.J.; Vinh, L.B.; Linh, K.T.P.; Huong, P.T.T.; Cuong, N.X.; Nam, N.H.; Van Minh, C.; Kim, Y.H.; Yang, S.Y. Chemical constituents from Vietnamese mangrove Calophyllum inophyllum and their anti-inflammatory effects. Bioorg Chem 2019, 88, 102921. [CrossRef]
Ding, Y.; An, F.; Zhu, X.; Yu, H.; Hao, L.; Lu, Y. Curdepsidones B(-)G, Six Depsidones with Anti-Inflammatory Activities from the Marine-Derived Fungus Curvularia sp. IFB-Z10. Mar Drugs 2019, 17. [CrossRef]
Ku, S.K.; Jeong, S.Y.; Yang, S.; Kim, K.M.; Choi, H.; Bae, J.S. Suppressive effects of collismycin C on polyphosphate-mediated vascular inflammatory responses. Fitoterapia 2019, 134, 447-453. [CrossRef]
Oh, S.; Son, M.; Byun, K.A.; Jang, J.T.; Choi, C.H.; Son, K.H.; Byun, K. Attenuating Effects of Dieckol on High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Decreasing the NLRP3 Inflammasome and Pyroptosis. Mar Drugs 2021, 19. [CrossRef]
Hu, T.Y.; Zhang, H.; Chen, Y.Y.; Jiao, W.H.; Fan, J.T.; Liu, Z.Q.; Lin, H.W.; Cheng, B.H. Dysiarenone from Marine Sponge Dysidea arenaria Attenuates ROS and Inflammation via Inhibition of 5-LOX/NF-kappaB/MAPKs and Upregulation of Nrf-2/OH-1 in RAW 264.7 Macrophages. J Inflamm Res 2021, 14, 587-597. [CrossRef]
Kim, E.N.; Nabende, W.Y.; Jeong, H.; Hahn, D.; Jeong, G.S. The marine-derived natural product epiloliolide isolated from Sargassum horneri regulates NLRP3 via PKA/CREB, promoting proliferation and anti-inflammatory effects of human periodontal ligament cells. Mar Drugs 2021, 19. [CrossRef]
Su, J.; Guo, K.; Huang, M.; Liu, Y.; Zhang, J.; Sun, L.; Li, D.; Pang, K.L.; Wang, G.; Chen, L.; et al. Fucoxanthin, a Marine Xanthophyll Isolated From Conticribra weissflogii ND-8: Preventive Anti-Inflammatory Effect in a Mouse Model of Sepsis. Front Pharmacol 2019, 10, 906. [CrossRef]
Zheng, J.; Tian, X.; Zhang, W.; Zheng, P.; Huang, F.; Ding, G.; Yang, Z. Protective Effects of Fucoxanthin against Alcoholic Liver Injury by Activation of Nrf2-Mediated Antioxidant Defense and Inhibition of TLR4-Mediated Inflammation. Mar Drugs 2019, 17. [CrossRef]
Ha, Y.J.; Choi, Y.S.; Oh, Y.R.; Kang, E.H.; Khang, G.; Park, Y.B.; Lee, Y.J. Fucoxanthin Suppresses Osteoclastogenesis via Modulation of MAP Kinase and Nrf2 Signaling. Mar Drugs 2021, 19. [CrossRef]
Li, X.; Huang, R.; Liu, K.; Li, M.; Luo, H.; Cui, L.; Huang, L.; Luo, L. Fucoxanthin attenuates LPS-induced acute lung injury via inhibition of the TLR4/MyD88 signaling axis. Aging (Albany NY) 2020, 13, 2655-2667. [CrossRef]
Li, Y.; Liu, L.; Sun, P.; Zhang, Y.; Wu, T.; Sun, H.; Cheng, K.W.; Chen, F. Fucoxanthinol from the Diatom Nitzschia Laevis Ameliorates Neuroinflammatory Responses in Lipopolysaccharide-Stimulated BV-2 Microglia. Mar Drugs 2020, 18. [CrossRef]
Jan, J.S.; Yang, C.H.; Wang, M.H.; Lin, F.L.; Yen, J.L.; Hsieh, I.; Khotimchenko, M.; Lee, T.H.; Hsiao, G. Hirsutanol A Attenuates Lipopolysaccharide-Mediated Matrix Metalloproteinase 9 Expression and Cytokines Production and Improves Endotoxemia-Induced Acute Sickness Behavior and Acute Lung Injury. Mar Drugs 2019, 17. [CrossRef]
Chen, H.; Yang, H.; Zhi, Y.; Yao, Q.; Liu, B. Evaluation of pyrrolidine-based analog of jaspine B as potential SphK1 inhibitors against rheumatoid arthritis. Bioorg Med Chem Lett 2021, 34, 127754. [CrossRef]
Daskalaki, M.G.; Vyrla, D.; Harizani, M.; Doxaki, C.; Eliopoulos, A.G.; Roussis, V.; Ioannou, E.; Tsatsanis, C.; Kampranis, S.C. Neorogioltriol and Related Diterpenes from the Red Alga Laurencia Inhibit Inflammatory Bowel Disease in Mice by Suppressing M1 and Promoting M2-Like Macrophage Responses. Mar Drugs 2019, 17. [CrossRef]
Herath, K.; Kim, H.J.; Jang, J.H.; Kim, H.S.; Kim, H.J.; Jeon, Y.J.; Jee, Y. Mojabanchromanol Isolated from Sargassum horneri Attenuates Particulate Matter Induced Inflammatory Responses via Suppressing TLR2/4/7-MAPK Signaling in MLE-12 Cells. Mar Drugs 2020, 18. [CrossRef]
Ha, T.M.; Kim, D.C.; Sohn, J.H.; Yim, J.H.; Oh, H. Anti-Inflammatory and Protein Tyrosine Phosphatase 1B Inhibitory Metabolites from the Antarctic Marine-Derived Fungal Strain Penicillium glabrum SF-7123. Mar Drugs 2020, 18. [CrossRef]
Kim, Y.N.; Ji, Y.K.; Kim, N.H.; Van Tu, N.; Rho, J.R.; Jeong, E.J. Isoquinolinequinone Derivatives from a Marine Sponge (Mar Drugs 2021, 19. [CrossRef]
Chu, Y.C.; Chang, C.H.; Liao, H.R.; Cheng, M.J.; Wu, M.D.; Fu, S.L.; Chen, J.J. Rare Chromone Derivatives from the Marine-Derived Penicillium citrinum with Anti-Cancer and Anti-Inflammatory Activities. Mar Drugs 2021, 19. [CrossRef]
Lee, S.M.; Kim, N.H.; Lee, S.; Kim, Y.N.; Heo, J.D.; Jeong, E.J.; Rho, J.R. Deacetylphylloketal, a New Phylloketal Derivative from a Marine Sponge, Genus Phyllospongia, with Potent Anti-Inflammatory Activity in In Vitro Co-Culture Model of Intestine. Mar Drugs 2019, 17. [CrossRef]
Liu, Z.; Qiu, P.; Liu, H.; Li, J.; Shao, C.; Yan, T.; Cao, W.; She, Z. Identification of anti-inflammatory polyketides from the coral-derived fungus Penicillium sclerotiorin: In vitro approaches and molecular-modeling. Bioorg Chem 2019, 88, 102973. [CrossRef]
Kim, M.J.; Jeong, S.M.; Kang, B.K.; Kim, K.B.; Ahn, D.H. Anti-Inflammatory Effects of Grasshopper Ketone from Sargassum fulvellum Ethanol Extract on Lipopolysaccharide-Induced Inflammatory Responses in RAW 264.7 Cells. J Microbiol Biotechnol 2019, 29, 820-826. [CrossRef]
Abdelfattah, M.S.; Elmallah, M.I.Y.; Ebrahim, H.Y.; Almeer, R.S.; Eltanany, R.M.A.; Abdel Moneim, A.E. Prodigiosins from a marine sponge-associated actinomycete attenuate HCl/ethanol-induced gastric lesion via antioxidant and anti-inflammatory mechanisms. PLoS One 2019, 14, e0216737. [CrossRef]
Hwang, J.; Kim, D.; Park, J.S.; Park, H.J.; Shin, J.; Lee, S.K. Photoprotective Activity of Topsentin, A Bis(Indole) Alkaloid from the Marine Sponge Spongosorites genitrix, by Regulation of COX-2 and Mir-4485 Expression in UVB-Irradiated Human Keratinocyte Cells. Mar Drugs 2020, 18. [CrossRef]
Kim, E.A.K., S.Y.; Kim, J.; Oh, J.Y.; Kim, H.S., Yoon, W.J.; Kang, D.H.; Heo, S.J. Tuberatolide B isolated from Sargassum macrocarpum inhibited LPS-stimulated inflammatory response via MAPKs and NF-κB signaling pathway in RAW264.7 cells and zebrafish model. J. Funct. Foods 2019, 52, 109-115. [CrossRef]
Yin, Y.; Xu, N.; Shi, Y.; Zhou, B.; Sun, D.; Ma, B.; Xu, Z.; Yang, J.; Li, C. Astaxanthin Protects Dendritic Cells from Lipopolysaccharide-Induced Immune Dysfunction. Mar Drugs 2021, 19. [CrossRef]
Lin, C.C.; Chang, Y.K.; Lin, S.C.; Su, J.H.; Chao, Y.H.; Tang, K.T. Crassolide Suppresses Dendritic Cell Maturation and Attenuates Experimental Antiphospholipid Syndrome. Molecules 2021, 26. [CrossRef]
Li, W.; Ye, S.; Zhang, Z.; Tang, J.; Jin, H.; Huang, F.; Yang, Z.; Tang, Y.; Chen, Y.; Ding, G.; et al. Purification and Characterization of a Novel Pentadecapeptide from Protein Hydrolysates of Cyclina sinensis and Its Immunomodulatory Effects on RAW264.7 Cells. Mar Drugs 2019, 17. [CrossRef]
Oh, S.; Shim, M.; Son, M.; Jang, J.T.; Son, K.H.; Byun, K. Attenuating Effects of Dieckol on Endothelial Cell Dysfunction via Modulation of Th17/Treg Balance in the Intestine and Aorta of Spontaneously Hypertensive Rats. Antioxidants (Basel) 2021, 10. [CrossRef]
Park, G.B.; Kim, M.J.; Vasileva, E.A.; Mishchenko, N.P.; Fedoreyev, S.A.; Stonik, V.A.; Han, J.; Lee, H.S.; Kim, D.; Jeong, J.Y. Echinochrome A Promotes Ex Vivo Expansion of Peripheral Blood-Derived CD34(+) Cells, Potentially through Downregulation of ROS Production and Activation of the Src-Lyn-p110delta Pathway. Mar Drugs 2019, 17. [CrossRef]
Oh, S.J.; Seo, Y.; Ahn, J.S.; Shin, Y.Y.; Yang, J.W.; Kim, H.K.; Han, J.; Mishchenko, N.P.; Fedoreyev, S.A.; Stonik, V.A.; et al. Echinochrome A Reduces Colitis in Mice and Induces In Vitro Generation of Regulatory Immune Cells. Mar Drugs 2019, 17. [CrossRef]
Park, G.T.; Yoon, J.W.; Yoo, S.B.; Song, Y.C.; Song, P.; Kim, H.K.; Han, J.; Bae, S.J.; Ha, K.T.; Mishchenko, N.P.; et al. Echinochrome A Treatment Alleviates Fibrosis and Inflammation in Bleomycin-Induced Scleroderma. Mar Drugs 2021, 19. [CrossRef]
Han, E.J.; Kim, H.S.; Sanjeewa, K.K.A.; Herath, K.; Jeon, Y.J.; Jee, Y.; Lee, J.; Kim, T.; Shim, S.Y.; Ahn, G. Eckol from Ecklonia cava Suppresses Immunoglobulin E-mediated Mast Cell Activation and Passive Cutaneous Anaphylaxis in Mice. Nutrients 2020, 12. [CrossRef]
Tai, H.C.; Lee, T.H.; Tang, C.H.; Chen, L.P.; Chen, W.C.; Lee, M.S.; Chen, P.C.; Lin, C.Y.; Chi, C.W.; Chen, Y.J.; et al. Phomaketide A Inhibits Lymphangiogenesis in Human Lymphatic Endothelial Cells. Mar Drugs 2019, 17. [CrossRef]
Yang, M.; Li, H.; Zhang, Q.; Wu, Q.H.; Li, G.; Chen, K.X.; Guo, Y.W.; Tang, W.; Li, X.W. Highly diverse cembranoids from the South China Sea soft coral Sinularia scabra as a new class of potential immunosuppressive agents. Bioorg Med Chem 2019, 27, 3469-3476. [CrossRef]
Laborde, R.J.; Ishimura, M.E.; Abreu-Butin, L.; Nogueira, C.V.; Grubaugh, D.; Cruz-Leal, Y.; Luzardo, M.C.; Fernández, A.; Mesa, C.; Pazos, F.; et al. Sticholysins, pore-forming proteins from a marine anemone can induce maturation of dendritic cells through a TLR4 dependent-pathway. Mol Immunol 2021, 131, 144-154. [CrossRef]
Manzo, E.; Gallo, C.; Sartorius, R.; Nuzzo, G.; Sardo, A.; De Berardinis, P.; Fontana, A.; Cutignano, A. Immunostimulatory Phosphatidylmonogalactosyldiacylglycerols (PGDG) from the Marine Diatom Thalassiosira weissflogii: Inspiration for a Novel Synthetic Toll-Like Receptor 4 Agonist. Mar Drugs 2019, 17. [CrossRef]
Wang, H.L.; Li, R.; Li, J.; He, J.; Cao, Z.Y.; Kurtan, T.; Mandi, A.; Zheng, G.L.; Zhang, W. Alternarin A, a Drimane Meroterpenoid, Suppresses Neuronal Excitability from the Coral-Associated Fungi Alternaria sp. ZH-15. Org Lett 2020, 22, 2995-2998. [CrossRef]
Andrud, K.; Xing, H.; Gabrielsen, B.; Bloom, L.; Mahnir, V.; Lee, S.; Green, B.T.; Lindstrom, J.; Kem, W. Investigation of the Possible Pharmacologically Active Forms of the Nicotinic Acetylcholine Receptor Agonist Anabaseine. Mar Drugs 2019, 17. [CrossRef]
Copmans, D.; Kildgaard, S.; Rasmussen, S.A.; Slezak, M.; Dirkx, N.; Partoens, M.; Esguerra, C.V.; Crawford, A.D.; Larsen, T.O.; de Witte, P.A.M. Zebrafish-Based Discovery of Antiseizure Compounds from the North Sea: Isoquinoline Alkaloids TMC-120A and TMC-120B. Mar Drugs 2019, 17. [CrossRef]
Yang, W.C.; Zhang, Y.Y.; Li, Y.J.; Nie, Y.Y.; Liang, J.Y.; Liu, Y.Y.; Liu, J.S.; Zhang, Y.P.; Song, C.; Qian, Z.J.; et al. Chemical Composition and Anti-Alzheimer’s Disease-Related Activities of a Functional Oil from the Edible Seaweed Hizikia fusiforme. Chem Biodivers 2020, 17, e2000055. [CrossRef]
Han, J.H.; Lee, Y.S.; Im, J.H.; Ham, Y.W.; Lee, H.P.; Han, S.B.; Hong, J.T. Astaxanthin Ameliorates Lipopolysaccharide-Induced Neuroinflammation, Oxidative Stress and Memory Dysfunction through Inactivation of the Signal Transducer and Activator of Transcription 3 Pathway. Mar Drugs 2019, 17. [CrossRef]
Taksima, T.; Chonpathompikunlert, P.; Sroyraya, M.; Hutamekalin, P.; Limpawattana, M.; Klaypradit, W. Effects of Astaxanthin from Shrimp Shell on Oxidative Stress and Behavior in Animal Model of Alzheimer’s Disease. Mar Drugs 2019, 17. [CrossRef]
Lee, J.; Jun, M. Dual BACE1 and Cholinesterase Inhibitory Effects of Phlorotannins from Ecklonia cava-An In Vitro and in Silico Study. Mar Drugs 2019, 17. [CrossRef]
Konoki, K.; Baden, D.G.; Scheuer, T.; Catterall, W.A. Molecular Determinants of Brevetoxin Binding to Voltage-Gated Sodium Channels. Toxins (Basel) 2019, 11. [CrossRef]
Jin, A.H.; Cristofori-Armstrong, B.; Rash, L.D.; Roman-Gonzalez, S.A.; Espinosa, R.A.; Lewis, R.J.; Alewood, P.F.; Vetter, I. Novel conorfamides from Conus austini venom modulate both nicotinic acetylcholine receptors and acid-sensing ion channels. Biochem Pharmacol 2019, 164, 342-348. [CrossRef]
Niu, C.; Leavitt, L.S.; Lin, Z.; Paguigan, N.D.; Sun, L.; Zhang, J.; Torres, J.P.; Raghuraman, S.; Chase, K.; Cadeddu, R.; et al. Neuroactive Type-A γ-Aminobutyric Acid Receptor Allosteric Modulator Steroids from the Hypobranchial Gland of Marine Mollusk,. J Med Chem 2021, 64, 7033-7043. [CrossRef]
Guo, M.; Yu, J.; Zhu, X.; Zhangsun, D.; Luo, S. Characterization of an α 4/7-Conotoxin LvIF from. Mar Drugs 2021, 19. [CrossRef]
Qiang, Y.; Wu, Y.; Zhao, D.; Zhao, B.; Wang, F.; Ren, S.; Wen, Y.; Gu, J.; Zhang, L.; Liu, K.; et al. Discovery and characterization of the novel conotoxin Lv1d from Conus lividus that presents analgesic activity. Toxicon 2021, 194, 70-78. [CrossRef]
Liu, Z.; Yu, Z.; Yu, S.; Zhu, C.; Dong, M.; Mao, W.; Hu, J.; Prorok, M.; Su, R.; Dai, Q. A Conantokin Peptide Con-T[M8Q] Inhibits Morphine Dependence with High Potency and Low Side Effects. Mar Drugs 2021, 19. [CrossRef]
Wu, J.; Xi, Y.; Li, G.; Zheng, Y.; Wang, Z.; Wang, J.; Fang, C.; Sun, Z.; Hu, L.; Jiang, W.; et al. Hydroazulene Diterpenes from a. J Nat Prod 2021, 84, 1306-1315. [CrossRef]
Kim, R.; Hur, D.; Kim, H.K.; Han, J.; Mishchenko, N.P.; Fedoreyev, S.A.; Stonik, V.A.; Chang, W. Echinochrome A Attenuates Cerebral Ischemic Injury through Regulation of Cell Survival after Middle Cerebral Artery Occlusion in Rat. Mar Drugs 2019, 17. [CrossRef]
Paudel, P.; Seong, S.H.; Wu, S.; Park, S.; Jung, H.A.; Choi, J.S. Eckol as a Potential Therapeutic against Neurodegenerative Diseases Targeting Dopamine D(3)/D(4) Receptors. Mar Drugs 2019, 17. [CrossRef]
Silva, J.; Alves, C.; Pinteus, S.; Susano, P.; Simoes, M.; Guedes, M.; Martins, A.; Rehfeldt, S.; Gaspar, H.; Goettert, M.; et al. Disclosing the potential of eleganolone for Parkinson’s disease therapeutics: Neuroprotective and anti-inflammatory activities. Pharmacol Res 2021, 168, 105589. [CrossRef]
Chalorak, P.; Sanguanphun, T.; Limboonreung, T.; Meemon, K. Neurorescue Effects of Frondoside A and Ginsenoside Rg3 in. Molecules 2021, 26. [CrossRef]
Gan, S.Y.; Wong, L.Z.; Wong, J.W.; Tan, E.L. Fucosterol exerts protection against amyloid beta-induced neurotoxicity, reduces intracellular levels of amyloid beta and enhances the mRNA expression of neuroglobin in amyloid beta-induced SH-SY5Y cells. Int J Biol Macromol 2019, 121, 207-213. [CrossRef]
Hannan, M.A.; Dash, R.; Sohag, A.A.M.; Moon, I.S. Deciphering Molecular Mechanism of the Neuropharmacological Action of Fucosterol through Integrated System Pharmacology and In Silico Analysis. Mar Drugs 2019, 17. [CrossRef]
Chen, S.J.; Lee, C.J.; Lin, T.B.; Peng, H.Y.; Liu, H.J.; Chen, Y.S.; Tseng, K.W. Protective Effects of Fucoxanthin on Ultraviolet B-Induced Corneal Denervation and Inflammatory Pain in a Rat Model. Mar Drugs 2019, 17. [CrossRef]
Wu, W.; Han, H.; Liu, J.; Tang, M.; Wu, X.; Cao, X.; Zhao, T.; Lu, Y.; Niu, T.; Chen, J.; et al. Fucoxanthin Prevents 6-OHDA-Induced Neurotoxicity by Targeting Keap1. Oxid Med Cell Longev 2021, 2021, 6688708. [CrossRef]
Kalina, R.S.; Koshelev, S.G.; Zelepuga, E.A.; Kim, N.Y.; Kozlov, S.A.; Kozlovskaya, E.P.; Monastyrnaya, M.M.; Gladkikh, I.N. APETx-Like Peptides from the Sea Anemone Heteractis crispa, Diverse in Their Effect on ASIC1a and ASIC3 Ion Channels. Toxins (Basel) 2020, 12. [CrossRef]
Tangrodchanapong, T.; Sornkaew, N.; Yurasakpong, L.; Niamnont, N.; Nantasenamat, C.; Sobhon, P.; Meemon, K. Beneficial Effects of Cyclic Ether 2-Butoxytetrahydrofuran from Sea Cucumber Holothuria scabra against Abeta Aggregate Toxicity in Transgenic Caenorhabditis elegans and Potential Chemical Interaction. Molecules 2021, 26. [CrossRef]
Fan, T.T.; Zhang, H.H.; Tang, Y.H.; Zhang, F.Z.; Han, B.N. Two New Neo-debromoaplysiatoxins-A Pair of Stereoisomers Exhibiting Potent Kv1.5 Ion Channel Inhibition Activities. Mar Drugs 2019, 17. [CrossRef]
Jiao, Y.; Wang, G.; Li, D.; Li, H.; Liu, J.; Yang, X.; Yang, W. Okadaic Acid Exposure Induced Neural Tube Defects in Chicken (Gallus gallus) Embryos. Mar Drugs 2021, 19. [CrossRef]
Benoit, E.; Couesnon, A.; Lindovsky, J.; Iorga, B.I.; Araoz, R.; Servent, D.; Zakarian, A.; Molgo, J. Synthetic Pinnatoxins A and G Reversibly Block Mouse Skeletal Neuromuscular Transmission In Vivo and In Vitro. Mar Drugs 2019, 17. [CrossRef]
Seong, S.H.; Paudel, P.; Choi, J.W.; Ahn, D.H.; Nam, T.J.; Jung, H.A.; Choi, J.S. Probing Multi-Target Action of Phlorotannins as New Monoamine Oxidase Inhibitors and Dopaminergic Receptor Modulators with the Potential for Treatment of Neuronal Disorders. Mar Drugs 2019, 17. [CrossRef]
Lee, J.P.; Kang, M.G.; Lee, J.Y.; Oh, J.M.; Baek, S.C.; Leem, H.H.; Park, D.; Cho, M.L.; Kim, H. Potent inhibition of acetylcholinesterase by sargachromanol I from Sargassum siliquastrum and by selected natural compounds. Bioorg Chem 2019, 89, 103043. [CrossRef]
Chen, L.; Liu, Y.C.; Tan, H.; Zhang, Y.; Xu, J.; Liu, W.L.; Li, Z.Y.; Li, W.P. Santacruzamate A Ameliorates AD-Like Pathology by Enhancing ER Stress Tolerance Through Regulating the Functions of KDELR and Mia40-ALR in vivo and in vitro. Front Cell Neurosci 2019, 13, 61. [CrossRef]
Jiang, C.S.; Ru, T.; Yao, L.G.; Miao, Z.H.; Guo, Y.W. Four new cembranoids from the Chinese soft coral Sinularia sp. and their anti-Abeta aggregation activities. Fitoterapia 2019, 136, 104176. [CrossRef]
Paudel, P.; Park, S.E.; Seong, S.H.; Jung, H.A.; Choi, J.S. Bromophenols from Symphyocladia latiuscula Target Human Monoamine Oxidase and Dopaminergic Receptors for the Management of Neurodegenerative Diseases. J Agric Food Chem 2020, 68, 2426-2436. [CrossRef]
Liu, Y.; Jin, W.; Deng, Z.; Zhang, Q.; Wang, J. Glucuronomannan GM2 from. Mar Drugs 2021, 19. [CrossRef]
Paudel, P.; Seong, S.H.; Zhou, Y.; Park, H.J.; Jung, H.A.; Choi, J.S. Anti-Alzheimer’s Disease Activity of Bromophenols from a Red Alga, Symphyocladia latiuscula (Harvey) Yamada. ACS Omega 2019, 4, 12259-12270. [CrossRef]
Feng, C.W.; Chen, N.F.; Wen, Z.H.; Yang, W.Y.; Kuo, H.M.; Sung, P.J.; Su, J.H.; Cheng, S.Y.; Chen, W.F. In Vitro and In Vivo Neuroprotective Effects of Stellettin B Through Anti-Apoptosis and the Nrf2/HO-1 Pathway. Mar Drugs 2019, 17. [CrossRef]
Sheng, L.; Lu, B.; Chen, H.; Du, Y.; Chen, C.; Cai, W.; Yang, Y.; Tian, X.; Huang, Z.; Chi, W.; et al. Marine-Steroid Derivative 5alpha-Androst-3beta, 5alpha, 6beta-triol Protects Retinal Ganglion Cells from Ischemia(-)Reperfusion Injury by Activating Nrf2 Pathway. Mar Drugs 2019, 17. [CrossRef]
Liang, X.; Luo, D.; Yan, J.L.; Rezaei, M.A.; Salvador-Reyes, L.A.; Gunasekera, S.P.; Li, C.; Ye, T.; Paul, V.J.; Luesch, H. Discovery of Amantamide, a Selective CXCR7 Agonist from Marine Cyanobacteria. Org Lett 2019, 21, 1622-1626. [CrossRef]
Chakraborty, K.; Krishnan, S.; Joy, M. Macrocyclic lactones from seafood Amphioctopus neglectus: Newly described natural leads to attenuate angiotensin-II induced cardiac hypertrophy. Biomed Pharmacother 2019, 110, 155-167. [CrossRef]
Shi, H. Two novel antioxidant peptides derived from Arca subcrenata against oxidative stress and extend lifespan in Caenorhabditis elegans. J. Funct. Foods 2021, 81, 104462. [CrossRef]
Park, S.C.; Chung, B.; Lee, J.; Cho, E.; Hwang, J.Y.; Oh, D.C.; Shin, J.; Oh, K.B. Sortase A-Inhibitory Metabolites from a Marine-Derived Fungus Aspergillus sp. Mar Drugs 2020, 18. [CrossRef]
Ohshiro, T.; Kobayashi, K.; Suzuki, A.; Yamazaki, H.; Uchida, R.; Namikoshi, M.; Tomoda, H. Inhibition of neutral lipid synthesis by avarols from a marine sponge. Bioorg Med Chem Lett 2019, 29, 2283-2285. [CrossRef]
Son, M.; Oh, S.; Jang, J.T.; Son, K.H.; Byun, K. Pyrogallol-Phloroglucinol-6 6-Bieckol on Attenuates High-Fat Diet-Induced Hypertension by Modulating Endothelial-to-Mesenchymal Transition in the Aorta of Mice. Oxid Med Cell Longev 2021, 2021, 8869085. [CrossRef]
Ryu, Y.S.; Fernando, P.; Kang, K.A.; Piao, M.J.; Zhen, A.X.; Kang, H.K.; Koh, Y.S.; Hyun, J.W. Marine Compound 3-bromo-4,5-dihydroxybenzaldehyde Protects Skin Cells against Oxidative Damage via the Nrf2/HO-1 Pathway. Mar Drugs 2019, 17. [CrossRef]
Chen, H.; Xu, Z.; Fan, F.; Shi, P.; Tu, M.; Wang, Z.; Du, M. Identification and mechanism evaluation of a novel osteogenesis promoting peptide from Tubulin Alpha-1C chain in Crassostrea gigas. Food Chem 2019, 272, 751-757. [CrossRef]
Chen, H.; Cheng, S.; Fan, F.; Tu, M.; Xu, Z.; Du, M. Identification and molecular mechanism of antithrombotic peptides from oyster proteins released in simulated gastro-intestinal digestion. Food Funct 2019, 10, 5426-5435. [CrossRef]
Utkina, N.K.; Likhatskaya, G.N.; Balabanova, L.A.; Bakunina, I.Y. Sponge-derived polybrominated diphenyl ethers and dibenzo-p-dioxins, irreversible inhibitors of the bacterial alpha-d-galactosidase. Environ Sci Process Impacts 2019, 21, 1754-1763. [CrossRef]
Pyeon, D.B.; Lee, S.E.; Yoon, J.W.; Park, H.J.; Park, C.O.; Kim, S.H.; Oh, S.H.; Lee, D.G.; Kim, E.Y.; Park, S.P. The antioxidant dieckol reduces damage of oxidative stress-exposed porcine oocytes and enhances subsequent parthenotes embryo development. Mol Reprod Dev 2021, 88, 349-361. [CrossRef]
Wang, L.; Je, J.G.; Yang, H.W.; Jeon, Y.J.; Lee, S. Dieckol, an Algae-Derived Phenolic Compound, Suppresses UVB-Induced Skin Damage in Human Dermal Fibroblasts and Its Underlying Mechanisms. Antioxidants (Basel) 2021, 10. [CrossRef]
Ding, Y.; Wang, L.; Im, S.; Hwang, O.; Kim, H.S.; Kang, M.C.; Lee, S.H. Anti-Obesity Effect of Diphlorethohydroxycarmalol Isolated from Brown Alga Ishige okamurae in High-Fat Diet-Induced Obese Mice. Mar Drugs 2019, 17. [CrossRef]
Kang, M.C.; Ding, Y.; Kim, H.S.; Jeon, Y.J.; Lee, S.H. Inhibition of Adipogenesis by Diphlorethohydroxycarmalol (DPHC) through AMPK Activation in Adipocytes. Mar Drugs 2019, 17. [CrossRef]
Lu, Y.A.; Jiang, Y.; Yang, H.W.; Hwang, J.; Jeon, Y.J.; Ryu, B. Diphlorethohydroxycarmalol Isolated from. Int J Mol Sci 2021, 22. [CrossRef]
Manandhar, B.; Wagle, A.; Seong, S.H.; Paudel, P.; Kim, H.R.; Jung, H.A.; Choi, J.S. Phlorotannins with Potential Anti-tyrosinase and Antioxidant Activity Isolated from the Marine Seaweed Ecklonia stolonifera. Antioxidants (Basel) 2019, 8. [CrossRef]
Zhen, A.X.; Hyun, Y.J.; Piao, M.J.; Fernando, P.; Kang, K.A.; Ahn, M.J.; Yi, J.M.; Kang, H.K.; Koh, Y.S.; Lee, N.H.; et al. Eckol Inhibits Particulate Matter 2.5-Induced Skin Keratinocyte Damage via MAPK Signaling Pathway. Mar Drugs 2019, 17. [CrossRef]
Jia, X.; Xu, M.; Yang, A.; Zhao, Y.; Liu, D.; Huang, J.; Proksch, P.; Lin, W. Reducing Effect of Farnesylquinone on Lipid Mass in C. elegans by Modulating Lipid Metabolism. Mar Drugs 2019, 17. [CrossRef]
Ohno, Y. Effect of phlorotannins isolated from Eisenia bicyclis on melanogenesis in mouse B16 melanoma cells Nat. Prod. Commun. 2021, 16.
Raji, V.; Loganathan, C.; Sadhasivam, G.; Kandasamy, S.; Poomani, K.; Thayumanavan, P. Purification of fucoxanthin from Sargassum wightii Greville and understanding the inhibition of angiotensin 1-converting enzyme: An in vitro and in silico studies. Int J Biol Macromol 2020, 148, 696-703. [CrossRef]
Yang, G.; Jin, L.; Zheng, D.; Tang, X.; Yang, J.; Fan, L.; Xie, X. Fucoxanthin Alleviates Oxidative Stress through Akt/Sirt1/FoxO3alpha Signaling to Inhibit HG-Induced Renal Fibrosis in GMCs. Mar Drugs 2019, 17. [CrossRef]
Kim, D.C.; Minh Ha, T.; Sohn, J.H.; Yim, J.H.; Oh, H. Protein tyrosine phosphatase 1B inhibitors from a marine-derived fungal strain aspergillus sp. SF-5929. Nat Prod Res 2020, 34, 675-682. [CrossRef]
Wang, Z.; Li, Z.X.; Zhao, W.C.; Huang, H.B.; Wang, J.Q.; Zhang, H.; Lu, J.Y.; Wang, R.N.; Li, W.; Cheng, Z.; et al. Identification and characterization of isocitrate dehydrogenase 1 (IDH1) as a functional target of marine natural product grincamycin B. Acta Pharmacol Sin 2021, 42, 801-813. [CrossRef]
Wang, Y.; Sun, L.; Yu, G.; Qi, X.; Zhang, A.; Lu, Z.; Li, D.; Li, J. Identification of a novel non-ATP-competitive protein kinase inhibitor of PGK1 from marine nature products. Biochem Pharmacol 2021, 183, 114343. [CrossRef]
Oh, Y.; Ahn, C.B.; Je, J.Y. Cytoprotective Role of Edible Seahorse (Mar Drugs 2021, 19. [CrossRef]
Lee, H.G.; Kim, H.S.; Je, J.G.; Hwang, J.; Sanjeewa, K.K.A.; Lee, D.S.; Song, K.M.; Choi, Y.S.; Kang, M.C.; Jeon, Y.J. Lipid Inhibitory Effect of (-)-loliolide Isolated from. Mar Drugs 2021, 19. [CrossRef]
Bakunina, I.; Likhatskaya, G.; Slepchenko, L.; Balabanova, L.; Tekutyeva, L.; Son, O.; Shubina, L.; Makarieva, T. Effect of Pentacyclic Guanidine Alkaloids from the Sponge Monanchora pulchra on Activity of alpha-Glycosidases from Marine Bacteria. Mar Drugs 2019, 17. [CrossRef]
Nagabhishek, S.N.K., A.M. ; B, S. ; Balakrishnan, A. ; Katakia, Y.T., Chatterjee, S. ; Nagasundaram, N. . A marine sponge associated fungal metabolite monacolin X suppresses angiogenesis by down regulating VEGFR2 signaling. RSC Adv 2019, 9, 26646-26667, doi:DOI: 10.1039/C9RA05262C.
D’Aniello, E.; Iannotti, F.A.; Falkenberg, L.G.; Martella, A.; Gentile, A.; De Maio, F.; Ciavatta, M.L.; Gavagnin, M.; Waxman, J.S.; Di Marzo, V.; et al. In Silico Identification and Experimental Validation of (-)-Muqubilin A, a Marine Norterpene Peroxide, as PPARalpha/gamma-RXRalpha Agonist and RARalpha Positive Allosteric Modulator. Mar Drugs 2019, 17. [CrossRef]
Hayashi-Takanaka, Y.; Kina, Y.; Nakamura, F.; Yamazaki, S.; Harata, M.; Soest, R.; Kimura, H.; Nakao, Y. Effect of mycalolides isolated from a marine sponge Mycale aff. nullarosette on actin in living cells. Sci Rep 2019, 9, 7540. [CrossRef]
Xu, Z.; Chen, H.; Fan, F.; Shi, P.; Tu, M.; Cheng, S.; Wang, Z.; Du, M. Bone formation activity of an osteogenic dodecapeptide from blue mussels (Mytilus edulis). Food Funct 2019, 10, 5616-5625. [CrossRef]
Chen, J.; Gong, F.; Chen, M.F.; Li, C.; Hong, P.; Sun, S.; Zhou, C.; Qian, Z.J. In Vitro Vascular-Protective Effects of a Tilapia By-Product Oligopeptide on Angiotensin II-Induced Hypertensive Endothelial Injury in HUVEC by Nrf2/NF-kappaB Pathways. Mar Drugs 2019, 17. [CrossRef]
Kong, F.D.; Fan, P.; Zhou, L.M.; Ma, Q.Y.; Xie, Q.Y.; Zheng, H.Z.; Zheng, Z.H.; Zhang, R.S.; Yuan, J.Z.; Dai, H.F.; et al. Penerpenes A-D, Four Indole Terpenoids with Potent Protein Tyrosine Phosphatase Inhibitory Activity from the Marine-Derived Fungus Penicillium sp. KFD28. Org Lett 2019, 21, 4864-4867. [CrossRef]
Dai, J.; Chen, A.; Zhu, M.; Qi, X.; Tang, W.; Liu, M.; Li, D.; Gu, Q.; Li, J. Penicisulfuranol A, a novel C-terminal inhibitor disrupting molecular chaperone function of Hsp90 independent of ATP binding domain. Biochem Pharmacol 2019, 163, 404-415. [CrossRef]
Wang, J.; Liang, Z.; Li, K.; Yang, B.; Liu, Y.; Fang, W.; Tang, L.; Zhou, X. Ene-yne Hydroquinones from a Marine-derived Strain of the Fungus Pestalotiopsis neglecta with Effects on Liver X Receptor Alpha. J Nat Prod 2020, 83, 1258-1264. [CrossRef]
Tang, W.Z.; Liu, J.T.; Hu, Q.; He, R.J.; Guan, X.Q.; Ge, G.B.; Han, H.; Yang, F.; Lin, H.W. Pancreatic Lipase Inhibitory Cyclohexapeptides from the Marine Sponge-Derived Fungus Aspergillus sp. 151304. J Nat Prod 2020, 83, 2287-2293. [CrossRef]
Wu, Y.; Liao, H.; Liu, L.Y.; Sun, F.; Chen, H.F.; Jiao, W.H.; Zhu, H.R.; Yang, F.; Huang, G.; Zeng, D.Q.; et al. Phakefustatins A-C: Kynurenine-Bearing Cycloheptapeptides as RXRalpha Modulators from the Marine Sponge Phakellia fusca. Org Lett 2020, 22, 6703-6708. [CrossRef]
Kim, J.H.; Lee, S.; Park, S.; Park, J.S.; Kim, Y.H.; Yang, S.Y. Slow-Binding Inhibition of Tyrosinase by Ecklonia cava Phlorotannins. Mar Drugs 2019, 17. [CrossRef]
Heo, S.Y.; Jeong, M.S.; Lee, H.S.; Kim, Y.J.; Park, S.H.; Jung, W.K. Phlorofucofuroeckol A from Ecklonia cava ameliorates TGF-beta1-induced fibrotic response of human tracheal fibroblasts via the downregulation of MAPKs and SMAD 2/3 pathways inactivated TGF-beta receptor. Biochem Biophys Res Commun 2020, 522, 626-632. [CrossRef]
Oh, J.H.; Ahn, B.N.; Karadeniz, F.; Kim, J.A.; Lee, J.I.; Seo, Y.; Kong, C.S. Phlorofucofuroeckol A from Edible Brown Alga Ecklonia Cava Enhances Osteoblastogenesis in Bone Marrow-Derived Human Mesenchymal Stem Cells. Mar Drugs 2019, 17. [CrossRef]
Guo, X.C.; Zhang, Y.H.; Gao, W.B.; Pan, L.; Zhu, H.J.; Cao, F. Absolute Configurations and Chitinase Inhibitions of Quinazoline-Containing Diketopiperazines from the Marine-Derived Fungus Penicillium polonicum. Mar Drugs 2020, 18. [CrossRef]
Ko, S.C.; Ding, Y.; Kim, J.; Ye, B.R.; Kim, E.A.; Jung, W.K.; Heo, S.J.; Lee, S.H. Bromophenol (5-bromo-3,4-dihydroxybenzaldehyde) isolated from red alga Polysiphonia morrowii inhibits adipogenesis by regulating expression of adipogenic transcription factors and AMP-activated protein kinase activation in 3T3-L1 adipocytes. Phytother Res 2019, 33, 737-744. [CrossRef]
Park, J.S.; Quang, T.H.; Thi Thanh Ngan, N.; Sohn, J.H.; Oh, H. New preaustinoids from a marine-derived fungal strain Penicillium sp. SF-5497 and their inhibitory effects against PTP1B activity. J Antibiot (Tokyo) 2019, 72, 629-633. [CrossRef]
Lee, M.K.; Choi, J.W.; Choi, Y.H.; Nam, T.J. Protective Effect of Pyropia yezoensis Peptide on Dexamethasone-Induced Myotube Atrophy in C2C12 Myotubes. Mar Drugs 2019, 17. [CrossRef]
Tseng, C.C.; Lai, Y.C.; Kuo, T.J.; Su, J.H.; Sung, P.J.; Feng, C.W.; Lin, Y.Y.; Chen, P.C.; Tai, M.H.; Cheng, S.Y.; et al. Rhodoptilometrin, a Crinoid-Derived Anthraquinone, Induces Cell Regeneration by Promoting Wound Healing and Oxidative Phosphorylation in Human Gingival Fibroblast Cells. Mar Drugs 2019, 17. [CrossRef]
Kwon, M.L., B. ; Lim, S.J. ; Choi, J.S. ; Kim, H.R. Sargahydroquinoic acid, a major compound in Sargassum serratifolium (C. Agardh) C. Agardh, widely activates lipid catabolic pathways, contributing to the formation of beige-like adipocytes. J. Funct. Foods 2019, 58, 355-366. [CrossRef]
Halkias, C.; Darby, W.G.; Feltis, B.N.; McIntyre, P.; Macrides, T.A.; Wright, P.F.A. Marine Bile Natural Products as Agonists of the TGR5 Receptor. J Nat Prod 2021, 84, 1507-1514. [CrossRef]
Ji-Yeon, H.; Beomkoo, C.; Oh-Seok, K.; sung, P.; Eunji, C.; Dong, O.; Jongheon, S.; Ki-bong, O. Inhibitory effects of epipolythiodioxopiperazine fungal metabolites on isocitrate lyase in the glyoxylate cycle of Candida albicans. Mar drugs 2021, 19, 295. [CrossRef]
Zhang, H.; Li, R.; Ba, S.; Lu, Z.; Pitsinos, E.N.; Li, T.; Nicolaou, K.C. DNA Binding and Cleavage Modes of Shishijimicin A. J Am Chem Soc 2019, 141, 7842-7852. [CrossRef]
Zheng, J.; Manabe, Y.; Sugawara, T. Siphonaxanthin, a carotenoid from green algae Codium cylindricum, protects Ob/Ob mice fed on a high-fat diet against lipotoxicity by ameliorating somatic stresses and restoring anti-oxidative capacity. Nutr Res 2020, 77, 29-42. [CrossRef]
Paudel, P.; Wagle, A.; Seong, S.H.; Park, H.J.; Jung, H.A.; Choi, J.S. A New Tyrosinase Inhibitor from the Red Alga Symphyocladia latiuscula (Harvey) Yamada (Rhodomelaceae). Mar Drugs 2019, 17. [CrossRef]
Qiao, X.; Gan, M.; Wang, C.; Liu, B.; Shang, Y.; Li, Y.; Chen, S. Tetracenomycin X Exerts Antitumour Activity in Lung Cancer Cells through the Downregulation of Cyclin D1. Mar Drugs 2019, 17. [CrossRef]
Keller, L.; Canuto, K.M.; Liu, C.; Suzuki, B.M.; Almaliti, J.; Sikandar, A.; Naman, C.B.; Glukhov, E.; Luo, D.; Duggan, B.M.; et al. Tutuilamides A-C: Vinyl-Chloride-Containing Cyclodepsipeptides from Marine Cyanobacteria with Potent Elastase Inhibitory Properties. ACS Chem Biol 2020, 15, 751-757. [CrossRef]
Feng, X.; Liao, D.; Sun, L.; Wu, S.; Lan, P.; Wang, Z.; Li, C.; Zhou, Q.; Lu, Y.; Lan, X. Affinity Purification of Angiotensin Converting Enzyme Inhibitory Peptides from Wakame (Undaria Pinnatifida) Using Immobilized ACE on Magnetic Metal Organic Frameworks. Mar Drugs 2021, 19. [CrossRef]
El-Baz, F.K.; Hussein, R.A.; Saleh, D.O.; Abdel Jaleel, G.A.R. Zeaxanthin Isolated from Dunaliella salina Microalgae Ameliorates Age Associated Cardiac Dysfunction in Rats through Stimulation of Retinoid Receptors. Mar Drugs 2019, 17. [CrossRef]
Carroll, A.R.; Copp, B.R.; Davis, R.A.; Keyzers, R.A.; Prinsep, M.R. Marine natural products. Nat Prod Rep 2021, 38, 362-413. [CrossRef]
Liang, X.; Luo, D.; Luesch, H. Advances in exploring the therapeutic potential of marine natural products. Pharmacol Res 2019, 147, 104373. [CrossRef]
Nunez-Pons, L.; Shilling, A.; Verde, C.; Baker, B.J.; Giordano, D. Marine Terpenoids from Polar Latitudes and Their Potential Applications in Biotechnology. Mar Drugs 2020, 18. [CrossRef]
Carroll, A.R.; Copp, B.R.; Davis, R.A.; Keyzers, R.A.; Prinsep, M.R. Marine natural products. Nat Prod Rep 2022, 39, 1122-1171. [CrossRef]
Carroll, A.R.; Copp, B.R.; Davis, R.A.; Keyzers, R.A.; Prinsep, M.R. Marine natural products. Nat Prod Rep 2023, 40, 275-325. [CrossRef]
Mateos, R.; Perez-Correa, J.R.; Dominguez, H. Bioactive Properties of Marine Phenolics. Mar Drugs 2020, 18. [CrossRef]
Martins, B.T.; Correia da Silva, M.; Pinto, M.; Cidade, H.; Kijjoa, A. Marine natural flavonoids: chemistry and biological activities. Nat Prod Res 2019, 33, 3260-3272. [CrossRef]
Braddock, A.A.; Theodorakis, E.A. Marine Spirotetronates: Biosynthetic Edifices That Inspire Drug Discovery. Mar Drugs 2019, 17. [CrossRef]
Vil, V.A.; Gloriozova, T.A.; Terent’ev, A.O.; Savidov, N.; Dembitsky, V.M. Hydroperoxides derived from marine sources: origin and biological activities. Appl Microbiol Biotechnol 2019, 103, 1627-1642. [CrossRef]
Althagbi, H.I.; Alarif, W.M.; Al-Footy, K.O.; Abdel-Lateff, A. Marine-Derived Macrocyclic Alkaloids (MDMAs): Chemical and Biological Diversity. Mar Drugs 2020, 18. [CrossRef]
Dahiya, R.; Dahiya, S.; Fuloria, N.K.; Kumar, S.; Mourya, R.; Chennupati, S.V.; Jankie, S.; Gautam, H.; Singh, S.; Karan, S.K.; et al. Natural Bioactive Thiazole-Based Peptides from Marine Resources: Structural and Pharmacological Aspects. Mar Drugs 2020, 18. [CrossRef]
El-Demerdash, A.; Kumla, D.; Kijjoa, A. Chemical Diversity and Biological Activities of Meroterpenoids from Marine Derived-Fungi: A Comprehensive Update. Mar Drugs 2020, 18. [CrossRef]
Li, G.; Dickschat, J.S.; Guo, Y.W. Diving into the world of marine 2,11-cyclized cembranoids: a summary of new compounds and their biological activities. Nat Prod Rep 2020, 37, 1367-1383. [CrossRef]
Zhang, H.; Zou, J.; Yan, X.; Chen, J.; Cao, X.; Wu, J.; Liu, Y.; Wang, T. Marine-Derived Macrolides 1990-2020: An Overview of Chemical and Biological Diversity. Mar Drugs 2021, 19. [CrossRef]
Demay, J.; Bernard, C.; Reinhardt, A.; Marie, B. Natural Products from Cyanobacteria: Focus on Beneficial Activities. Mar Drugs 2019, 17. [CrossRef]
Fidor, A.; Konkel, R.; Mazur-Marzec, H. Bioactive Peptides Produced by Cyanobacteria of the Genus Nostoc: A Review. Mar Drugs 2019, 17. [CrossRef]
Huang, I.S.; Zimba, P.V. Cyanobacterial bioactive metabolites-A review of their chemistry and biology. Harmful Algae 2019, 86, 139-209. [CrossRef]
Li, Y.; Naman, C.B.; Alexander, K.L.; Guan, H.; Gerwick, W.H. The Chemistry, Biochemistry and Pharmacology of Marine Natural Products from Leptolyngbya, a Chemically Endowed Genus of Cyanobacteria. Mar Drugs 2020, 18. [CrossRef]
Tan, L.T.; Phyo, M.Y. Marine Cyanobacteria: A Source of Lead Compounds and their Clinically-Relevant Molecular Targets. Molecules 2020, 25. [CrossRef]
Qamar, H.; Hussain, K.; Soni, A.; Khan, A.; Hussain, T.; Chénais, B. Cyanobacteria as Natural Therapeutics and Pharmaceutical Potential: Role in Antitumor Activity and as Nanovectors. Molecules 2021, 26. [CrossRef]
Lauritano, C.; Ferrante, M.I.; Rogato, A. Marine Natural Products from Microalgae: An -Omics Overview. Mar Drugs 2019, 17. [CrossRef]
Sathasivam, R.; Radhakrishnan, R.; Hashem, A.; Abd Allah, E.F. Microalgae metabolites: A rich source for food and medicine. Saudi J Biol Sci 2019, 26, 709-722. [CrossRef]
Salehi, B.; Sharifi-Rad, J.; Seca, A.M.L.; Pinto, D.; Michalak, I.; Trincone, A.; Mishra, A.P.; Nigam, M.; Zam, W.; Martins, N. Current Trends on Seaweeds: Looking at Chemical Composition, Phytopharmacology, and Cosmetic Applications. Molecules 2019, 24. [CrossRef]
Cikos, A.M.; Jurin, M.; Coz-Rakovac, R.; Jokic, S.; Jerkovic, I. Update on Monoterpenes from Red Macroalgae: Isolation, Analysis, and Bioactivity. Mar Drugs 2019, 17. [CrossRef]
Freile-Pelegrin, Y.T., D. Seaweeds to the rescue of forgotten diseases: a review. Bot. Mar. 2019, 62, 211-226. [CrossRef]
Hannan, M.A.; Sohag, A.A.M.; Dash, R.; Haque, M.N.; Mohibbullah, M.; Oktaviani, D.F.; Hossain, M.T.; Choi, H.J.; Moon, I.S. Phytosterols of marine algae: Insights into the potential health benefits and molecular pharmacology. Phytomedicine 2020, 69, 153201. [CrossRef]
Rosa, G.P.; Tavares, W.R.; Sousa, P.M.C.; Pages, A.K.; Seca, A.M.L.; Pinto, D. Seaweed Secondary Metabolites with Beneficial Health Effects: An Overview of Successes in In Vivo Studies and Clinical Trials. Mar Drugs 2019, 18. [CrossRef]
Rushdi, I.A.-R., I.; Saber, H.; Attia, E.; Abdelraheem, W.; Madkour, H.; Hassan, H.; Elmaidomv, A.; Abdelmohsen, U. Pharmacological and natural products diversity of the brown algae genus Sargassum. RSC Adv. 2020, 10, 24951-24972. [CrossRef]
Purcell-Meyerink, D.; Packer, M.A.; Wheeler, T.T.; Hayes, M. Aquaculture Production of the Brown Seaweeds. Molecules 2021, 26. [CrossRef]
Shannon, E.; Conlon, M.; Hayes, M. Seaweed Components as Potential Modulators of the Gut Microbiota. Mar Drugs 2021, 19. [CrossRef]
Thangaraj, S.B., S. ; Gokula, V. Bioactive compounds of sea anemones: a review. Int. J. Pept. Res. Ther. 2019, 25, 1405-1416. [CrossRef]
Tinta, T.; Kogovsek, T.; Klun, K.; Malej, A.; Herndl, G.J.; Turk, V. Jellyfish-Associated Microbiome in the Marine Environment: Exploring Its Biotechnological Potential. Mar Drugs 2019, 17. [CrossRef]
Ciavatta, M.L.; Lefranc, F.; Vieira, L.M.; Kiss, R.; Carbone, M.; van Otterlo, W.A.L.; Lopanik, N.B.; Waeschenbach, A. The Phylum Bryozoa: From Biology to Biomedical Potential. Mar Drugs 2020, 18. [CrossRef]
Guillen, P.O.; Jaramillo, K.B.; Genta-Jouve, G.; Thomas, O.P. Marine natural products from zoantharians: bioactivity, biosynthesis, systematics, and ecological roles. Nat Prod Rep 2020, 37, 515-540. [CrossRef]
Youssef, D.T.A.; Almagthali, H.; Shaala, L.A.; Schmidt, E.W. Secondary Metabolites of the Genus Didemnum: A Comprehensive Review of Chemical Diversity and Pharmacological Properties. Mar Drugs 2020, 18. [CrossRef]
Barone, G.V., S.; Tangherlini, M.; Rastelli, E.; Dell’Anno, A.; Danovaro, R.; Corinaldesi, C. . Marine fungi: biotechnological perspectives from deep-hypersaline anoxic basins. Diversity 2019, 11, 113. [CrossRef]
Youssef, F.S.; Ashour, M.L.; Singab, A.N.B.; Wink, M. A Comprehensive Review of Bioactive Peptides from Marine Fungi and Their Biological Significance. Mar Drugs 2019, 17. [CrossRef]
Youssef, F.S.; Simal-Gandara, J. Comprehensive Overview on the Chemistry and Biological Activities of Selected Alkaloid Producing Marine-Derived Fungi as a Valuable Reservoir of Drug Entities. Biomedicines 2021, 9. [CrossRef]
Pandey, A. Pharmacological significance of marine microbial bioactive compounds. Environ Chem Lett 2019, 17, 1741-1751. [CrossRef]
Sang, V.T.; Dat, T.T.H.; Vinh, L.B.; Cuong, L.C.V.; Oanh, P.T.T.; Ha, H.; Kim, Y.H.; Anh, H.L.T.; Yang, S.Y. Coral and Coral-Associated Microorganisms: A Prolific Source of Potential Bioactive Natural Products. Mar Drugs 2019, 17. [CrossRef]
Santos, J.D.; Vitorino, I.; Reyes, F.; Vicente, F.; Lage, O.M. From Ocean to Medicine: Pharmaceutical Applications of Metabolites from Marine Bacteria. Antibiotics (Basel) 2020, 9. [CrossRef]
Sayed, A.M.; Abdel-Wahab, N.M.; Hassan, H.M.; Abdelmohsen, U.R. Saccharopolyspora: an underexplored source for bioactive natural products. J Appl Microbiol 2020, 128, 314-329. [CrossRef]
Xu, J.L.; Liu, Z.F.; Zhang, X.W.; Liu, H.L.; Wang, Y. Microbial Oligosaccharides with Biomedical Applications. Mar Drugs 2021, 19. [CrossRef]
Shady, N.H.; Fouad, M.A.; Salah Kamel, M.; Schirmeister, T.; Abdelmohsen, U.R. Natural Product Repertoire of the Genus Amphimedon. Mar Drugs 2018, 17. [CrossRef]
Varijakzhan, D.; Loh, J.Y.; Yap, W.S.; Yusoff, K.; Seboussi, R.; Lim, S.E.; Lai, K.S.; Chong, C.M. Bioactive Compounds from Marine Sponges: Fundamentals and Applications. Mar Drugs 2021, 19. [CrossRef]
Nabeelah Bibi, S.; Fawzi, M.M.; Gokhan, Z.; Rajesh, J.; Nadeem, N.; Kannan, R.R.R.; R, D.D.G.A.; Pandian, S.K. Ethnopharmacology, Phytochemistry, and Global Distribution of Mangroves-A Comprehensive Review. Mar Drugs 2019, 17. [CrossRef]
Islam, M.T.; Sharifi-Rad, J.; Martorell, M.; Ali, E.S.; Asghar, M.N.; Deeba, F.; Firoz, C.K.; Mubarak, M.S. Chemical profile and therapeutic potentials of Xylocarpus moluccensis (Lam.) M. Roem.: A literature-based review. J Ethnopharmacol 2020, 259, 112958. [CrossRef]
Jia, S.L.; Chi, Z.; Liu, G.L.; Hu, Z.; Chi, Z.M. Fungi in mangrove ecosystems and their potential applications. Crit Rev Biotechnol 2020, 40, 852-864. [CrossRef]
Hanif, N.; Murni, A.; Tanaka, C.; Tanaka, J. Marine Natural Products from Indonesian Waters. Mar Drugs 2019, 17. [CrossRef]
El-Hossary, E.M.; Abdel-Halim, M.; Ibrahim, E.S.; Pimentel-Elardo, S.M.; Nodwell, J.R.; Handoussa, H.; Abdelwahab, M.F.; Holzgrabe, U.; Abdelmohsen, U.R. Natural Products Repertoire of the Red Sea. Mar Drugs 2020, 18. [CrossRef]
Sun, W.; Wu, W.; Liu, X.; Zaleta-Pinet, D.A.; Clark, B.R. Bioactive Compounds Isolated from Marine-Derived Microbes in China: 2009-2018. Mar Drugs 2019, 17. [CrossRef]
Pech-Puch, D.; Perez-Povedano, M.; Gomez, P.; Martinez-Guitian, M.; Lasarte-Monterrubio, C.; Vazquez-Ucha, J.C.; Novoa-Olmedo, M.L.; Guillen-Hernandez, S.; Villegas-Hernandez, H.; Bou, G.; et al. Marine Organisms from the Yucatan Peninsula (Mexico) as a Potential Natural Source of Antibacterial Compounds. Mar Drugs 2020, 18. [CrossRef]
Shinde, P.; Banerjee, P.; Mandhare, A. Marine natural products as source of new drugs: a patent review (2015-2018). Expert Opin Ther Pat 2019, 29, 283-309. [CrossRef]
Pereira, F. Have marine natural product drug discovery efforts been productive and how can we improve their efficiency? Expert Opin Drug Discov 2019, 14, 717-722. [CrossRef]
Newman, D.J. Natural Product Based Antibody Drug Conjugates: Clinical Status as of November 9, 2020. J Nat Prod 2021, 84, 917-931. [CrossRef]
Andryukov, B.M., V. ; Besednova, N. The biotechnological potential of secondary metabolites from marine bacteria. J. Mar. Sci. Eng 2019, 7, 176. [CrossRef]
Stincone, P.; Brandelli, A. Marine bacteria as source of antimicrobial compounds. Crit Rev Biotechnol 2020, 40, 306-319. [CrossRef]
Datta, S.R.; Roy, A. Antimicrobial peptides as potential therapeutic agents: a review. Int. J. Pept. Res. Ther 2021, 27, 555-577. [CrossRef]
Zhang, S.; Liang, X.; Gadd, G.M.; Zhao, Q. Marine Microbial-Derived Antibiotics and Biosurfactants as Potential New Agents against Catheter-Associated Urinary Tract Infections. Mar Drugs 2021, 19. [CrossRef]
Borges, A.; Simoes, M. Quorum Sensing Inhibition by Marine Bacteria. Mar Drugs 2019, 17. [CrossRef]
Chen, J.; Wang, B.; Lu, Y.; Guo, Y.; Sun, J.; Wei, B.; Zhang, H.; Wang, H. Quorum Sensing Inhibitors from Marine Microorganisms and Their Synthetic Derivatives. Mar Drugs 2019, 17. [CrossRef]
Torres, M.; Dessaux, Y.; Llamas, I. Saline Environments as a Source of Potential Quorum Sensing Disruptors to Control Bacterial Infections: A Review. Mar Drugs 2019, 17. [CrossRef]
Zhao, J.; Li, X.; Hou, X.; Quan, C.; Chen, M. Widespread Existence of Quorum Sensing Inhibitors in Marine Bacteria: Potential Drugs to Combat Pathogens with Novel Strategies. Mar Drugs 2019, 17. [CrossRef]
Liu, Y.; Ding, S.; Shen, J.; Zhu, K. Nonribosomal antibacterial peptides that target multidrug-resistant bacteria. Nat Prod Rep 2019, 36, 573-592. [CrossRef]
Barbosa, F.; Pinto, E.; Kijjoa, A.; Pinto, M.; Sousa, E. Targeting antimicrobial drug resistance with marine natural products. Int J Antimicrob Agents 2020, 56, 106005. [CrossRef]
Liu, M.; El-Hossary, E.M.; Oelschlaeger, T.A.; Donia, M.S.; Quinn, R.J.; Abdelmohsen, U.R. Potential of marine natural products against drug-resistant bacterial infections. Lancet Infect Dis 2019, 19, e237-e245. [CrossRef]
Casertano, M.; Menna, M.; Imperatore, C. The Ascidian-Derived Metabolites with Antimicrobial Properties. Antibiotics (Basel) 2020, 9. [CrossRef]
Neshani, A.; Zare, H.; Akbari Eidgahi, M.R.; Khaledi, A.; Ghazvini, K. Epinecidin-1, a highly potent marine antimicrobial peptide with anticancer and immunomodulatory activities. BMC Pharmacol Toxicol 2019, 20, 33. [CrossRef]
Portelinha, J.; Duay, S.S.; Yu, S.I.; Heilemann, K.; Libardo, M.D.J.; Juliano, S.A.; Klassen, J.L.; Angeles-Boza, A.M. Antimicrobial Peptides and Copper(II) Ions: Novel Therapeutic Opportunities. Chem Rev 2021, 121, 2648-2712. [CrossRef]
Willems, T.; De Mol, M.L.; De Bruycker, A.; De Maeseneire, S.L.; Soetaert, W.K. Alkaloids from Marine Fungi: Promising Antimicrobials. Antibiotics (Basel) 2020, 9. [CrossRef]
Wang, C.; Tang, S.; Cao, S. Antimicrobial compounds from marine fungi. Phytochem. Rev 2021, 20. [CrossRef]
Karpinski, T.M. Marine Macrolides with Antibacterial and/or Antifungal Activity. Mar Drugs 2019, 17. [CrossRef]
Alves, E.; Dias, M.; Lopes, D.; Almeida, A.; Domingues, M.D.R.; Rey, F. Antimicrobial Lipids from Plants and Marine Organisms: An Overview of the Current State-of-the-Art and Future Prospects. Antibiotics (Basel) 2020, 9. [CrossRef]
Almeida, M.C.; Resende, D.; da Costa, P.M.; Pinto, M.M.M.; Sousa, E. Tryptophan derived natural marine alkaloids and synthetic derivatives as promising antimicrobial agents. Eur J Med Chem 2021, 209, 112945. [CrossRef]
Arockianathan, P.M.; Mishra, M.; Niranjan, R. Recent Status and Advancements in the Development of Antifungal Agents: Highlights on Plant and Marine Based Antifungals. Curr Top Med Chem 2019, 19, 812-830. [CrossRef]
Christy, M.P.; Uekusa, Y.; Gerwick, L.; Gerwick, W.H. Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2. J Nat Prod 2021, 84, 161-182. [CrossRef]
Hamoda, A.M.; Fayed, B.; Ashmawy, N.S.; El-Shorbagi, A.A.; Hamdy, R.; Soliman, S.S.M. Marine Sponge is a Promising Natural Source of Anti-SARS-CoV-2 Scaffold. Front Pharmacol 2021, 12, 666664. [CrossRef]
Khan, M.T.; Ali, A.; Wang, Q.; Irfan, M.; Khan, A.; Zeb, M.T.; Zhang, Y.J.; Chinnasamy, S.; Wei, D.Q. Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2-a molecular dynamic study. J Biomol Struct Dyn 2021, 39, 3627-3637. [CrossRef]
El-Tantawy, W.H.; Temraz, A. Natural products for the management of the hepatitis C virus: a biochemical review. Arch Physiol Biochem 2020, 126, 116-128. [CrossRef]
Sun, T.T.; Zhu, H.J.; Cao, F. Marine Natural Products as a Source of Drug Leads against Respiratory Viruses: Structural and Bioactive Diversity. Curr Med Chem 2021, 28, 3568-3594. [CrossRef]
Sansone, C.; Brunet, C.; Noonan, D.M.; Albini, A. Marine Algal Antioxidants as Potential Vectors for Controlling Viral Diseases. Antioxidants (Basel) 2020, 9. [CrossRef]
Pagarete, A.; Ramos, A.S.; Puntervoll, P.; Allen, M.J.; Verdelho, V. Antiviral Potential of Algal Metabolites-A Comprehensive Review. Mar Drugs 2021, 19. [CrossRef]
Besednova, N.N.; Andryukov, B.G.; Zaporozhets, T.S.; Kryzhanovsky, S.P.; Fedyanina, L.N.; Kuznetsova, T.A.; Zvyagintseva, T.N.; Shchelkanov, M.Y. Antiviral Effects of Polyphenols from Marine Algae. Biomedicines 2021, 9. [CrossRef]
Diaz-Marrero, A.R.; Lopez-Arencibia, A.; Bethencout-Estrella, C.J.; Cen-Pacheco, F.; Sifaoui, I.; Hernandez Creus, A.; Duque-Ramirez, M.C.; Souto, M.L.; Hernandez Daranas, A.; Lorenzo-Morales, J.; et al. Antiprotozoal activities of marine polyether triterpenoids. Bioorg Chem 2019, 92, 103276. [CrossRef]
Lee, S.M.; Kim, M.S.; Hayat, F.; Shin, D. Recent Advances in the Discovery of Novel Antiprotozoal Agents. Molecules 2019, 24. [CrossRef]
Zhang, S.K., I.; Brimble, M. Naturally occurring antitubercular cyclic peptides. Tetrahedron Lett. 2019, 60, 151339. [CrossRef]
Alvarez-Bardon, M.; Perez-Pertejo, Y.; Ordonez, C.; Sepulveda-Crespo, D.; Carballeira, N.M.; Tekwani, B.L.; Murugesan, S.; Martinez-Valladares, M.; Garcia-Estrada, C.; Reguera, R.M.; et al. Screening Marine Natural Products for New Drug Leads against Trypanosomatids and Malaria. Mar Drugs 2020, 18. [CrossRef]
Nweze, J.A.; Mbaoji, F.N.; Li, Y.M.; Yang, L.Y.; Huang, S.S.; Chigor, V.N.; Eze, E.A.; Pan, L.X.; Zhang, T.; Yang, D.F. Potentials of marine natural products against malaria, leishmaniasis, and trypanosomiasis parasites: a review of recent articles. Infect Dis Poverty 2021, 10, 9. [CrossRef]
Aguiar, A.C.C.; Parisi, J.R.; Granito, R.N.; de Sousa, L.R.F.; Renno, A.C.M.; Gazarini, M.L. Metabolites from Marine Sponges and Their Potential to Treat Malarial Protozoan Parasites Infection: A Systematic Review. Mar Drugs 2021, 19. [CrossRef]
Hou, X.M.; Wang, C.Y.; Gerwick, W.H.; Shao, C.L. Marine natural products as potential anti-tubercular agents. Eur J Med Chem 2019, 165, 273-292. [CrossRef]
Khan, M.T.; Kaushik, A.C.; Bhatti, A.I.; Zhang, Y.J.; Zhang, S.; Wei, A.J.; Malik, S.I.; Wei, D.Q. Marine Natural Products and Drug Resistance in Latent Tuberculosis. Mar Drugs 2019, 17. [CrossRef]
Zhao, M.M.Z., K. W. . Marine natural products with anti-inflammation effects. Trad. Med. Res. 2020, 5, 252-260. [CrossRef]
Bilal, M.; Qindeel, M.; Nunes, L.V.; Duarte, M.T.S.; Ferreira, L.F.R.; Soriano, R.N.; Iqbal, H.M.N. Marine-Derived Biologically Active Compounds for the Potential Treatment of Rheumatoid Arthritis. Mar Drugs 2020, 19. [CrossRef]
Souza, C.R.M.; Bezerra, W.P.; Souto, J.T. Marine Alkaloids with Anti-Inflammatory Activity: Current Knowledge and Future Perspectives. Mar Drugs 2020, 18. [CrossRef]
Xu, J.; Yi, M.; Ding, L.; He, S. A Review of Anti-Inflammatory Compounds from Marine Fungi, 2000-2018. Mar Drugs 2019, 17. [CrossRef]
Di Costanzo, F.; Di Dato, V.; Ianora, A.; Romano, G. Prostaglandins in Marine Organisms: A Review. Mar Drugs 2019, 17. [CrossRef]
Kemp, D.C.; Kwon, J.Y. Fish and Shellfish-Derived Anti-Inflammatory Protein Products: Properties and Mechanisms. Molecules 2021, 26. [CrossRef]
Ahmad, S.; Saleem, M.; Riaz, N.; Lee, Y.S.; Diri, R.; Noor, A.; Almasri, D.; Bagalagel, A.; Elsebai, M.F. The Natural Polypeptides as Significant Elastase Inhibitors. Front Pharmacol 2020, 11, 688. [CrossRef]
Zhang, Y.R.M.J.X.Z.L.J. Anti-inflammatory and immunomodulatory effects of marine n-3 polyunsaturated fatty acids on human health and diseases. J. Ocean Univ. China 2019, 18, 481-492. [CrossRef]
Rausch, J.; Gillespie, S.; Orchard, T.; Tan, A.; McDaniel, J.C. Systematic review of marine-derived omega-3 fatty acid supplementation effects on leptin, adiponectin, and the leptin-to-adiponectin ratio. Nutr Res 2021, 85, 135-152. [CrossRef]
Wei, Y.; Meng, Y.; Li, N.; Wang, Q.; Chen, L. The effects of low-ratio n-6/n-3 PUFA on biomarkers of inflammation: a systematic review and meta-analysis. Food Funct 2021, 12, 30-40. [CrossRef]
Liu, M.; Li, W.; Chen, Y.; Wan, X.; Wang, J. Fucoxanthin: A promising compound for human inflammation-related diseases. Life Sci 2020, 255, 117850. [CrossRef]
Alharbi, R. Antioxidant properties of marine algae: an overview. Biosci. Res. 2019, 16, 986-996.
Saraswati; Giriwono, P.E.; Iskandriati, D.; Tan, C.P.; Andarwulan, N. Sargassum Seaweed as a Source of Anti-Inflammatory Substances and the Potential Insight of the Tropical Species: A Review. Mar Drugs 2019, 17. [CrossRef]
Riccio, G.; Lauritano, C. Microalgae with Immunomodulatory Activities. Mar Drugs 2019, 18. [CrossRef]
Dolmatova, L.S.; Dolmatov, I.Y. Different Macrophage Type Triggering as Target of the Action of Biologically Active Substances from Marine Invertebrates. Mar Drugs 2020, 18. [CrossRef]
Rubilar, T.; Barbieri, E.S.; Gazquez, A.; Avaro, M. Sea Urchin Pigments: Echinochrome A and Its Potential Implication in the Cytokine Storm Syndrome. Mar Drugs 2021, 19. [CrossRef]
Sanina, N. Vaccine Adjuvants Derived from Marine Organisms. Biomolecules 2019, 9. [CrossRef]
Cao, Q.; Zhao, J.; Xing, M.; Xiao, H.; Zhang, Q.; Liang, H.; Ji, A.; Song, S. Current Research Landscape of Marine-Derived Anti-Atherosclerotic Substances. Mar Drugs 2020, 18. [CrossRef]
Zhao, J.; Cao, Q.; Xing, M.; Xiao, H.; Cheng, Z.; Song, S.; Ji, A. Advances in the Study of Marine Products with Lipid-Lowering Properties. Mar Drugs 2020, 18. [CrossRef]
Dwivedi, R.; Pomin, V.H. Marine Antithrombotics. Mar Drugs 2020, 18. [CrossRef]
Doshi, G.; Nailwal, N. A Review on Molecular Mechanisms and Patents of Marine-derived Anti-thrombotic Agents. Curr Drug Targets 2021, 22, 318-335. [CrossRef]
Carvalhal, F.; Cristelo, R.R.; Resende, D.; Pinto, M.M.M.; Sousa, E.; Correia-da-Silva, M. Antithrombotics from the Sea: Polysaccharides and Beyond. Mar Drugs 2019, 17. [CrossRef]
Barkia, I.; Saari, N.; Manning, S.R. Microalgae for High-Value Products Towards Human Health and Nutrition. Mar Drugs 2019, 17. [CrossRef]
Yang, H.W.; Fernando, K.H.N.; Oh, J.Y.; Li, X.; Jeon, Y.J.; Ryu, B. Anti-Obesity and Anti-Diabetic Effects of Ishige okamurae. Mar Drugs 2019, 17. [CrossRef]
Chen, L.; Liu, R.; He, X.; Pei, S.; Li, D. Effects of brown seaweed polyphenols, a class of phlorotannins, on metabolic disorders via regulation of fat function. Food Funct 2021, 12, 2378-2388. [CrossRef]
Pradhan, B.; Nayak, R.; Patra, S.; Jit, B.P.; Ragusa, A.; Jena, M. Bioactive Metabolites from Marine Algae as Potent Pharmacophores against Oxidative Stress-Associated Human Diseases: A Comprehensive Review. Molecules 2020, 26. [CrossRef]
Rayapu, L.; Chakraborty, K.; Valluru, L. Marine Algae as a Potential Source for Anti-diabetic Compounds - A Brief Review. Curr Pharm Des 2021, 27, 789-801. [CrossRef]
Sachithanandam, V.; Lalitha, P.; Parthiban, A.; Mageswaran, T.; Manmadhan, K.; Sridhar, R. A Review on Antidiabetic Properties of Indian Mangrove Plants with Reference to Island Ecosystem. Evid Based Complement Alternat Med 2019, 2019, 4305148. [CrossRef]
Bae, M.; Kim, M.B.; Park, Y.K.; Lee, J.Y. Health benefits of fucoxanthin in the prevention of chronic diseases. Biochim Biophys Acta Mol Cell Biol Lipids 2020, 1865, 158618. [CrossRef]
Landon, R.; Gueguen, V.; Petite, H.; Letourneur, D.; Pavon-Djavid, G.; Anagnostou, F. Impact of Astaxanthin on Diabetes Pathogenesis and Chronic Complications. Mar Drugs 2020, 18. [CrossRef]
Gabbia, D.; De Martin, S. Brown Seaweeds for the Management of Metabolic Syndrome and Associated Diseases. Molecules 2020, 25. [CrossRef]
Gunathilaka, T.L.; Samarakoon, K.; Ranasinghe, P.; Peiris, L.D.C. Antidiabetic Potential of Marine Brown Algae-a Mini Review. J Diabetes Res 2020, 2020, 1230218. [CrossRef]
Balasa, A.F.; Chircov, C.; Grumezescu, A.M. Marine Biocompounds for Neuroprotection-A Review. Mar Drugs 2020, 18. [CrossRef]
Catanesi, M.; Caioni, G.; Castelli, V.; Benedetti, E.; d’Angelo, M.; Cimini, A. Benefits under the Sea: The Role of Marine Compounds in Neurodegenerative Disorders. Mar Drugs 2021, 19. [CrossRef]
Ahmmed, M.A., F.; Tian, H.; Carne, A.; Bekhit, A. Marine omega-3 (n-3) phospholipids: a comprehensive review of their properties, sources, bioavailability, and relation to brain health. Compr. Rev. Food Sci. Food Saf. 2019, 19, 64-123. [CrossRef]
Jin, A.H.; Muttenthaler, M.; Dutertre, S.; Himaya, S.W.A.; Kaas, Q.; Craik, D.J.; Lewis, R.J.; Alewood, P.F. Conotoxins: Chemistry and Biology. Chem Rev 2019, 119, 11510-11549. [CrossRef]
Jimenez, E.C. Post-translationally modified conopeptides: Biological activities and pharmacological applications. Peptides 2021, 139, 170525. [CrossRef]
Baj, A.; Bistoletti, M.; Bosi, A.; Moro, E.; Giaroni, C.; Crema, F. Marine Toxins and Nociception: Potential Therapeutic Use in the Treatment of Visceral Pain Associated with Gastrointestinal Disorders. Toxins (Basel) 2019, 11. [CrossRef]
Barbalace, M.C.; Malaguti, M.; Giusti, L.; Lucacchini, A.; Hrelia, S.; Angeloni, C. Anti-Inflammatory Activities of Marine Algae in Neurodegenerative Diseases. Int J Mol Sci 2019, 20. [CrossRef]
Olasehinde, T.A.; Olaniran, A.O.; Okoh, A.I. Macroalgae as a Valuable Source of Naturally Occurring Bioactive Compounds for the Treatment of Alzheimer’s Disease. Mar Drugs 2019, 17. [CrossRef]
Hannan, M.A.; Dash, R.; Haque, M.N.; Mohibbullah, M.; Sohag, A.A.M.; Rahman, M.A.; Uddin, M.J.; Alam, M.; Moon, I.S. Neuroprotective Potentials of Marine Algae and Their Bioactive Metabolites: Pharmacological Insights and Therapeutic Advances. Mar Drugs 2020, 18. [CrossRef]
Rathnayake, A.U.; Abuine, R.; Kim, Y.J.; Byun, H.G. Anti-Alzheimer’s Materials Isolated from Marine Bio-resources: A Review. Curr Alzheimer Res 2019, 16, 895-906. [CrossRef]
Ciccone, L.; Vandooren, J.; Nencetti, S.; Orlandini, E. Natural Marine and Terrestrial Compounds as Modulators of Matrix Metalloproteinases-2 (MMP-2) and MMP-9 in Alzheimer’s Disease. Pharmaceuticals (Basel) 2021, 14. [CrossRef]
Kabir, M.T.; Uddin, M.S.; Jeandet, P.; Emran, T.B.; Mitra, S.; Albadrani, G.M.; Sayed, A.A.; Abdel-Daim, M.M.; Simal-Gandara, J. Anti-Alzheimer’s Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential. Mar Drugs 2021, 19. [CrossRef]
Rahman, M.A.; Dash, R.; Sohag, A.A.M.; Alam, M.; Rhim, H.; Ha, H.; Moon, I.S.; Uddin, M.J.; Hannan, M.A. Prospects of Marine Sterols against Pathobiology of Alzheimer’s Disease: Pharmacological Insights and Technological Advances. Mar Drugs 2021, 19. [CrossRef]
Silva, M.; Seijas, P.; Otero, P. Exploitation of Marine Molecules to Manage Alzheimer’s Disease. Mar Drugs 2021, 19. [CrossRef]
Castaneda, A.; Ferraz, R.; Vieira, M.; Cardoso, I.; Vasconcelos, V.; Martins, R. Bridging Cyanobacteria to Neurodegenerative Diseases: A New Potential Source of Bioactive Compounds against Alzheimer’s Disease. Mar Drugs 2021, 19. [CrossRef]
Huang, C.; Zhang, Z.; Cui, W. Marine-Derived Natural Compounds for the Treatment of Parkinson’s Disease. Mar Drugs 2019, 17. [CrossRef]
Fakhri, S.; Aneva, I.Y.; Farzaei, M.H.; Sobarzo-Sanchez, E. The Neuroprotective Effects of Astaxanthin: Therapeutic Targets and Clinical Perspective. Molecules 2019, 24. [CrossRef]
Sorrenti, V.; Davinelli, S.; Scapagnini, G.; Willcox, B.J.; Allsopp, R.C.; Willcox, D.C. Astaxanthin as a Putative Geroprotector: Molecular Basis and Focus on Brain Aging. Mar Drugs 2020, 18. [CrossRef]
Bahbah, E.I.; Ghozy, S.; Attia, M.S.; Negida, A.; Emran, T.B.; Mitra, S.; Albadrani, G.M.; Abdel-Daim, M.M.; Uddin, M.S.; Simal-Gandara, J. Molecular Mechanisms of Astaxanthin as a Potential Neurotherapeutic Agent. Mar Drugs 2021, 19, 201. [CrossRef]
Liao, Q.; Feng, Y.; Yang, B.; Lee, S.M. Cnidarian peptide neurotoxins: a new source of various ion channel modulators or blockers against central nervous systems disease. Drug Discov Today 2019, 24, 189-197. [CrossRef]
Finol-Urdaneta, R.K.; Belovanovic, A.; Micic-Vicovac, M.; Kinsella, G.K.; McArthur, J.R.; Al-Sabi, A. Marine Toxins Targeting Kv1 Channels: Pharmacological Tools and Therapeutic Scaffolds. Mar Drugs 2020, 18. [CrossRef]
Stonik, V.A.; Stonik, I.V. Marine Excitatory Amino Acids: Structure, Properties, Biosynthesis and Recent Approaches to Their Syntheses. Molecules 2020, 25. [CrossRef]
Hong, A.; Tu, L.C.; Yang, I.; Lim, K.M.; Nam, S.J. Marine natural products with monoamine oxidase (MAO) inhibitory activity. Pharm Biol 2020, 58, 716-720. [CrossRef]
Barbosa, A.J.M.; Roque, A.C.A. Free Marine Natural Products Databases for Biotechnology and Bioengineering. Biotechnol J 2019, 14, e1800607. [CrossRef]
van Santen, J.A.; Kautsar, S.A.; Medema, M.H.; Linington, R.G. Microbial natural product databases: moving forward in the multi-omics era. Nat Prod Rep 2021, 38, 264-278. [CrossRef]
Stuart, K.A.; Welsh, K.; Walker, M.C.; Edrada-Ebel, R. Metabolomic tools used in marine natural product drug discovery. Expert Opin Drug Discov 2020, 15, 499-522. [CrossRef]
Williams, D.E.; Andersen, R.J. Biologically active marine natural products and their molecular targets discovered using a chemical genetics approach. Nat Prod Rep 2020, 37, 617-633. [CrossRef]
Wang, L.; Umezawa, K. Cellular Signal Transductions and Their Inhibitors Derived from Deep-Sea Organisms. Mar Drugs 2021, 19. [CrossRef]
Juarez-Portilla, C.; Olivares-Banuelos, T.; Molina-Jimenez, T.; Sanchez-Salcedo, J.A.; Moral, D.I.D.; Meza-Menchaca, T.; Flores-Munoz, M.; Lopez-Franco, O.; Roldan-Roldan, G.; Ortega, A.; et al. Seaweeds-derived compounds modulating effects on signal transduction pathways: A systematic review. Phytomedicine 2019, 63, 153016. [CrossRef]
Kim, S.H.; Kim, H. Astaxanthin Modulation of Signaling Pathways That Regulate Autophagy. Mar Drugs 2019, 17. [CrossRef]
Giannaccare, G.; Pellegrini, M.; Senni, C.; Bernabei, F.; Scorcia, V.; Cicero, A.F.G. Clinical Applications of Astaxanthin in the Treatment of Ocular Diseases: Emerging Insights. Mar Drugs 2020, 18. [CrossRef]
Li, T.; Wang, N.; Zhang, T.; Zhang, B.; Sajeevan, T.P.; Joseph, V.; Armstrong, L.; He, S.; Yan, X.; Naman, C.B. A Systematic Review of Recently Reported Marine Derived Natural Product Kinase Inhibitors. Mar Drugs 2019, 17. [CrossRef]
Parate, S.; Kumar, V.; Lee, G.; Rampogu, S.; Hong, J.C.; Lee, K.W. Marine-Derived Natural Products as ATP-Competitive mTOR Kinase Inhibitors for Cancer Therapeutics. Pharmaceuticals (Basel) 2021, 14. [CrossRef]
Raghuvanshi, R.; Bharate, S.B. Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review. Curr Top Med Chem 2020, 20, 1124-1135. [CrossRef]
Wu, R.; Chen, H.; Chang, N.; Xu, Y.; Jiao, J.; Zhang, H. Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications. Chemistry 2020, 26, 1166-1195. [CrossRef]
Luesch, H.; Paavilainen, V.O. Natural products as modulators of eukaryotic protein secretion. Nat Prod Rep 2020, 37, 717-736. [CrossRef]
Nishimura, S.; Matsumori, N. Chemical diversity and mode of action of natural products targeting lipids in the eukaryotic cell membrane. Nat Prod Rep 2020, 37, 677-702. [CrossRef]
Risinger, A.L.; Du, L. Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products. Nat Prod Rep 2020, 37, 634-652. [CrossRef]
Carazo, A.; Mladenka, P.; Pavek, P. Marine Ligands of the Pregnane X Receptor (PXR): An Overview. Mar Drugs 2019, 17. [CrossRef]
Vasilopoulou, M.; Ioannou, E.; Roussis, V.; Chondrogianni, N. Modulation of the ubiquitin-proteasome system by marine natural products. Redox Biol 2021, 41, 101897. [CrossRef]
González-Andrés, P.; Fernández-Peña, L.; Díez-Poza, C.; Villalobos, C.; Nuñez, L.; Barbero, A. Marine Heterocyclic Compounds That Modulate Intracellular Calcium Signals: Chemistry and Synthesis Approaches. Mar Drugs 2021, 19. [CrossRef]
Kageyama, H.; Waditee-Sirisattha, R. Antioxidative, Anti-Inflammatory, and Anti-Aging Properties of Mycosporine-Like Amino Acids: Molecular and Cellular Mechanisms in the Protection of Skin-Aging. Mar Drugs 2019, 17. [CrossRef]
Rosic, N.N. Mycosporine-Like Amino Acids: Making the Foundation for Organic Personalised Sunscreens. Mar Drugs 2019, 17. [CrossRef]
Nowruzi, B.S., G.; Blanco, S. The cosmetic application of cyanobacterial secondary metabolites. Algal Res. 2020, 49, 101959. [CrossRef]
Jesumani, V.; Du, H.; Aslam, M.; Pei, P.; Huang, N. Potential Use of Seaweed Bioactive Compounds in Skincare-A Review. Mar Drugs 2019, 17. [CrossRef]
SHANNON, E.A.-G., N. Seaweeds as nutraceuticals for health and nutrition. Phycologia 2019, 58, 563-577. [CrossRef]
Thiyagarasaiyar, K.; Goh, B.H.; Jeon, Y.J.; Yow, Y.Y. Algae Metabolites in Cosmeceutical: An Overview of Current Applications and Challenges. Mar Drugs 2020, 18. [CrossRef]

Figure 1. Marine pharmacology in 2019-2021: marine compounds with antibacterial, antifungal, antiprotozoal, antituberculosis and antiviral activities.

Figure 2. Marine pharmacology in 2019-2021: marine compounds with antidiabetic and anti-inflammatory activity; and affecting the immune and nervous system.

Figure 3. Marine pharmacology in 2019-2021: marine compounds with miscellaneous mechanisms of action.

Table 1. Marine pharmacology in 2019-2021: mechanism of action studies with marine compounds demonstrating antibacterial, antifungal, antituberculosis, antiprotozoal and antiviral activities.

Drug Class	Compound/Organism ^a	Chemistry	Pharmacologic Activity	IC₅₀ ^b	MMOA ^c	Country ^d	References
Antibacterial	adipostatin E (1)/bacterium	Polyketide ^d	B. subtilis and L monocytogenes inhibition	3.4, 5.9 µM	PPCS inhibition	CRI, USA	[14]
Antibacterial	arenicin-3 (2)/worm	Peptide ^f	E. coli & K. pneumoniae inhibition	1-2 μg/mL⁺	Cell membrane disruption and ATP release	AUS, CHE, CHN, DNK, DEU, GBR, IRL	[15]
Antibacterial	bisanhydroaklavinone (3)/bacterium	Polyketide ^d	S. aureus inhibition	6.25 μg/mL⁺	Cell membrane damage and DNA leakage	PHL, SGP	[16]
Antibacterial	cladodionen (4)/fungus	Polyketide ^d	P. aeruginosa quorum sensing inhibition	<400 µM	Downregulation of quorum sensing genes	CHN	[17]
Antibacterial	cyclo(L-leucyl-L-prolyl) (5)/bacterium	Peptide ^f	S. marcescens inhibition	200 μg/mL⁺	Biofilm formation inhibition	IND	[18]
Antibacterial	C. cervicornis diterpene (6)/alga	Terpenoid ^e	MR S. aureus inhibition	8 μg/mL⁺	Inhibition of efflux pump	BRA	[19]
Antibacterial	chrysophaentin I (7)/alga	Polyketide ^d	S. aureus inhibition	10 μg/mL⁺	Cytoskeletal protein FtsZ inhibition	USA	[20]
Antibacterial	crustin (8)/shrimp	Peptide ^f	M. luteus inhibition	2.5 μM⁺	Membrane disruption and depolarization	CHN	[21]
Antibacterial	D. candidum alkaloid (9)/ascidian	Alkaloid ^f	S. aureus, E. Coli, K. pneumoniae inhibition	8 μg/mL⁺	Biofilm formation inhibition	ITA	[22]
Antibacterial	doscadenamide A (10)/cyanobacterium	Peptide ^f -Polyketide ^d	P. aeruginosa quorum sensing activation	<10 µM	AHL-binding site	USA	[23]
Antibacterial	kalafungin (11)/bacterium	Polyketide ^d	S. aureus inhibition	8, 16 μg/mL⁺	Non-competitive β-lactamase inhibition	IND	[24]
Antibacterial	korormicin A (12)/bacterium	Polyketide ^d	V. cholerae and P. aeruginosa inhibition	10-30 μM⁺	Reactive oxygen species production	BRA, JPN, USA	[25]
Antibacterial	lactoquinomycin A (13)/bacterium	Polyketide ^d	MR S. aureus and S. enterica inhibition	0.03-0.25 μg/mL⁺	Induction of DNA damage	S. KOR	[26]
Antibacterial	octominin(14)/octopus	Peptide ^f	S. parauberis inhibition	50 μg/mL⁺	Membrane disruption and chromosomal DNA binding	S. KOR	[27]
Antibacterial	P. chrysogenum dipeptide (15)/fungus	Peptide ^f	C. violaceum and P. aeruginosa inhibition	6.2 mg/mL⁺	Anti-quorum sensing activity	CHN	[28]
Antibacterial	piscidin 5 (16)/fish	Peptide ^f	V. parahaemolyticus & P. damselae inhibition	1.5-6.2 µM	Membrane disruption and DNA binding	CHN	[29]
Antibacterial	phorbaketal B and C (17, 18)/sponge	Terpenoid ^e	S. aureus biofilm inhibition	< 50 μg/mL	Downregulation of hemolysin-related genes	S. KOR	[30]
Antibacterial	S. algae polyketide (19)/bacterium	Polyketide ^d	E. coli and MR S. aureus inhibition	3.75 μg/mL⁺	MRSA penicillin-binding protein active site docking	IND	[31]
Antibacterial	S. algae polyketide (20)/bacterium	Polyketide ^d	VR E. faecalis and MR S. aureus inhibition	1-3 μg/mL⁺	Siderophore mechanism of action	IND	[32]
Antibacterial	securamine H (21)/bryozoan	Alkaloid ^f	S. aureus inhibition	3.13 μM⁺	Reduction of metabolic activity	NOR	[33]
Antibacterial	turgencin A(22)/ascidian	Peptide ^f	C. glutamicum and B. subtilis inhibition	0.4 μM⁺	Cell membrane disruption	AUS, NOR	[34]
Antibacterial	tyramine (23)/bacterium	Alkaloid ^f	P. aeruginosa quorum sensing inhibition	1 mg/mL⁺	Pyoverdine production inhibition	ESP	[35]
Antifungal	amantelide A (24)/cyanobacterium	Polyketide ^d	S. cervisiae inhibition	12.5, 50 μM	Ergosterol binding and actin polymerization promotion	JPN, PHL, USA	[36]
Antifungal	atranone Q (25)/fungus	Terpenoid ^e	C. albicans growth inhibition	8 μg/mL	Cytoplasm agglutination and cell membrane alterations	CHN	[37]
Antifungal	fusarilactone A (26)/fungus	Polyketide ^d	P. theae growth inhibition	38.1 μg/mL	HMG-CoA inhibition	CHN	[38]
Antifungal	2-n-heptyl-4-hydroxyquinoline (27)/bacterium	Alkaloid ^f	C. albicans hyphal growth inhibition	11.4 μg/mL	cAMP-Efg1 pathway inhibition	S. KOR	[39]
Antifungal	oceanapiside (28)/sponge	Polyketide ^d	C. glabrata inhibition	10 μg/mL	Sphingolipid synthesis inhibition	PHL, USA	[40]
Antifungal	puupehenone (29)/sponge	Terpenoid ^e	CAS- insensitive C. neoformans inhibition	2.5-5 μg/mL⁺	CWI integrity pathway disruption	USA	[41]
Antifungal	S. olivaceus butyrylamide (30)/bacterium	Shikimate ^h	C. albicans hyphal growth inhibition and adhesion	100 μg/mL⁺	Downregulation of hyphal formation genes	CHN	[42]
Antimalarial	capillasterquinone B (31)/bacterium	Polyketide ^d	P. falciparum 3D7 inhibition	9.2 µg/mL	Lysyl-tRNA synthetase binding	DEU, EGY, GBR, SAU	[43]
Antimalarial	kakeromamide B (32)/cyanobacterium	Peptide ^f	Blood-stage P. falciparum inhibition	8.9 μM	Binding to Plasmodium actin and sortilin	USA	[44]
Antimalarial	friomaramide (33)/sponge	Peptide ^f	P. falciparum sporozoites liver infection inhibition	<6.1 μM*	Hepatocyte nuclei viability confirmed	AUS, USA	[45]
Antimalarial	nitenin (34)/sponge	Terpenoid ^e	P. falciparum inhibition	0.29 μM	Ring to trophozoite transition	USA	[46]
Antiprotozoal	4-epi-arbusculin A (35)/zoanthid	Terpenoid ^e	A. castellanii inhibition	26 μM	Programmed cell death induction	ESP	[47]
Antiprotozoal	epinecidin-1 (36)/fish	Peptide ^f	Trichomonas vaginalis inhibition	< 62.5 µg/mL	Membrane disruption	TWN	[48]
Antiprotozoal	isololiolide (37)/hydroid	Terpenoid ^e	T. cruzi trypomastigotes and amastigotes inhibition	32, 40 μM	Disruption of membrane integrity	BRA, USA	[49]
Antiprotozoal	dehydrothyrsiferol (38)/alga	Terpenoid ^e	A. castellanii growth inhibition	5.3 μM	Mitochondrial malfunction	MEX, ESP	[50]
Antiprotozoal	gallinamide A (39)/cyanobacterium	Peptide ^f	T. cruzi amastigote inhibition	14.7 nM	Recombinant cruzain inhibition	USA	[51]
Antiprotozoal	7-oxostaurosporine (40)/bacterium	Alkaloid ^f	A. castellanii growth inhibition	0.8, 0.9, 5.5 μM	Mitochondrial malfunction	ECU, ESP	[52]
Antiprotozoal	polyaurine A (41)/ ascidian	Alkaloid ^f	S. mansoni inhibition	> 100 μM	Egg production impairment in vitro	IDN, ITA	[53]
Antituberculosis	fiscpropionate A (42) /fungus	Polyketide ^d	M. tuberculosis MptpB inhibition	5.1 μM	Noncompetitive inhibition	CHN	[54]
Antituberculosis	fucoxanthin (43)/alga	Terpenoid ^e	M. tuberculosis strains inhibition	2.8-4.1 μM⁺	TBNAT inhibition	CHL, CZE, IRN, ROU	[55]
Antiviral	chartarlactam T (44)/fungus	Alkaloid ^f	Zika virus inhibition	10 μM*	Protein E inhibition	CHN	[56]
Antiviral	harzianoic acids A & B (45, 46)/fungus	Terpenoid ^e	HCV inhibition	35,43 μM	Virus replication and entry inhibition	CHN, DEU	[57]
Antiviral	homoseongomycin (47)/bacterium	Polyketide ^d	VEEV and EEEV inhibition	8.6 μM	Viral replication inhibition	TWN, USA	[58]
Antiviral	penicillixanthone A (48)/fungus	Polyketide ^d	HIV-1 replication inhibition	0.36 μM	CCR5/CXCR4 receptor antagonist	CHN	[59]
Antiviral	portimine (49)/dinoflagellate	Polyketide ^d	HIV-1 replication inhibition	4.1 nM	Reverse transcriptase inhibition	JPN	[60]

^a Organism, Kingdom Animalia: worm (Phylum Annelida); shrimp (Phylum Arthropoda); bryozoa (Phylum Bryozoa); ascidian, fish (Phylum Chordata); hydroid, zoanthid (Phylum Cnidaria), dinoflagellate (Phylum Dinoflagellata); octopus (Phylum Mollusca); sponge (Phylum Porifera); Kingdom Monera: bacterium, cyanobacterium (Phylum Cyanobacteria); Kingdom Fungi: fungus; Kingdom Plantae: alga; ^b IC₅₀: concentration of a compound required for 50% inhibition in vitro, *: estimated IC₅₀; ⁺ MIC: minimum inhibitory concentration, ^c MMOA: molecular mechanism of action; ^d Country: AUS: Australia; BRA: Brazil; CHE: Switzerland; CHL: Chile; CHN: China; CRI: Costa Rica; CZE: Czech Republic; DNK: Denmark; DEU: Germany; ECU: Ecuador; EGY: Egypt; ESP: Spain; GBR: United Kingdom; IDN: Indonesia; IND: India; IRL: Ireland; IRN: Iran; ITA: Italy ; JPN: Japan; MEX: Mexico; NOR: Norway; PHL: Philippines (the); ROU: Romania; SAU: Saudi Arabia; SGP: Singapore; S. KOR: South Korea; TWN: Taiwan; Chemistry: ^d Polyketide; ^e Terpene; ^f Nitrogen-containing compound;^g Polysaccharide, ^h Shikimate; Abbreviations: AHL: acylated homoserine lactone; cAMP: cyclic AMP; CAS: caspofungin; CCR5: C-C chemokine receptor type 5; CWI: cell wall integrity; CXCR4: C-X-C chemokine receptor type 4; EEEV: eastern equine encephalitis virus; Efg1: elongation factor 1 transcription factor; HCV: hepatitis C virus; HIV-1: human immunodeficiency virus type-1; HMG-CoA: 3-hydroxy-3-methylglutaryl-CoA; M: Mycobacterium; MptpB: protein tyrosine phosphatase B; MR: methicillin-resistant; MRSA: methicillin-resistant Staphylococcus aureus; PPCS: phosphopantothenoylcysteine synthetase; S: Staphylococcus; TBNAT: arylamine-N-acetyltransferase; VEEV: Venezuelan equine encephalitis virus; T.: Trypanosoma; VR: Vancomycin-resistant.

Table 2. Marine pharmacology in 2019-2021: mechanism of action studies with marine compounds with antidiabetic and anti-inflammatory activity; and affecting the immune and nervous system.

Drug Class	Compound/organism ^a+	Chemistry	Pharmacological activity	IC₅₀ ^b	MMOA ^c	Country ^d	References
Antidiabetic	xyloccensin-1 (50)/mangrove	Terpenoid ^f	α-glucosidase inhibition	0.16 mg/mL	Docking studies completed	IND	[61]
Antidiabetic	CYC27 (51)/alga	Shikimate ^h	Reduction in blood glucose	50 mg/kg/day**	Insulin signaling pathways enhanced	CHN	[62]
Antidiabetic	fucoxanthin (43)/alga	Terpenoid ^f	α-amylase and α-glucosidase inhibition	80 µg/mL	Mixed-type inhibition kinetics	DNK, MYS, S. KOR, THA	[63,64]
Antidiabetic	fucoxanthin (43)/alga	Terpenoid ^f	Decrease ROS production in kidney mensangial cell line	0.5 µM*	Epigenomic and transcriptomic effects	USA	[65]
Antidiabetic	abeo-oleanene (52)/alga	Terpenoid ^f	α-amylase and α-glucosidase inhibition	0.29 mM	Docking studies completed	IND	[66]
Antidiabetic	isophloroglucin A (53)/alga	Polyketide ^d	Glucose homeostasis improvement	1.35 mg/kg/day**	GLUT4 levels increased	S. KOR	[67]
Antidiabetic	S. latiuscula bromophenol (54)/ alga	Shikimate ^h	α-glucosidase inhibition	1.92 µM	PTP1B competitive inhibition	S. KOR	[68]
Antidiabetic	H. fusiformis fatty acid (55)/alga	Fatty Acids	α-glucosidase inhibition	48 µM	PTP1B inhibition	S. KOR	[69]
Antidiabetic	tripalmitin (56)/fungus	Fatty Acids	α-glucosidase inhibition	3.75 µM	Mixed-type inhibition kinetics	PAN	[70]
Anti-inflammatory	A. depilans EnP(5,8) (57)/sea hare	Terpenoid ^f	Macrophage NO, COX-2, IL-6 and TNF-α	18.4 μM	Nos2 and COX-2 expression decrease	ESP, PRT	[71]
Anti-inflammatory	Aspergillus sp. aglycone (58)/fungus	Polyketide ^d	Macrophage NO release inhibition	6 μM	NF-kB inhibition	CHN	[72]
Anti-inflammatory	brevenal (59)/dinoflagellate	Polyketide ^d	Macrophage TNF-α inhibition	0.1 ng	Macrophage activation inhibition	USA	[73]
Anti-inflammatory	caniferolide A (60)/ bacterium	Polyketide ^d	Microglia NO, IL-1β, IL-6 release inhibition	0.01 μM*	iNOS, ERK, JNK expression inhibition	ESP	[74]
Anti-inflammatory	C. inophyllum terpenoids (61,62)/mangrove	Terpenoid ^f	Macrophage NO and IL-1β release inhibition	2.4, 7 μM	iNOS induction and NF-kB inhibition	VNM, S. KOR	[75]
Anti-inflammatory	curdepsidone C (63)/ fungus	Polyketide^d/Shikimate^h	Human macrophage IL-1β release inhibition	7.5 μM	JNK and ERK inhibition	CHN	[76]
Anti-inflammatory	collismycin C (64)/bacterium	Alkaloid ^g	Murine sepsis inhibition and survival	4 mg/kg**	NF-kB and p38 inhibition	S. KOR	[77]
Anti-inflammatory	dieckol (65)/alga	Polyketide ^d	Decreased murine liver NLRP3 synthesis	2.5 mg/kg/day**	NF-kB and NLRP3 inhibition	S. KOR	[78]
Anti-inflammatory	dysiarenone (66)/sponge	Terpenoid ^f	Macrophage IL-6, TNF-α and LTB₄ release inhibition	2-8 μM*	NF-kB, p38, ERK, Akt inhibition	CHN	[79]
Anti-inflammatory	epiloliolide (67)/alga	Terpenoid ^f	Human periodontal ligament cell iNOS, IL-1, IL-6, and TNF-α inhibition	>10 μM*	NLRP3 decrease and PKA/CREB increase	S. KOR	[80]
Anti-inflammatory	fucoxanthin (43)/diatom	Terpenoid ^f	Murine sepsis inhibition and survival	1 mg/kg**	NF-kB inhibition	CHN, TWN, USA	[81]
Anti-inflammatory	fucoxanthin (43)/diatom	Terpenoid ^f	Murine liver inflammation inhibition	10-40 mg/kg**	NF-kB inhibition and NRF2 increase	CHN	[82]
Anti-inflammatory	fucoxanthin (43)/alga	Terpenoid ^f	Macrophage osteoclastogenesis inhibition	< 5 μM*	ERK, p38 inhibition and NRF2 increase	S. KOR	[83]
Anti-inflammatory	fucoxanthin (43)/alga	Terpenoid ^f	Macrophage iNOS and COX-2 expression inhibition	5,10 μM*	NF-kB inhibition	CHN, USA	[84]
Anti-inflammatory	fucoxanthinol (68)/ diatom	Terpenoid ^f	Microglia NO and PGE₂ expression inhibition	20 μM*	NF-kB, Akt, MAPK inhibition and NRF2 increase	CHN	[85]
Anti-inflammatory	hirsutanol A (69)/fungus	Terpenoid ^f	LPS-induced MMP-9 release and lung injury attenuation	30 mg/kg**	NF-kB, STAT3, ERK inhibition	RUS, TWN	[86]
Anti-inflammatory	2-epi-jaspine B (70)/sponge	Polyketide ^d	Rat arthritis inhibition	30 mg/kg**	SphK1 inhibition	CHN	[87]
Anti-inflammatory	L. glandulifera diterpenes (71,72)/ alga	Terpenoid ^f	Macrophage NO release inhibition	2.3, 2.9 μM	iNOS induction inhibition	GRC	[88]
Anti-inflammatory	mojabanchromanol (73)/alga	Terpenoid ^f	Murine alveolar epithelial cell line lipid peroxidation inhibition	62.5 µg/mL*	ERK, JNK inhibition	S. KOR	[89]
Anti-inflammatory	neuchromenin (74)/fungus	Polyketide ^d	Microglia NO and PGE₂ inhibition	2.7, 3.2 μM	NF-kB and p38 inhibition	S. KOR	[90]
Anti-inflammatory	O-demethylrenierone (75)/sponge	Alkaloid ^g	Human macrophage NO and PGE₂, inhibition	10 µM*	NF-kB inhibition and increase	S. KOR, VNM	[91]
Anti-inflammatory	penicitrinone A(76)/fungus	Polyketide ^d	Human neutrophil superoxide anion inhibition	2.7 µM	caspase-3 dependent apoptosis induction	TWN	[92]
Anti-inflammatory	phyllohemiketal A (77)/sponge	Terpenoid ^f	Human macrophage NO and PGE₂, inhibition	5 µM*	NF-kB, p38, ERK and JNK inhibition and NRF2 increase	S. KOR	[93]
Anti-inflammatory	sclerketide C (78)/fungus	Polyketide ^d	Macrophage NO release inhibition	2.7 µM	iNOS and COX-2 mRNA expression decrease	CHN	[94]
Anti-inflammatory	grasshopper ketone (79)/alga	Terpenoid ^f	Macrophage NO, IL-1β, IL-6 release inhibition	1-10 µg/mL*	NF-kB, p38, ERK, JNK inhibition	S. KOR	[95]
Anti-inflammatory	S. mastoidea prodigiosins (80,81)/bacterium	Alkaloid ^g	Rat gastric inflammation inhibition	> 100 mg/kg**	NF-kB inhibition and HO-1 increase	EGY	[96]
Anti-inflammatory	topsentin (82)/sponge	Alkaloid ^g	Human keratinocyte COX-2 expression inhibition	1.2 µM	AP-1, p38, JNK, and Erk inhibition	S. KOR	[97]
Anti-inflammatory	tuberatolide B (83)/alga	Polyketide ^d/ Terpenoid ^f	Macrophage NO, IL-1β, IL-6 release inhibition	12.5 µg/mL*	NF-kB, p38, ERK, JNK inhibition	S. KOR	[98]
Immune system	astaxanthin (84)/alga	Terpenoid ^f	Inhibition of LPS-induced dendritic cell dysfunction	5-20 µM*	HO-1 and NRF-2 increase	CHN	[99]
Immune system	crassolide (85)/soft coral	Terpenoid ^f	Suppression of dendritic cell maturation and T cell responses	2.5 µM*	DC maturation and pro-inflammatory cytokines inhibition	TWN	[100]
Immune system	C. sinensis peptide (86)/mollusk	Peptide ^g	Increased murine macrophage phagocytosis	25 µM*	NF-kB and NLRP3 increase	CHN	[101]
Immune system	dieckol (65)/alga	Polyketide ^d	Decreased intestinal Th17 cells and increased Treg cells	2.5 mg/kg/day	NF-kB and IL-6 decrease	S. KOR	[102]
Immune system	echinochrome A (87)/sea urchin	Polyketide ^d	Expansion of PBMC-derived CD34+ cells	10 µM*	ROS and p38MAPK/JNK phosphorylation decrease	S. KOR, RUS	[103]
Immune system	echinochrome A (87)/sea urchin	Polyketide ^d	Protection against murine inflammatory bowel disease	10 mg/kg	Regulatory T cell production increase	S. KOR, RUS	[104]
Immune system	echinochrome A (87)/sea urchin	Polyketide ^d	Inhibition of murine bleomycin-induced scleroderma	1 µM*	STAT3 phosphorylation decrease	S. KOR, RUS	[105]
Immune system	eckol (88)/alga	Polyketide ^d	Inhibition murine IgE-mediated PCA reaction	50 µg/mouse	FCεR and NF-kB activation decrease	S. KOR	[106]
Immune system	phomaketide A (89)/fungus	Polyketide ^d/ Terpenoid ^f	Lymphangiogenesis inhibition	3.7 µM	VEGFR-3 phosphorylation and PKCδ activation decrease	TWN	[107]
Immune system	S. scabra cembranoid (90)/soft coral	Terpenoid ^f	LPS-induced B lymphocyte proliferation	4.4 µM	B cell proliferation decrease and IL-10 increase	CHN	[108]
Immune system	sticholysins I & II(proteins of about 20KD)/sea anemone	Peptide ^g	Maturation of dendritic cells	1 µg/mL*	TLR4 and MYD88 activation decrease	BRA, CUB, USA	[109]
Immune system	T. weissflogii phosphoglycolipid (91)/diatom	Polyketide ^d	Immunestimulation of human monocyte-derived dendritic cells	10 µg/mL*	TLR4 and NF-kB activation decrease	ITA	[110]
Nervous system	alternarin A (92)/fungus	Terpenoid ^f	Neuronal spontaneous Ca²⁺ oscillations (SCO) inhibition	3.2 µM	SCO frequency and amplitude decreased	CHN, HU	[111]
Nervous system	anabaseine (93)/ worm	Alkaloid ^g	α7 nAChR inhibition	1.85-3.85 µM	Membrane depolarization	USA	[112]
Nervous system	A. insuetus TMC-120Ac& TMC-120B (94,95)/fungus	Alkaloid ^g	Mouse focal seizure duration reduction	10 mg/kg**	undetermined	BEL, DNK, NOR	[113]
Nervous system	Ara and ETrA (96,97)/alga	Fatty Acids	AChE inhibition	0.5-0.78 mg/mL	Non-competitive inhibition	CHN	[114]
Nervous system	astaxanthin (84)/shrimp	Terpenoid ^f	Reduction of LPS-induced memory impairment	30 or 50 mg/kg**	Inhibits STAT3 phosphorylation	S. KOR, USA	[115]
Nervous system	astaxanthin (84)/shrimp	Terpenoid ^f	Cognitive dysfunction protection	10 mg/kg**	ROS reduction and decreased Ab	THA	[116]
Nervous system	8,8’-bieckol (98)/alga	Polyketide ^d	BACE1 and AChE inhibition	1.6-4.6 µM	Non-competitive or competitive inhibition	S. KOR	[117]
Nervous system	brevetoxin (99)/dinoflagellate	Polyketide ^d	VGSC activator	2.4 nM	Shifts voltage dependence, slows inactivation	JPN, USA	[118]
Nervous system	C. austini conorfamides (100,101)/ cone snail	Peptide ^g	α7 nAChR inhibition	0.68-0.76 µM	Inhibition of Ca²⁺ ion flow	AUS, MEX	[119]
Nervous system	C. geographus conosteroid (102)/ cone snail	Terpenoid ^f	Hot plate murine pain model inhibition	2-10 mg/kg**	GABA_AR negative allosteric modulator	USA	[120]
Nervous system	C. lividus conotoxin Lv1F(103)/cone snail	Peptide ^g	α3β2 nAChR inhibition; hotplate and formalin murine pain inhibition	0.0089 µM; 25-100 µg/kg**	Competitive binding; unknown	CHN	[121,122]
Nervous system	Con-T[M8Q] (104)/	Peptide ^g	Inhibition of murine morphine dependence	15 nmol/kg	NMDAR GluN2B antagonist	CHN, USA	[123]
Nervous system	dictyol C (105)/alga	Terpenoid ^f	Neuroprotection of rat CIRI	80 µg/kg	Increased Nrf2/ARE signaling pathway	CHN	[124]
Nervous system	echinochrome A (87)/sea urchin	Polyketide ^d	Mitigation of cerebral ischemic injury	10 µM**	Decreases pro-apoptotic factors; increased survival factors	S. KOR, RUS	[125]
Nervous system	eckol (88)/alga	Polyketide ^d	Dopamine D3/D4 agonist	42,43 µM	GPCR-signaling	S. KOR	[126]
Nervous system	eleganolone (106)/alga	Terpenoid ^f	Human neuroblastoma cells neurotoxicity inhibition	0.1-1 µM*	Decreases ROS levels and apoptotic factors	BRA, ESP, PRT	[127]
Nervous system	frondoside A (107)/sea cucumber	Terpenoid ^f	Dopaminergic degeneration inhibition	0.1,0.5 µM*	Increase in protein degradation pathway, decrease apoptotic factors	THA	[128]
Nervous system	fucosterol (108)/alga	Terpenoid ^f	Aβ-induced neuronal apoptosis	10 µM*	Decreased pro-apoptotic factors; decreased APP mRNA	MYS	[129]
Nervous system	fucosterol (108)/alga	Terpenoid ^f	Neurodegenerative disorders system pharmacology	NA	Neuronal survival pathways	S.KOR,	[130]
Nervous system	fucoxanthin (43)/alga	Terpenoid ^f	Reduced corneal denervation	10 mg/kg**	Increased Nrf2 expression	TWN	[131]
Nervous system	fucoxanthin (43)/alga	Terpenoid ^f	Reduction of PC12 neurons intracellular ROS	1 µM*	Binds to Keap1	CHN	[132]
Nervous system	H. crispa peptides (109-111)/sea anemone	Peptide ^g	Inhibition of ASIC ion channels	1.25-4.95 µM	rASIC1a ion channel inhibition	RUS	[133]
Nervous system	H. scabra 2-BTHF (112)/sea cucumber	Polyketide ^d	Aβ-induced C. elegans paralysis inhibition	1 µg/mL*	Decreased the formation of Ab oligomers and fibrils	THA	[134]
Nervous system	neo-debromoaplysiatoxins E and F (113, 114)/cyanobacterium	Terpenoid ^f/ Shikimate^h	Kv1.5 inhibition	1.22-2.85 µM	Binding to Kv1.5 S6 domain	CHN	[135]
Nervous system	okadaic acid (115)/ dinoflagellate	Polyketide ^d	Chick embryos neural tube defects	0.5 µM*	Increased ROS, decreased Nrf2-signaling pathway	CHN	[136]
Nervous system	pinnatoxins A and G (116, 117)/dinoflagellate	Polyketide ^d	Synaptic transmission block at neuromuscular junction	2.8-3.1 nmol/kg**	AChE inhibition	FRA, USA	[137]
Nervous system	PFF-A (118)/alga	Polyketide ^d	hMAO-A inhibition	9.2 µM	Noncompetitive inhibition	S. KOR	[138]
Nervous system	sargachromanol (119)/alga	Terpenoid ^f	AChE inhibition	0.79 µM	Mixed reversible inhibition	S. KOR	[139]
Nervous system	santacruzamate A (120)/cyanobacterium	Alkaloid ^g	Amelioration of AD-like pathology	10 mg/kg**	Increased KDELR, decreased ER stress	CHN	[140]
Nervous system	Sinularia sp. cembranoid (121)/soft coral	Terpenoid ^f	Aβ₄₂ inhibition	>10 µM	Binds to c-terminal of Ab monomer	CHN	[141]
Nervous system	S. latiuscula bromophenol (54)/alga	Shikimate^h	HD₃R inhibition	18.7 µM	Binding to HD₃R orthosteric site	S. KOR	[142]
Nervous system	S. japonica GM2 (122)/alga	Sugar	PC12 neurons increased viability	200,400 µg/mL	Increased autophagy factors; decreased pro-apoptotic factors	CHN	[143]
Nervous system	S. latiuscula bromophenol (54)/alga	Shikimate^h	BACE1, AChE and BChe inhibition	2.3-4.03 µM	Non-competitive or competitive inhibition	S. KOR	[144]
Nervous system	stelletin B (123)/sponge	Terpenoid ^f	Reversal of zebrafish locomotor deficiency	1 nM *	Increased Nrf2/ARE signaling; decreased pro-apoptotic factors	TWN	[145]
Nervous system	androstatriol (124)/soft coral	Terpenoid ^f	Retinal ganglion cells protection	80 µg/eye**	Negative regulation of Keap1	CHN	[146]

^a Organism: Kingdom Animalia: worm (Phylum Annelida); shrimp (Phylum Arthropoda); coral, sea anemone (Phylum Cnidaria); sea cucumber, sea urchin (Phylum Echinodermata); cone snail, mollusk, sea hare (Phylum Mollusca); sponge (Phylum Porifera); Kingdom Chromista: dinoflagellate; Kingdom Fungi: fungus; Kingdom Plantae: alga; diatoms, mangrove; Kingdom Monera: bacterium; cyanobacterium (Phylum Cyanobacteria); ^b IC₅₀: concentration of a compound required for 50% inhibition, *: apparent IC₅₀, ** in vivo study; ^c MMOA: molecular mechanism of action; ^d Country: AUS: Australia; BEL: Belgium; BRA: Brazil; CHN: China; CUB: Cuba; DNK: Denmark; EGY: Egypt; ESP: Spain; FRA: France; GRC: Greece; HU: Hungary; IND, India; ITA: Italy; JPN: Japan; MEX: Mexico; MYS: Malaysia; NLD: Netherlands; NOR: Norway; PAN: Panama; PRT: Portugal; RUS: Russia; S. KOR: South Korea; THA: Thailand; TWN: Taiwan; VNM: Vietnam; Chemistry: ^e Polyketide; ^f Terpene; ^g Nitrogen-containing compound; ^h Shikimate. Abbreviations: Aβ: amyloid-β peptide; Ach: acetylcholine; AChE: acetylcholinesterase; AD: Alzheimer’s disease: AP-1: dimeric transcription factor; BChe: butyrylcholinesterase; Akt: also known as protein kinase B is a serine/threonine protein kinase; APP: amyloid precursor protein; ASIC: acid-sensing ion channel; BACE1: β-Secretase; 2-BTHF: 2-butoxytetrahydrofuran; CIRI: cerebral ischemia-reperfusion injury; COX: cyclooxygenase; CREB: cAMP-response element binding protein; ER: endoplasmic reticulum; ERK: extracellular signal-regulated kinase; EnP(5,8): 5α,8α-epidioxycholest-6-en-3β-ol; FCεR: high affinity IgE receptor; GLUT4: glucose transporter 4; GM2: Saccharina japonica fucoidan-derived glucuronomannan oligosaccharide; GPCR: G-protein coupled receptor; HD₃R: Human dopamine receptor 3; hMAO: human monoamine oxidase; HO-1: heme oxygenase-1 protein; IgE: Immunoglobulin E; IL: interleukin; iNOS: inducible nitric oxide synthase; JNK: c-jun N-terminal kinase; KDELR: Endoplasmic reticulum retention signal receptor; Keap1: Kelch-like ECH-associated protein 1; Kv: voltage-gated potassium channel; LPS: Lipopolysaccharide; LTB4: leukotriene B4; MAPK: mitogen-activated protein kinase; MMP-9: matrix metalloproteinase 9; MAO: monoamine oxidase; nAChR: nicotinic acetylcholine receptor; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; NLRP3: NLR family pyrin domain containing 3; NMDAR: N-methyl-D-aspartate receptor; NO: nitric oxide; Nos2: nitric oxide synthase 2; Nrf2-ARE: nuclear transcription factor E2-related factor antioxidant response element; PBMC: PB mononuclear cells; PCA: Passive cutaneous anaphylaxis; PFF-A: phlorofucofuroeckol-A; PGE₂: prostaglandin E₂; PK: protein kinase; PTP1B: tyrosine phosphatase 1B; rASIC: rat acid-sensing ion channel; ROS: reactive oxygen species; SPHK1: sphingosine kinase 1; STAT3: signal transducer and activator of transcription 3; Th17: T helper 17 cells, a subset of CD4⁺ T helper cells; TNF-α: tumor necrosis factor-α; Tregs: regulatory T cells; TRIOL: 5α-androst-3β, 5α, 6β-triol; VEGFR-3: vascular endothelial growth factor receptor-3; VGSC: voltage-gated sodium channel.

Table 3. Marine pharmacology in 2019-2021: marine compounds with miscellaneous mechanisms of action.

Compound/Organism ^a	Chemistry	Pharmacological Activity	IC₅₀ ^b	MMOA ^c	Country ^d	References
amantamide (125)/cyanobacterium	Peptide ^g	CXCR7 stimulation	2.5 µM	Erk1/2 phosphorylation increase	CHN, PHL, USA	[147]
A.neglectus macrocyclic lactone (126)/octopus	Polyketide ^e	DPPH radical scavenging	0.9 mM	ACE-1 non-competitive inhibition	IND	[148]
A. subcrenata peptides (127, 128)/shellfish	Peptide ^g	DPPH radical scavenging	1 mM	Insulin/IGF-1 signaling modulation	CHN	[149]
aspermytin A (129)/fungus	Polyketide ^e	S. aureus-derived SrtA inhibition	0.146 mM	Reversible mixed inhibition	S. KOR	[150]
avarol (130)/sponge	Terpenoid ^f	Cholesteryl ester synthesis inhibition	5.7 μM	SOAT inhibition	JPN	[151]
bieckol (131)/alga	Polyketide ^e	Murine cholesterol, LDL and triglyceride decrease	2.5 mg/kg/day**	Aortic LOX-1 and PKC-α expression decreased	S. KOR	[152]
3-BDB (132)/alga	Shikimate ^h	HO-1 antioxidant enzyme upregulation	10 µM*	Nrf2/HO-1 pathway activation	S. KOR	[153]
C. gigas peptide (133)/oyster	Peptide ^g	Osteogenesis induction	0.1 µM*	Integrin α5β1 binding	CHN	[154]
C. gigas peptide (134)/oyster	Peptide ^g	Thrombin inhibition	5 mg/mL*	Competitive inhibition	CHN	[155]
D. herbacea diphenyl ether (135)/sponge	Polyketide ^e	Bacterial α-_D-galactosidase inhibition	4.26 µM	Irreversible active-site inactivation	RUS	[156]
dieckol (65)/alga	Shikimate ^h	ROS inhibition	0.5 µM*	Enhanced NFE2L and SOD1 gene expression	S. KOR	[157]
dieckol (65)/alga	Shikimate ^h	UVB-induced skin damage reduction	25 µM*	Enhanced collagen synthesis and pro-inflammatory cytokines reduction	S. KOR	[158]
DPHC (136)/alga	Polyketide ^e	High-fat diet-induced adiposity inhibition	25, 50 mg/kg/day**	Lipogenesis enzymes inhibition	S. KOR	[159,160]
DHPC (136)/alga	Polyketide ^e	NO stimulation	20 µM*	AchR and VEGFR2 expression activation	S. KOR	[161]
eckol (88)/alga	Polyketide ^e	ROS inhibition	30 µM*	MAPK signaling inhibition	S. KOR	[163]
E. stolonifera phlorotannin (137)/alga	Polyketide ^e	Tyrosinase inhibition	1.6 µM	Competitive inhibition	S. KOR	[162]
farnesylquinone (138)/fungus	Polyketide ^e	Lipid-lowering activity	0.5 mM	Mitochondrial β-oxidation enhancement	CHN, DEU	[164]
fucofuroeckol-A (139)/ alga	Polyketide ^e	Melanogenesis inhibition	25 µM*	Tyrosinase-related protein-activity inhibition	JPN	[165]
fucoxanthin (43)/alga	Terpenoid ^f	ACE inhibition	0.8 mM	Non-competitive inhibition	IND	[166]
fucoxanthin (43)/alga	Terpenoid ^f	Reduction of GMC’s collagen IV and fibronectin	2 μM*	Akt/Sirt1/FoxO3α signaling regulation	CHN	[167]
funalenone (140)/fungus	Polyketide ^e	PTP1B inhibition	6.1 μM	Non-competitive inhibition	S. KOR	[168]
GQQ-792 (141)/fungus	Alkaloid ^g	PGK1 inhibition	1.2 μM	Non-competitive inhibition	CHN	[170]
grincamycin B (142)/fungus	Polyketide ^e	IDH1 inhibition	1.25 μM*	Increased CHOP and GADD34 gene expression	CHN, USA	[169]
H. abdominalis peptides (143, 144)/seahorse	Peptide ^g	ROS inhibition in HUVEC	100 µg/mL*	Nrf2 signaling activation	S. KOR	[171]
(-)-loliolide (145)/alga	Terpenoid ^g	Lipid accumulation suppresion	62 μM*	Decreased adipogenic protein expression	S. KOR	[172]
monanchomycalin B (146) /sponge	Alkaloid ^g	α-PsGal inhibition	Not shown	Slow-biding irreversible inhibition	RUS	[173]
monacolin X (147)/fungus	Polyketide ^e	HUVEC tube formation inhibition	30 μM*	VEGFR2 signaling modulation	IND, SGP	[174]
(-)-muqubilin A (148)/sponge	Terpenoid ^f	RXRα and PPARα agonist	10 μM*	Positive RARα allosteric modulation	CAN, ITA, USA	[175]
mycalolide A (149)/sponge	Polyketide ^e	Cytokinesis inhibition	0.01 µg/mL	F actin inhibition and binucleation induction	JPN	[176]
M. edulis dodecapeptide (150)/mussel	Peptide ^g	Osteoblast growth stimulation	100 µg/mL	Binding to cellular 1L5G and 3V14 integrins	CHN	[177]
O. niloticus oligopeptide (151)/fish	Peptide ^g	NO and ROS inhibition	10 μM*	NF-kB pathway suppression	CHN	[178]
penerpene A (152))/fungus	Terpenoid ^f	PTP inhibition	1.7 μM	Docking studies completed	CHN	[179]
penicisulfuranol A (153)/fungus	Alkaloid ^g	Hsp90 inhibition	0.5 μM	Binding to Hsp90α C-terminus	CHN	[180]
pestalotioquinoside C (154)/fungus	Polyketide ^e	ABCA1 mRNA upregulation	50 μM	LXRα receptor binding	CHN	[181]
petrosamide C (155)/fungus	Peptide ^g	Pancreatic lipase inhibition	0.5 μM	Competitive inhibition	CHN	[182]
phakefustantin A (156) sponge	Peptide ^g	Akt expression inhibition	10 µM*	RXR-α binding	CHN	[183]
2-phloroeckol (157)/alga	Polyketide ^e	Tyrosinase inhibition	7 µM	Slow-binding competitive inhibition	S. KOR	[184]
phlorofucofuroeckol A (118)/alga	Polyketide ^e	Collagen type 1 expression inhibition	25 µM*	MAPK and SMAD 2/3 pathway downregulation	S. KOR	[185]
phlorofucofuroeckol A (118)/alga	Polyketide ^e	Osteoblastogenesis stimulation	5 µM*	BMP and Wnt/β catenin- signaling activation	S. KOR	[186]
polonimide analogue (158)/fungus	Alkaloid ^g	Insect GH18 chitinase ofChi-h inhibition	<1 µM*	Docking studies completed	CHN	[187]
P. morrowii bromophenol (132)/alga	Shikimate ^h	Adipogenesis inhibition	25 µM*	PPAR-γ, C/EBPα, leptin inhibition and AMPK enhancement	S. KOR	[188]
preaustinoid A6 (159)/fungus	Terpenoid ^f	PTP inhibition	17.6 µM	Non-competitive inhibition	S. KOR, VNM	[189]
P. yezoensis peptide (160)/alga	Peptide ^g	Dexamethasone-induced atrophy protection	0.5 µg/mL	IFG-1 signaling activation	S. KOR	[190]
rhodoptilometrin (161)/crinoid	Polyketide ^e	Wound healing and cell migration stimulation	1 µM*	FAK, fibronectin and type 1 collagen increased	TWN	[191]
sargahydroquinoic acid (162)/alga	Terpenoid ^f	Activation of lipid catabolism	2.5 µM*	PPAR-γ and AMPKα activation	S. KOR	[192]
scymnol (163)/shark	Terpenoid ^f	Activation of TGR5 receptor	0.5 mM*	Sustained intracellular Ca²⁺ release	AUS	[193]
secoemestrin C (164)/fungus	Alkaloid ^g	ICL inhibition	4.77 µM	ICL mRNA expression inhibition	S. KOR	[194]
shishijimicin A (165)/ascidian	Alkaloid ^g	DNA cleavage	0.014 µM	Binding to double-stranded DNA minor groove	GRC, SGP, USA,	[195]
siphonaxanthin (166)/alga	Terpenoid ^f	Cellular Nrf2 protein expression activation	1 μM*	Nrf2 signaling activation	JPN	[196]
S. latiuscula bromophenol (54)/alga	Polyketide ^e	Tyrosinase inhibition	2.9 µM	Competitive inhibition	S. KOR	[197]
tetracenomycin X (167)/bacterium	Polyketide ^e	Cyclin D1 downregulation	2.5 µM*	Cyclin D1 proteosomal degradation	CHN	[198]
tutuilamide A (168)/cyanobacterium	Peptide ^g	Elastase inhibition	0.001 μM	Docking studies completed	BRA, CHN, DEU, USA	[199]
U. pinnatifida peptide (169)/alga	Peptide ^g	ACE inhibition	225 μM	Mixed-type inhibition	CHN	[200]
zeaxanthin heneicosylate (170)/alga	Terpenoid ^f	In vivo inhibition of age-associated cardiac dysfunction	250 µg/kg**	RXR-α activation	EGY	[201]

^a Organism, Kingdom Animalia: ascidian, seahorse, shark (Phylum Chordata), crinoid (Phylum Echinodermata), octopus, mussel, oyster, (Phylum Mollusca), sponge (Phylum Porifera); Kingdom Fungi: fungus; Kingdom Plantae: alga; Kingdom Monera: bacterium; cyanobacterium (Phylum Cyanobacteria); ^b IC₅₀: concentration of a compound required for 50% inhibition in vitro; *: estimated IC₅₀; ** in vivo study; ^c MMOA: molecular mechanism of action; ^d Country: AUS: Australia; BRA: Brazil; CAN: Canada; CHN: China; DEU: Germany; EGY: Egypt; GRC: Greece; IND, India; ITA: Italy; JPN: Japan; PHL: Philippines; RUS: Russian Federation; SGP: Singapore; S. KOR: South Korea; TWN: Taiwan; VNM: Vietnam; Chemistry: ^ePolyketide; ^f Terpene; ^g Nitrogen-containing compound; ^h shikimate; Abbreviations: ABCA1: a well-known LXR target gene; ACE: angiotensin 1-converting enzyme; AchR: acetylcholine receptorcv; Akt: protein kinase B; α-PsGal: α-galactosidase from marine γ-proteobacterium Pseudoalteromonas sp. KMM 701; AMPK: AMP-activated protein kinase; 3-BDB: 3-bromo-4,5-dihydroxybenzaldehyde; BMP: bone morphogenic protein; C/EBPα: CCAAT/enhancer-binding protein α; CHOP: C/EBP homologous protein; CXCR7: C-X-C chemokine receptor type 7; DPHC: diphlorethohydroxycarmalol; DPPH: 1,1-diphenyl-2-picryl-hydrazil; ERK: extracellular signal-regulated kinase; FAK: focal adhesion kinase; GADD34: an apoptosis- and DNA Damage-inducible gene; GMC: glomerular mesangial cells; HO-1: heme oxygenase-1; HUVEC: Human umbilical vein endothelial cells; ICL: isocitrate lyase; IDH1: isocitrate dehydrogenase 1; IGF-1: insulin-like growth factor; IL5g: integrin IL5; LDL: low-density lipoproteins; LOX-1: lectin-type oxidized LDL receptor-1; LXRα: liver X receptor α; MAPK: mitogen-activated protein kinase; NFE2L: nuclear factor erythroid 2-like 2; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; NO: nitric oxide; Nrf2: nuclear factor-erythroid 2-related factor 2; PGK1: phosphoglycerate kinase 1; PKC: protein kinase C; PPAR-γ: peroxisome proliferator-activated receptor-γ; α-PsGal: α-D-galactosidase; PTP: protein tyrosine phosphatase; RAR: retinoic acid receptor; ROS: reactive oxygen species; RXRα: retinoic X receptor-α; SMAD: an acronym from the fusion of Caenorhabditis elegans Sma genes and the Drosophila Mad, mothers against decapentaplegic proteins; SOAT: sterol O-acyltransferase; SOD: superoxide dismutase; SrtA: sortase A;TGR5: G protein-coupled bile acid receptor 1; UV: ultraviolet; VEGFR: vascular endothelial growth factor receptor; Wnt/β-catenin signaling pathway: proteins in the wingless/Integrated signaling pathway are involved in embryonic development and adult tissue homeostasis.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

MDPI Initiatives

Important Links

Choose an area of interest and we will send you notifications of new preprints at your preferred frequency.

Disclaimer

Marine Pharmacology in 2019‐2021: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti‐Inflammatory, Antiprotozoal, Antituberculosis and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action

Abstract

1. Introduction

2. Marine Compounds with Antibacterial, Antifungal, Antiprotozoal, Antituberculosis and Antiviral Activities

2.1. Antibacterial Activity

2.2. Antifungal Activity

2.3. Antiprotozoal and Antituberculosis Activity

2.4. Antiviral Activity

3. Marine Compounds with Antidiabetic and Anti-Inflammatory Activity, and Affecting the Immune and Nervous System

3.1. Antidiabetic Activity

3.2. Anti-Inflammatory Activity

3.3. Marine Compounds with Activity on the Immune System

3.4. Marine Compounds Affecting the Nervous System

4. Marine Compounds with Miscellaneous Mechanisms of Action

5. Reviews on Marine Pharmacology and Pharmaceuticals

6. Conclusions

Author Contributions

Acknowledgments

Declarations of Interest

References

MDPI Initiatives

Important Links

Subscribe